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ABSTRACT 
 
Content levels, in vitro dissolution and predicted bioavailability of flavonoids from 
Sutherlandia frutescens leaf powder and aqueous extracts 
O. N. Mbamalu 
PhD thesis, School of Pharmacy, University of the Western Cape.  
 
Various formulations of the popular South African medicinal plant, Sutherlandia frutescens, 
are commercially available, with no documented specifications for quality assessment. With 
plans already underway for a clinical trial to assess its efficacy in HIV patients, there is a 
need for scientifically validated tests for the quality control of products of this plant. 
Chemical constituents of the plant are many and varied but it is still unclear which might be 
the most appropriate ones to monitor for activity or to describe the quality of the plant’s 
products. For quality control and regulatory purposes, the content and dissolution of 
flavonoids in the plant products can be assessed. However, these compounds are not 
monitored for regulation and there are as yet no HPLC or dissolution methods that can be 
employed for quality control of herbals like S. frutescens. Therefore, the objectives of this 
study were to assess the suitability of its flavonoid constituents as quality control (QC) 
marker compounds, and the suitability of content levels and dissolution tests of flavonoids 
as QC tools for S. frutescens products.  
 
To realise the afore-mentioned objectives, non-commercially available flavonoid 
compounds (sutherlandins) that could be used as marker compounds were isolated from S. 
frutescens. An HPLC assay was developed and validated for determination of flavonoid 
content in solution. Five S. frutescens materials viz leaf powder (LP), spray-dried aqueous 
extract (SDAE) and freeze-dried aqueous extracts (FDAE) were analysed for flavonoid 
content and dissolution. Dissolution tests were conducted for different S. frutescens 
materials and dissolution profiles of flavonoids in capsules containing these materials were 
compared using Q-release values, the similarity factor (f2) and mathematical models. To 
predict in vivo bioavailability of the flavonoids, in silico assessment of in vivo bioavailability 
of flavonoids (glycosides and aglycones) that may be contained in different S. frutescens 
materials was conducted.   
 
 
 
 
iv 
 
Sutherlandins A, B, C and D were successfully isolated (percentage purity approximately 
99 % for sutherlandins A, C and D, and 90 % for sutherlandin B) and identified, and used, 
along with other flavonoid compounds, for the development of a simple and robust HPLC 
method. Content of sutherlandins A, B, C and D, quercetin and kaempferol in different plant 
materials were 0.4 ± 0.3, 0.8 ± 0.2, 1.3 ± 0.2, 0.6 ± 0.1, 0.01 ± 0.02 and 0.08 ±0.1 %, 
respectively, and differed significantly (p < 0.001). In vitro dissolution showed faster 
dissolution of flavoniod glycosides compared to aglycones. The flavonoids from the LP and 
SDAE materials showed characteristics of immediate release with Q75 in ≤ 45 minutes, and 
delayed release from the FDAE material, i.e. Q75 > 45 minutes. The dissolution profiles of 
each flavonoid compared from different S. frutescens materials were different as signified 
by their f2 values which were all below 50. The mathematical models describing release 
were also different for each flavonoid from the different S. frutescens materials. For in vivo 
bioavailability modelling and prediction studies, the flavonoid aglycones met the conditions 
for oral bioavailability while the flavonoid glycosides did not. 
 
In conclusion, the sutherlandins isolated from S. frutescens proved to be good markers for 
HPLC assay and dissolution tests of S. frutescens materials. The HPLC method was suitable 
for assessing flavonoid levels in S. frutescens materials, and also showed differences in 
flavonoid content in these materials. The dissolution method was simple and reproducible, 
and Q-release values, the f2 and mathematical models proved to be good tools for 
differentiating between S. frutescens materials. In silico modelling showed that the 
flavonoid glycosides and aglycones differed in oral bioavailability. Although not presently 
required by the Medicines Control Council (MCC), quantification, release and dissolution 
studies and specifications may be employed as tools for routine analysis and for quality 
control of herbal drug formulations containing S. frutescens.  
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CHAPTER ONE 
 
INTRODUCTION 
 
Sutherlandia frutescens, the famous South African traditionally used medicinal plant, is now 
also widely available commercially, in a variety of dosage forms and formulations.1 Like 
many herbal medicinal products, it contains a myriad of constituent compounds, some of 
which are reported to be responsible for its many pharmacological effects.2,3 While many 
cures have traditionally been linked to this plant, none of the many constituents of S. 
frutescens has been conclusively linked to the pharmacological effects of this product in a 
clinical trial. Presently, tentative approval has been sought and obtained for a clinical trial to 
assess its efficacy.4 However, it is not clear which of the many formulations available is of 
the best quality and so would be the most appropriate to use. In addition, very little is 
known of its potential actives and how oral dosage forms containing different forms of the 
plant material (i.e. leaf powder or extract) compare in the levels, in vitro release and 
dissolution, and oral absorption of such actives. Various marker compounds have been 
found in this plant, among them the flavonoid glycosides, sutherlandins A, B, C and D. 
Assessment and comparison of the levels and release of flavonoids from different materials 
of this plant might show how differences in content and in vitro release translate to 
differences in quality and therapeutic efficacy. 
 
A recently introduced formulation of S. frutescens, a freeze-dried aqueous extract, is also 
claimed to be better and more efficacious than the older formulation (the powdered leaf 
powder) even though this has not been confirmed.5 In light of such claims, it is pertinent to 
assess the different S. frutescens formulations commercially available, in order to gain an 
insight into their differences, and how these may translate to pharmacological effects. 
Differences in pharmacological effect or efficacy may also be due to differences in quality of 
different products.  
 
If different products differ in quality, how do we know for certain, how do we assess the 
quality of S. frutescens products? How do we determine a better and more efficacious 
formulation? Is it the one that releases the drug faster or more slowly? Is it the one with 
more of the active component or marker compound? Which marker compound is suitable, 
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and can indicate quality status? What parameters should be assessed for with this marker? 
The market for herbal medicinal products has grown considerably over the past years but of 
great concern is the fact that quality control measures that can provide answers to such 
questions have not kept pace with such growth. With the increasing popularity of herbal 
medicinal products like S. frutescens in recent times, answers are needed to such questions 
in order to protect consumers who may be at risk of danger from inappropriately prepared 
and unsafe products.6,7 
 
Many S. frutescens products are commercially available with no tests or specifications to 
indicate quality or efficacy. However, the quality control of S. frutescens products, as with all 
herbal products, needs to be more stringent. The European Medicines Agency (EMEA) 
concurs with this and regards most herbal products as drugs. Therefore, scientifically proven 
evidence of efficacy is required in order for such products to be registered in Europe.8 This is 
not the case in countries like the United States and South Africa where herbal medicinal 
products are marketed as dietary supplements without proof of quality or efficacy.9,10 
However, the scene is set to change with recent updates as the FDA aims to introduce 
measures to ensure herbal product approval only if benefits are demonstrated by safety and 
efficacy studies.8 Within the past few years, the Medicines Control Council (MCC) of South 
Africa has also passed guidelines requiring registration of all herbal products in South Africa 
as a means of ensuring product quality.11 For such registration, tests that can indicate 
quality and efficacy status of herbal products like S. frutescens are required.     
  
Currently, quality control studies of S. frutescens products are non-existent. The setting up 
of quality control tests for herbals like S. frutescens poses great challenges largely because 
of the multi-component nature of and limited research on herbals.12,13 This makes it difficult 
to select an ideal ‘active component’ which can be used to assess quality. In addition, there 
is potential for variation with the same herbal product as a result of different growth, 
harvesting, processing and storage conditions that may have been applied.14,15 Variation in 
content of herbals like S. frutescens may also translate to variation in quality, and the 
question still remains: how do we assess and compare the quality of different S. frutescens 
materials?              
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For quality assessment and comparison of S. frutescens materials, suitable marker 
compounds and analytical assays are required. The marker compounds may be supposed or 
known actives of the product which are suspected or known to contribute to its activities. 
For S. frutescens, some of its biological effects, specifically the antioxidant effects, have 
been attributed to the presence of phenolic compounds such as flavonoids16,17  which exist 
in this plant in both glycosidic and aglycone forms. Because of differences in chemistry 
between flavonoid glycosides and aglycones, their presence and levels could be 
representative of the different forms and conditions under which active components of S. 
frutescens might occur, enabling their use as marker compounds and quality indicators for 
different materials of this plant.  
 
In addition, appropriate assays for the suitable marker compounds need to be developed for 
S. frutescens quality assessment. Such assays may be conducted using high performance 
liquid chromatography (HPLC), a technique used to separate, identify and quantify 
component compounds present in plant matrices.18 HPLC identification and quantification 
can be used to differentiate between materials, and between different batches of the same 
material, enabling its use in quality control and for the setup of regulatory specifications. In 
order to conveniently set up HPLC assays for quality control of S. frutescens, good resolution 
of peaks representing different compounds of interest is desired, and appropriate marker 
compounds need to be selected.  
 
Previous HPLC assays of S. frutescens focused on the flavonol and cycloartanol glycosides or 
the sutherlandiosides in aerial parts of S. frutescens.5,19,20 However, the selected marker 
compounds in these assays did not include related compounds that can indicate quality 
status by serving as products of marker compound degradation. We propose the use of 
selected flavonoid glycosides and their corresponding aglycones in quality control and 
assessment of S. frutescens materials. Flavonoid aglycones may be formed from flavonoid 
glycosides as products of glycoside degradation in unstable conditions;21 therefore 
quantification of these two forms in which the flavoniods exist can be used to detect 
changes in material or product which can translate to changes in quality.   
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The quality of S. frutescens materials can also be evaluated and compared via dissolution 
testing. The dissolution test is a widely used technique employed for quality and 
bioequivalence assessment, as well as for comparison of release for orally administered 
conventional pharmaceutical products. As very little is known regarding the release and 
dissolution of flavonoid glycosides from S. frutescens materials, this test can also be 
employed for release studies, and may detect differences between different S. frutescens 
materials. However, the dissolution test is a novel approach that has not been widely 
adopted for herbal products,22 and so its application may present challenges.  
 
The challenges which may be encountered with dissolution testing of S. frutescens may 
include the very low content of flavonoid compounds in plant materials, and extensive 
within-batch variation which is common in herbal products.23,24 These shortcomings limit 
the use of herbal products in conventional settings and may negate the use of standard 
methods for dissolution testing and dissolution data analyses. In such a case, the standard 
methods may be modified for analyses of S. frutescens dissolution data. These modifications 
may include changes in the dissolution method as well as in dissolution data comparison 
methods, and may be used to differentiate S. frutescens materials.       
 
For quality comparison of materials using the dissolution test, materials with different 
dissolution profiles are deemed different. Differences in dissolution profiles of flavonoids 
may also be due to differences in their release from different matrices of the different plant 
materials, e.g. leaf powder versus extract. As such, mathematical modelling can be 
employed to compare release from different S. frutescens materials. These models describe 
release curves and elucidate the underlying mechanisms involved in flavonoid release from 
different S. frutescens materials, which has hitherto not been done for in vitro release of any 
marker compound or for any herbal product. The mathematical models may also offer 
explanations which can be used to predict in vivo pharmacokinetics of S. frutescens 
flavonoids from different materials.   
 
It is very likely that some of the flavoniod glycoside compounds found in S. frutescens 
materials may not be orally bioavailable. However, the in vivo pharmacokinetics, e.g. 
bioavailability, of marker compounds in different S. frutescens materials can perhaps be 
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predicted via in silico modelling studies, conducted with the use of chemoinformatic 
resources.  
 
The present study as such focuses on quality control and expected in vivo pharmacokinetics 
of flavonoid glycosides and aglycones of S. frutescens leaf powder and aqueous extracts. The 
leaf powder and aqueous extracts are commonly available commercially, and one of these 
forms, most likely one of good quality, may be used for the upcoming clinical trial. This study 
therefore stems from a need for quality control methods for S. frutescens products, which 
can identify S. frutescens-containing products as well as differentiate between them. The 
focus is on the quality of commercially available S. frutescens materials, and involves the 
selection of appropriate markers to use for their quality control, the tools (flavonoid content 
and dissolution) to use for quality assessment, and the bioavailability of flavonoid marker 
compounds selected for quality control tests.      
 
Essentially, S. frutescens is employed in this study as a template with which to introduce 
investigations into quality control and regulation of herbal products. The quality control of 
herbal products is still a work in progress for most countries, largely because the multi-
component nature of herbal products presents considerable challenges to quality control 
efforts. To date, attempts to modernize and integrate these products into the main health 
care stream have been stalled by these quality control and regulatory challenges. Such 
limitations to the use of these materials, once addressed, would benefit development and 
regulation of herbal products to a great extent. In future, guidelines and regulatory 
specifications will ensure that it will no longer be sufficient to tout a herbal product as 
possessing different preventive and curative properties, and biological tests and efficacy-
indicating tests like the dissolution test may be required to support the health benefits 
easily claimed for many herbal products. The good quality of the product will need to be 
ascertained as well in order to confirm purported efficacy as only products of acceptable 
quality can produce the desired pharmacological effects.  
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CHAPTER TWO 
 
LITERATURE BACKGROUND 
 
This chapter discusses Sutherlandia frutescens as an important South African herbal 
medicinal product. It also reviews relevant problems associated with the quality of herbal 
medicinal products and proffers possible solutions that can be used to address these, using 
S. frutescens as a template. The dissolution test as a quality control tool for herbal medicinal 
formulations is also reviewed. Dissolution profile comparison methods are presented, 
including the modifications that may be applied for natural products when criteria set for 
dissolution profiles comparison of conventional drug formulations are violated. In addition, 
mathematical models of drug release are explored, as well as the relationship between 
molecular properties and predicted oral bioavailability.  
  
2.1  Sutherlandia frutescens, an important herbal medicinal plant 
Sutherlandia frutescens (S. frutescens), a common herbal medicinal plant indigenous to 
Southern Africa, is widely used for the treatment of various ailments.3,16,25-27 Among its 
many reputed pharmacological effects, S. frutescens is also widely used by HIV patients who 
attest to improved clinical conditions on using this plant and its products. Such activity 
against HIV has also been supported by in vitro studies.26 Due to its popularity and the 
purported activities of the plant, tentative approval has been obtained for a clinical trial to 
assess its efficacy.4 To prove or disprove efficacy, a product of suitable quality would be 
required. However, assessment of S. frutescens quality, like that of other herbal materials, is 
challenging because specifications for such are not readily available.28 In view of the fact 
that products of this plant are easily accessible and various forms of different species are 
widely distributed, there is a need to introduce measures for its quality control. The wide 
distribution of the plant form, as well as its description, is briefly discussed below.  
 
2.1.1  Distribution and description  
Sutherlandia frutescens is widely distributed throughout the dry and stony areas of 
Southern Africa: in the Western Cape and Lesotho; from the western Karoo to the Eastern 
Cape and up the West Coast in a northerly direction to Namibia and Botswana. Within this 
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geographical distribution, it shows great variation in chemistry and genetics.2 Several 
species have been identified, which are nevertheless closely related, necessitating a revision 
of taxonomic classification from six to two species, S. frutescens and S. tomentosa. S. 
frutescens is further sub-divided into three subspecies or chemotypes, namely subsp. 
frutescens, subsp. microphylla and subsp. speciosa.29 For the purpose of this study, S. 
frutescens subsp. microphylla is the specific chemotype under evaluation.   
 
S. frutescens subspecies microphylla elite (PN1™) is a small, soft, woody flowering perennial 
shrub, about 1.4 m high with prostrate to erect stems. It has green, compound-pinnate 
leaves, with ovate-oblong and glabrous leaflets. The plant produces spectacular red flowers 
borne in terminal racemes and the fruit from the plant is a large, inflated, green pod 
producing black, flattened seeds approximately 3mm in diameter (Fig 2.1).-2,30 The aerial 
parts of the plant, most commonly the leaves and twigs, are utilized in the treatment of 
various ailments. 
 
      
(a)               (b) 
    Figure 2.1: Sutherlandia frutescens showing   (a) the fruit and   (b) the flowers30 
 
 
2.1.2  Uses and pharmacological effects 
S. frutescens has many varied uses, for some of which mechnisms of pharmacological effects 
have been established. It is used to wash wounds, and as a remedy for everything from 
colds and inflammation to liver problems and depression.27 One of its most common names 
is ‘cancer bush’, due to its reputation as a cure for cancer. There is as yet no scientific 
support for the numerous claims and anecdotes that this plant can cure cancer, but there is 
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preliminary clinical evidence of its immune stimulating properties and its direct anti-cancer 
effect in some cancers.3,31 It is also known to decrease anxiety and irritability, to elevate 
mood, and dramatically improves appetite in cachectic patients who gain weight as a 
result.2,26 Its activity against HIV target enzymes and its success in the treatment of septic 
shock (a development of AIDS progression) may also be possible ways in which this plant 
improves outcome in HIV /AIDS patients.26,32-37 
 
Among its other uses, studies have shown that S. frutescens decreases blood sugar levels in 
diabetic rats possibly due to its pinitol component although a preliminary study with pinitol 
in type 2 diabetic individuals did not show encouraging results.38,39 Its antioxidant and anti-
inflammatory effects in polar and non-polar extracts has been demonstrated; the latter in 
vitro and in vivo possibly through inhibition of cyclooxygenase (COX)-2 expression.16,27,40-43 
Hexane extracts were also found to produce antibacterial effects.16  
 
Additionally, S. frutescens has shown anticonvulsant and antithrombotic activity.27,44 Its 
ability to serve as an adaptogenic agent in stress-related disorders may be by attenuation of 
adrenal P450 enzymes leading to a reduction in glucocorticoid levels (and by extension 
stress symptoms).45,46 These various pharmacological effects of the plant have been 
attributed to some of its constituent compounds.  
 
2.1.3  Chemical constituents of S. frutescens  
Various chemical constituents have been identified in S. frutescens. The potential actives of 
the plant are pinitol, L-canavanine, GABA, parabens, saponins, arginine, cycloartane 
glycosides and triterpenoid glucosides.2,20,45,47-49 The major triterpenoids of this plant are 
structurally similar to the cycloartane terpenoids which have proven cancer 
chemopreventive activity50 and in in vitro tests, have been shown to possess evidence of 
anti-cancer activity.3,40,43,49  
 
S. frutescens also contains flavonoids, a group of polyphenolic phytochemicals known to 
produce many biological effects. Some of these flavonoids in the plant include the flavonol 
aglycones, quercetin and kaempferol, and their recently identified corresponding glycosides, 
referred to as sutherlandins A, B, C and D (Figure 2.2).2,47-49,51 Other glycosides of these 
 
 
 
 
9 
 
aglycones which may be present in S. frutescens include rutin, kaempferol-3-O-rutinoside 
and quercitrin. Sutherlandins A and B, rutin and quercitrin  are glycosides of the aglycone, 
quercetin; while sutherlandins C and D, and kaempferol-3-O-rutinoside are glycosides of the 
aglycone, kaempferol. Can these constituent compounds be employed to address problems 
associated with quality of S. frutescens formulations? 
 
 
  
Figure 2.2: Structures of the flavonoid glycosides (sutherlandins A to D), and aglycones  
       (quercetin and kaempferol) possibly present in S. frutescens     
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2.1.4  Formulations of S. frutescens and associated problems 
Although not yet registered by the South African regulatory authority (i.e. the Medicines 
Control Council, MCC), S. frutescens is commercially available and used in various forms. 
Some of these forms include the dried powdered material, extracts, tablets, capsules, 
tonics, dried powdered material in tea bag for oral consumption, as well as creams and gels 
for topical administration. A recent entrant into the commercial circle is the dried aqueous 
plant extract, which is claimed to be closer to the traditionally used dosage forms, and 
presumably more efficacious than previous formulations. Such claims spur patients to buy 
the different forms of this plant, as supplements to their diet or as a cure for an illness.  
 
With its increasing popularity, especially among HIV patients who attest to its immune-
boosting properties, there is a need for quality control in order to ensure the safety, quality 
and efficacy of this plant for consumers. The South African Herbal Sciences and Medicines 
Institute (SAHSMI) has for the past few years conducted extensive research on these 
products, and a phase I clinical trial  on the leaf powder (Trial # TICIPS002_RP01) showed no 
evidence of toxicity at very high doses.52 Arrangements are underway for a phase II clinical 
trial to assess the efficacy of an S. frutescens extract in HIV patients.4 A formulation of 
appropriate quality is required for this, but how do we assess and compare qualities of 
different S. frutescens formulations? Another limitation to the choice of an appropriate 
product for the clinical trial is the fact that very little is known concerning the 
pharmacokinetics of any potential actives such as flavonoids in these preparations, and how 
oral dosage forms containing different forms of the plant material (i.e. leaf powder or 
extract) compare in levels, release and oral absorption (i.e. in vivo bioavailability) of such 
actives. 
  
The afore-mentioned quality and other problems of S. frutescens are not specific to this 
plant, but are also encountered with other herbal medicinal products. As such, they can be 
addressed by the same method(s) that may be proposed for quality control and regulation 
of other herbal products. With the popular use of herbal medicines today, and the 
possibility of modified and “improved” versions of such products being introduced as the 
market for herbals grows, there is a need for quality control measures so as to effectively 
regulate their use among consumers.  
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2.2  The need for quality control of herbals  
The use of herbal medicinal plants for treating diseases is probably the oldest existing 
method that humanity has used to cope with illness. Herbal medicinal products are crude 
plant materials from different parts of the plant as well as extracts from the plant. Recently, 
the use of herbal medicines has gained popularity, and major pharmaceutical companies 
have joined in, producing more herbal remedies for the treatment and management of a 
wide range of conditions. Prominent scientific journals have also devoted significant effort 
to the publication of both basic and clinical scientific studies on herbal medicines and their 
products.53 This has created a scientific platform, internationalising herbal product use and 
may well enable the physician’s prescription of herbal medicinal products.  
 
Internationally, widespread views also support the integration of traditional herbal medicine 
into conventional health care systems.35,54 Many organisations such as the World Health 
Organization (WHO) and the Joint United Nations Programme on HIV/AIDS (UNAIDS) have 
shown their support for traditional (herbal) medicine integration by developing guidelines 
for quality control and regulation of these products.35,54 This has offered some assistance; 
however, following the introduction of these guidelines, insufficient programmes have so 
far been established in different countries to attain the set goals.13,55 Only about four 
countries – China, the Democratic People’s Republic of Korea, the Republic of Korea and 
Vietnam – are considered to have attained the desired level of integration of traditional 
herbal medicine into conventional health systems.56,57 
 
A considerable challenge to herbal medicine integration is posed by the paucity of research 
on these products. Insufficient data exist for most herbal products to guarantee their safety, 
quality and efficacy, and knowledge cum resource sustenance of these products still remain 
challenges.8,13,58-62 While many pharmaceutical companies invest in the production and 
marketing of herbal products, they can present their products as dietary supplements and 
remedies and so do not necessarily have to provide evidence of quality and efficacy for such 
products.9,55,63 As such, their products do not have to undergo the extensive quality control 
and performance tests required for conventional drug formulations, a situation obtained in 
countries like the USA.10  
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In South Africa, the Medicines Control Council (MCC) is charged with the regulation of 
medicines. In order to be registered as a medicine in South Africa, a product has to comply 
with the MCC’s standards of safety, quality and efficacy. Despite their popularity, 
appropriate methods for quality and efficacy assessment of herbal medicinal products are 
not readily available. While current legislation in South Africa seeks to implement guidelines 
for the regulation of herbal medicines,4 developing standards for such regulation is quite 
time consuming and rife with challenges due to a number of reasons.   
 
Firstly, unlike conventional drugs where activity is due to (a) known active ingredient(s), 
herbal medicinal products are a combination of several different compounds whose net 
effect may be agonistic, synergistic, complementary, antagonistic or even toxic to name but 
a few.14,15 Secondly, the pharmacological effect of the herbal medicinal product may be 
from just one component or a combination of several other compounds, whose ratio in the 
product may also influence safety, quality and efficacy. The safety, quality and efficacy in 
turn, can be affected by seasonal changes, growth conditions, harvesting, processing and 
preparation methods.12,14 Thirdly, there may be challenges with identification of different 
plants, deliberate adulteration of plant materials as well as multicomponent changes during 
transportation and storage.64 This necessitates appropriate standards to monitor these 
materials and their formulations. Such standards will ensure consistency of formulations, as 
well as an improvement in their quality.  
 
The Pharmaceutical Manufacturers Association of the United States defines quality as “the 
sum of all the factors which contribute directly or indirectly to the safety, effectiveness and 
acceptability of the product”.65 It refers to conformance to requirements and the ability to 
meet desired standards, and is of utmost significance in relation to drug products or any 
product with the potential to cure or manage a (perceived) health condition. Quality control 
measures serve to ensure that each dosage unit of the drug product delivers the same 
amount of active ingredients within specified limits in order to assure quality and efficacy. 66 
This is of importance in herbal product use, as the quality and content of perceived active 
pharmaceutical ingredients (APIs) in such products can influence safety and efficacy.  
 
 
 
 
 
13 
 
There may also be differences in efficacy of different formulations of the same herbal 
product. This is due to the fact that many herbal products are not necessarily prepared 
according to current good manufacturing practices (cGMP), and their quality, which can 
influence their efficacy, may still give room for concern. In view of this, initiatives to address 
the poor quality of some herbal products are not only necessary, but in the public’s best 
interest. Such quality assessments can be conducted via analytical tests which can be 
introduced as prerequisites for product registration and product introduction into the 
commercial stream, such as is obtained for conventional drug products. The analytical tests 
may very well involve studies on the content, stability and dissolution of perceived active 
ingredients from herbal products, with specifications set for product approval. This will 
contribute in no small measure to an improvement in herbal products quality, as it will 
ensure that marketed products meet the specified standards set.    
 
2.3  Towards improving the quality control of herbal medicinal products  
Quality control of herbal medicinal products is still in its infancy, and generally very poor. 
Attempts have been made to draw attention to this problem, with calls being made for 
improved measures which can translate to better safety, quality and efficacy for these 
products.13,67-69 Such improved measures can also be employed to substantiate herbal 
medicinal product use.  
 
In vitro screening programmes, using the ethnobotanical approach, are important in 
validating the traditional use of herbal remedies and for providing leads in the search for 
new active principles. Whereas activity identified by an in vitro test does not necessarily 
confirm that a plant extract is an effective medicine, nor a suitable candidate for drug 
development, it does however provide a basic understanding of a plant’s efficacy and, in 
some cases toxicity, in a traditional herbal remedy. This is certainly a primary concern of 
ethnopharmacological research in developing countries. Scientific validation of herbal 
medicine use also lends support to the continued practice of “traditional medicine” in 
Africa. Eventually, this may lead to more widespread use of African Traditional Medicine 
(ATM) in health care systems, as in India and China, provided thorough toxicological 
investigations are carried out and sufficient guidelines for regulation are put in place.53,70,71  
 
 
 
 
 
14 
 
Regulation of herbals, though better than non-regulation, is still not as harmonised as 
regulation of conventional drug formulations. Herbal product regulatory guidelines differ 
from one country to the next depending on the definition of herbals in the country and also 
on whether the products are being used for diagnosis, cure, mitigation, treatment or 
prevention of diseases.13,14,72 In the United States for instance, herbal products can be sold 
as “dietary supplements” and so are exempt from regulation.10,62 More recent guidelines by 
the FDA however aim to approve herbal mixtures if safety and efficacy data show benefits.8 
Under European standards, herbal products can be licensed as medicines, and are 
registered after due quality assurance tests. In Korea, proof of quality is required prior to 
the marketing of herbal medicines, and a licensing system to ensure product safety is in 
place.73 The Ayurvedic Pharmacopoeia of India contains monographs for over 250 products; 
however, the documented standards are deficient for quality assessment. The Government 
of India has announced regulations for traditional medicines in an effort to improve their 
quality.53,74 In China, traditional herbal medicines have been integrated into the primary 
health care system, and regulations require safety and efficacy evaluation as well as GMP-
compliant production. Extensive scientific studies have been conducted, and this has 
assisted in the promotion of Traditional Chinese Medicine (TCM). The traditional medicine 
departments are accommodated in almost all the general hospitals in China, and the 
Pharmacopoeia of the People’s Republic of China contained 992 monographs of Chinese 
crude drugs and traditional Chinese patent medicines as at the year 2000.8,53,74 
 
In Africa and many other low income countries, the use of herbal products is largely 
unregulated, posing a risk to consumer safety.6 A major challenge in these countries is the 
slow pace of quality standards and regulatory development compared to the demand for 
traditional herbal medicines.7 Guidelines were proposed by the World Health Organisation 
(WHO) for the quality control and promotion of herbal medicines over a decade ago, and 
were regularly updated.75 These guidelines have been adopted by some African countries 
like Nigeria, Ghana, Mali and South Africa, among others, who are progressing towards 
attainment of the set goals;4,74,76 however, there is still considerable room for improvement. 
In South Africa, the regulatory body, the Medicines Control Council, has set up guidelines for 
the regulation of herbal medicinal products. Current legislation in South Africa aims to 
register all herbal products, a means of ensuring product quality.4,11  
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For safe and efficacious use of herbal medicinal products, whether in South Africa or 
elsewhere, product quality has to be assured. Such quality and efficacy may be attained by 
standardization of the herbal products. Standardization encompasses all measures taken 
from plant cultivation to clinical use or application of the final product, which serve to 
ensure product consistency. This includes assessment of macroscopic and microscopic 
parameters, chemical assays, moisture content and foreign matter to mention a few.73,77 
HPLC chromatographic fingerprints have also been employed in order to assess the degree 
of “sameness or difference” in herbal formulations.78,79 In addition, the quality and efficacy 
of herbal medicinal products can be monitored by stability and dissolution studies, which 
have been reported for some herbal medicinal products.24,67,80,81 Although not a 
requirement for the regulation of herbal medicinal products in many countries,81,82 
dissolution testing of formulated herbal products can serve as a useful tool for the quality 
control of these products.  
 
For conventional drug products, dissolution testing is a very important tool employed in 
drug development and quality control.22 This is because a drug’s rate of dissolution under in 
vitro settings can be employed for bioequivalence assessment of formulations as well as to 
predict its in vivo bioavailability. For this reason, dissolution tests for oral dosage forms are 
designed to replicate physiological conditions of the gastrointestinal tract,83 enabling 
extrapolation of results from such tests to in vivo conditions. This quality control test 
therefore serves as one of the basic tests in the formulation and bioequivalence assessment 
of drug products containing chemically defined, synthetically produced active 
ingredients.14,22,83-85 
 
With respect to herbal medicinal products however, quality control tests such as dissolution 
tests are not a prerequisite for their acceptance and introduction into the consumers’ 
circle.14,22 Even if such quality control tests were to be performed, chemical marker 
compounds (which can serve as standards) are not readily available for most herbal 
medicinal products. This is due to the nature of herbal medicinal products, which contain 
multiple components, the exact ones which are responsible for activity and the mechanisms 
of such activity not yet fully elucidated. Because of such limitations, setting up quality 
control tests such as dissolution tests for herbal medicinal products, with specifications, will 
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present enormous challenges. Such challenges have to be addressed in order to introduce 
discriminating tests that can be used for quality control and regulation of herbal medicinal 
products. Among the first challenges to be addressed is the selection of perceived active 
pharmaceutical ingredients (APIs) of the plant, so-called chemical marker compounds, which 
can be employed as reference and marker compounds for quality control.  
 
2.4    Chemical marker compounds as quality control tools 
The European Medicines Agency (EMEA) defines chemical markers as chemically defined 
constituents or groups of constituents of a herbal medicinal product which are of interest 
for quality control purposes regardless of whether they possess any therapeutic activity. A 
chemical marker can be used to assess the quality of a herbal medicinal product as its 
concentration can indicate potency and quality status of the product.12,86 An ideal chemical 
marker should exhibit therapeutic effects of the herbal medicinal product. Because only a 
limited number of compounds contained in herbs have been shown to possess 
pharmacological actions, other chemical components that may or may not exhibit 
pharmacological effects may also be employed as markers.12 Such markers could be from 
any appropriate class of secondary metabolites found in the plant from which the herbal 
product is sourced. The secondary metabolites in question can be flavonoids, which are 
known to be abundant in plant materials,87,88 and are also present in S. frutescens.2,51 As 
such, flavonoid compounds can serve as chemical marker compounds for S. frutescens 
formulations and materials. 
 
2.4.1    Flavonoids as chemical markers 
2.4.1.1   What are flavonoids? 
Flavonoids are polyphenolic plant pigments synthesized from the amino acid, phenylalanine. 
They are common in green plant cells, and are responsible for the bright colours of flower 
petals.89 In the last decade, these compounds have become of interest due to their many 
documented health benefits. They have been reported to prevent and cure many diseases, 
with very low toxicity to animal cells. Flavonoid use in disease prevention and treatment has 
been attributed to pharmacological effects produced through antioxidant activity via 
scavenging of free radicals.90-92 Chemically, they are characterized by two aromatic rings (A 
and B) linked by a heterocyclic C-ring (Figure 2.3).             
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Figure 2.3: Basic structure of a flavonoid 
  
Five major subgroups of the flavonoids are characterised based on the structure of the C-
ring (Figure 2.4). These are flavonols (with a hydroxyl group in position C3), flavones (with a 
double bond between positions 2 and 3 and a ketone group in C4), flavanones (with the C-
ring saturated), dihydroflavonols/flavanonols (the 3-hydroxy derivatives of flavanones), and 
flavanols (also called flavan-3ols because of a hydroxyl group almost always at C3 but with 
no double bond between C2 and C3). In plant materials, some of these different subgroups 
may be present, and their levels may vary with the type and quality of plant material. 
 
 
 
Figure 2.4: Subgroups of the flavonoids 
 
2.4.1.2    Levels and types in herbals 
Flavonoids are secondary plant metabolites and are abundant in nature. Over 7000 different 
flavonoids have been discovered, with the list regularly updated as new ones are 
discovered.93 They are present in plants and by default, in most plant-based products. In the 
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plants, they exist either as the free aglycone or as flavonoid glycosides (where the aglycone 
is bound to a sugar via a glycosidic bond). The more abundant form of flavonoids is the 
flavonoid glycoside, which is soluble in aqueous media. The aglycone is more soluble in 
organic solvents, and less soluble in water.  
 
In traditional settings, herbal medicinal plant materials are usually prepared as aqueous-
based decoctions and infusions. In these formulations, the different active 
phytopharmaceutical ingredients (APPI) such as the aqueous-soluble flavonoid glycoside 
compounds will be released. Thus, the flavonoid glycosides represent the form in which 
actives from many traditional medicinal products (such as S. frutescens) are released when 
prepared for oral consumption, and are inherently more abundant than the non-soluble 
flavonoid aglycones in aqueous media used for their extraction.  
 
Despite their abundance, it is difficult to quantify individual flavonoid glycosides due to their 
inherently large number in plant samples. These glycosides however, are derived from a 
limited number of flavonoid aglycones, and have actually been described as “sustained-
release natural prodrugs of their aglycones”.94  
 
  
 
 
 
In quantification studies therefore, the glycosides are usually acid-hydrolysed to the 
aglycones and glycoside levels quantified in terms of the aglycone content.87,95 Either form, 
flavonoid glycoside or flavonoid aglycone, can be employed as marker compound in quality 
control and pharmacokinetic studies of herbal products as both forms may be available in in 
vitro settings and following human intake.   
 
2.4.1.3     Human intake  
Flavonoids are present in fruits (e.g. berries, apples, and oranges), vegetables (onion, 
spinach, broccoli, green pepper, and tomato), soy beans, herbs, grain and tea. Higher 
concentrations can be found in fruit peels, leaves and flowers of plants.94 Recently, due to 
Flavonoid glycoside 
(in gut) 
glucosyltransferase 
acid hydr.     /     enzyme hydr. 
    (HCl)           β-glycosidase Flavonoid aglycone      +     sugar  
                           (e.g. glucose)  
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their many reported health benefits, they have become a focus of interest, with many 
consumers purchasing actively developed components marketed as herbal remedies or 
dietary supplements.94 From food sources, the mean daily total flavonoid intake by humans 
ranges from 158.3 to 203.0 mg/day.96,97 Various amounts are absorbed and eliminated from 
this intake, and these amounts can be calculated using pharmacokinetic theories developed 
for such. Due to their abundance in plants and other advantageous characteristics, they can 
be employed as chemical markers for herbal product research.        
 
2.4.1.4  Suitability of flavonoids as chemical markers 
In green plant cells where flavonoids can be detected, they are much diversified.88,98 The 
different classes and sub-groups are susceptible to extreme modification and can be readily 
hydrolysed, oxidized, hydroxylated, methylated, glycosylated, acylated or phenylated, giving 
rise to the variety of compounds within a class.99,100 This can be applied in quality control of 
herbal drug materials as follows.    
 
Generally, most forms of instability in drug products are due to hydrolytic and oxidative 
reactions.101,102 These reactions and the subsequent instability caused can lead to poor 
quality of the affected drugs. In herbal materials which most likely contain flavonoids, 
flavonoid susceptibility to different chemical processes can be used to monitor product 
quality. For instance, if the flavonoid glycoside or aglycone content and /or type increases or 
decreases, this can be an indication of some form of product instability, which can indicate 
quality status. An understanding of the flavonoid glycoside and aglycone content in herbal 
materials is however needed for such interpretation.  
 
Oxidative reactions of flavonoids are common, and are catalysed by three major enzymes: 
catechol oxidases, laccases and peroxidases.103 As phenolic compounds, the flavonoids are 
easily oxidized to quinones.89 The existence of vicinal hydroxyl groups in the flavonoid 
structure provides a site for oxidative attack that opens up the flavonoid ring.89 In the 
presence of ultraviolet light (and sometimes heavy metal ions), oxidation proceeds with a 
ring opening at C1. The first step in the oxidative degradation of organic compounds in air is 
hydroxylation. Hydroxylation reactions of flavonoids occur at positions 3, 5, 7, 3’, 4’ and 5’ 
which are suitably vacant. Some of the hydroxyl groups may undergo further reactions – 
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sulphation, methylation, glucuronidation or acetylation to yield other compounds, shown 
using the flavonoid aglycone, quercetin, as an example (Figure 2.5). Such oxidative reactions 
of flavonoids in plants can influence their biological effects.104 For instance, during food 
processing of plant material and storage, flavonoids can be oxidized by enzymes. This can 
compromise cell integrity, resulting in discolourations, one of the key symptoms of reduced 
quality in a product.105,106 
 
 
Figure 2.5: Common reactions of flavonoids, using quercetin as a template 
 
Flavonoid glycosides also undergo hydrolysis in the presence of acids or enzymes. The ease 
of hydrolysis depends on the nature of the flavonoid glycoside (whether an O-glycoside, C-
glycoside, or both), the identity of the sugar and the site of attachment.107 Flavonoids with 
an O-glycosidic bond are easily hydrolysed by acids while C-glycosides exhibit resistance to 
such hydrolysis.108 Glucose conjugates of flavonoids are reportedly easier to hydrolyse than 
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glycosides formed by flavonoid aglycone conjugation with other sugars such as rutin, 
quercitrin and naringin and galactose.109,110 On the influence of attachment site to flavonoid 
glycoside hydrolysis, the C7 position of the flavonoid aglycone has been found to be more 
prone to hydrolysis than the C3 position.  
 
Flavonol glycosides are believed to be hydrolysed to their corresponding aglycones prior to 
absorption. Because of this, in addition to difficulty in obtaining reference standards for all 
flavonoid glycosides, the glycosides are usually acid-hydrolysed to the aglycones which are 
then identified and quantified in analytical procedures.111 
 
To summarize, quality assessment of herbal medicinal products can be used to ensure 
efficacy and batch consistencies. A material of good quality should be able to maintain as 
much of its original characteristics as possible over its envisaged period of use. Changes in 
quality and efficacy of herbal medicinal products may result from chemical processes which 
may be enhanced by changes in temperature, moisture and pH conditions during 
preparation and or/ storage of the product. The flavonoid compounds may be very sensitive 
to such changes, and so can serve as quality and by extension, efficacy indicators. Because 
they can also be affected by changes in the pH of the medium, they can serve as appropriate 
references for evaluating in vitro release from S. frutescens materials in different dissolution 
media. These different media are indicative of different sections of the gastrointestinal tract 
as well as their prevailing pH conditions, and so are ideal for dissolution testing, a quality 
control tool which can be employed for S. frutescens products.   
 
 
2.5  Dissolution testing  
2.5.1  Brief history of the drug dissolution test  
Dissolution has been defined as the amount of substance that goes into solution per unit 
time under standardised conditions of liquid/solid interface, solvent composition and 
temperature.112 
  
This quality control test originated with the early physical chemists. The first known 
reference to dissolution testing was made by Noyes and Whitney in their publication, “Rate 
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of solution of solid substances in their own solution”.113 Their paper suggested that the layer 
of saturated solution formed around a solid particle during dissolution determines the 
mechanism and rate of dissolution. Physical and chemical factors as determinants of solid 
dissolution rate were proposed at the start of the 20th century.114 Later, the Noyes-Whitney 
equation, as we know it today, was modified by Nernst and Brunner, relating dissolution 
rate and diffusion coefficient.115,116 It was not till 1930 that experiments on dissolution 
testing of drugs commenced, with in vitro in vivo correlations (IVIVC) established by the 
1950s. Prior to 1950, experimental work on dissolution as a release mechanism for drugs 
from dosage forms was limited.117   
 
 
2.5.2  Dissolution testing of herbals 
Currently, dissolution testing is a very important tool employed for quality control of 
conventional drug formulations. It is also used for optimization of formulations, and desired 
release specifications for drug products can be determined with this test. As a quality 
control test that assesses release of actives from pharmaceutical formulations and 
materials, the dissolution test can be used to assess whether an orally administered drug 
product will realise the objective for which it is formulated, which is to release the API in the 
right environment (stomach or intestine, depending on formulation) so that it can further be 
subjected to the pharmacokinetic processes of absorption, distribution, metabolism and /or 
excretion.118 
 
As widely accepted as this test is for conventional drug and active pharmaceutical ingredient 
(API) formulations, it is still a novelty for herbal medicinal products. Considering the fact 
that herbal (medicinal) products have gained tremendous popularity in recent years, and 
may diversify in the pharmaceutical industry, perhaps serving as new formulations or 
“improved” modified versions of previous formulations, there is a need for the introduction 
and implementation of new approaches that will improve their quality and efficacy 
profiles.67 Dissolution studies of these materials, conducted according to relevant developed 
guidelines, may well provide the desired advancement. As herbal products are complex 
multicomponent materials, their dissolution tests may be conducted using one or more 
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suitable reference marker compounds for development of compendial and regulatory 
standards.  
Development of compendial standards for herbal product dissolution is still in its infancy, 
and presents considerable challenges. Currently, only four herbal products classified as 
dietary supplements – arginine, curcuminoids, soy isoflavonoids and turmeric – have 
monographs with dissolution specifications in the USP.24 Commercially available herbal 
products and dietary supplements, like most natural products, are inherently variable in the 
quantity and quality of constituent “active” and non-active compounds. This, coupled with 
deficiency in standardisation and processing methods, may result in batch to batch variation 
and even within batch variation of formulations.23,24 Such variations may also offer an 
explanation for the differences in efficacy observed in clinical trials with herbal products.23,24 
 
The wide variability in quality and content is in itself a limitation to the use of these 
products, and methods to address these challenges have become of interest to the 
stakeholders involved (regulatory authorities, research institutes, manufacturers and 
marketers alike). Such variability in quality and content may also contribute to significant 
differences in percentages released and dissolved in dissolution test media at various 
sampling times, and these factors will need to be considered in method development.  
 
A few studies have reported on dissolution studies of herbal materials, and the percentages 
of reference compounds released in the medium. Nair and Kanfer reported a minimum of 
75 % release of hypoxoside and sterols in one hour, from dissolution studies of African 
potato (Hypoxis hemerocallidea) conducted at pH 1.2 and 5.0 respectively, using the USP 
basket apparatus.81 Dissolution tests on Passiflora products demonstrated 50 % and almost 
100% dissolution of actives from capsules containing the powder and capsules containing 
the extract, respectively, in 10 minutes (USP paddle method at a speed of 50 rpm, using 
water at 37 ± 0.5 °C and UV spectrophotometric detection at 340 nm).22   
 
A further study by Jackson et al. has intimated that the quick release of a drug from its 
enclosing matrix at earlier time points, which we have encountered with some herbal 
materials in our labs (unpublished study), may be a disadvantage.119 For APIs which exhibit 
quick release, all the active components may be dissolved in the test medium almost 
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immediately while very little will be absorbed. In such a case, there is a need to determine 
the bioavailability of the active from the product, in order to assess whether all the released 
actives can be absorbed, and whether such absorption will maintain effective therapeutic 
concentrations of the actives in plasma. These and other similar issues may need to be 
addressed for appropriate dissolution method development.  
 
 
2.5.3  Method development for dissolution studies  
The drug dissolution test is an official quality control test designed to evaluate drug release 
and dissolution within the gastrointestinal tract. Such a test is conducted according to 
specifications set out in the pharmacopoeia.120 These specifications may be modified as 
necessary, though such modifications need to be validated.121  Depending on the part of the 
GIT where drug dissolution is expected, dissolution tests can be conducted using different 
media and conditions that mimic the gastrointestinal tract (GIT) environment.83  
 
Under certain circumstances, the drug dissolution test may also be used to assess 
bioavailability and bioequivalence. In such cases, in vitro dissolution testing is used as a 
substitute for in vivo bioequivalence (BE) studies, and two formulations are deemed 
therapeutically equivalent if their dissolution profiles are similar. Briefly, a dissolution profile 
assesses the cumulative percentage of the API that goes into solution over time. For 
predicting bioavailability and bioequivalence from dissolution data, the Biopharmaceutics 
Classification Scheme (BCS) class of the drug should be considered.  
 
The Biopharmaceutics Classification Scheme is a scientific classification of drug substances 
according to their solubility and permeability profiles.122 Details of this classification are 
explored under the section on in vitro in vivo correlation models (Section 2.7.3.2). For orally 
administered drugs in BCS class I, and for non bioproblem drugs, bioequivalence can be 
documented using in vitro dissolution studies.123 Non bioproblem drugs are products for 
which bioequivalence may be shown by in vitro tests only while bioproblem drugs are 
products that require in vitro and in vivo tests in order to prove bioequivalence to the 
innovator or standard drug.124 Products that may be classified as bioproblem drugs include 
but are not limited to:124  
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- drugs with narrow therapeutic indices,  
- drugs known to show intra- and interpatient responses 
- drugs contained in dosage forms that may give rise to significantly improved 
bioavailability (superbioavailability) 
- drugs intended for the critically ill, geriatric or paediatric patient                  
Typically, drugs in BCS class I that do not have bioproblem restrictions may be viewed as non 
bioproblem drugs while drugs in the other classes may not be.  
 
When using in vitro tests as substitute for in vivo bioavailability and bioequivalence, the 
Food and Drug Administration (FDA) of the United States and the Southern African 
Development Community (SADC) recommend that an appropriate USP method be used for 
such tests.123,125 If such a method is not available, the FDA method for the reference drug 
should be used. In cases where neither USP nor FDA methods are available, a dissolution 
test method should be developed for the products under study. For method development, 
dissolution profiles should be generated in aqueous-based media with a pH range of 1.2 to 
6.8, taking samples at not more than 15-minute intervals (12 units each).  
 
FDA regulatory guidelines further state that for drug dissolution testing, the volume of the 
medium is usually 500 ml, 900 ml or 1000 ml.126 Sink conditions are desired (but not 
mandatory). While aqueous-based media with a pH range of 1.2 to 6.8   are recommended, 
the use of water as a dissolution medium is not encouraged. This is due to the fact that 
water has no buffering capacity and test conditions (e.g. pH and surface tension) may vary 
depending on the water source. In addition, these conditions may change during the actual 
dissolution test itself, as a result of other ingredients which may be active or inactive,127 and 
may return untrue results for dissolution tests and profiles.   
 
Dissolution tests are used to generate dissolution profiles, which can be used to compare 
products. Two products with similar dissolution, though not necessarily similar release 
characteristics, will have similar dissolution profiles. When using dissolution tests for 
bioequivalence assessment, the primary concern is to quantify differences in 
bioavailabilities of different formulations or products, and to demonstrate the unlikelihood 
of clinically or therapeutically important differences.125 This is certainly a primary goal for 
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the dissolution scientist in dissolution method development, and necessitates the 
development of a discriminatory dissolution method.  
The discriminating power of a dissolution test method is its ability to detect changes 
(formulation, manufacturing, storage or otherwise) in a product.128 Discriminatory methods 
are employed for quality control and can be used to assess batch to batch similarity, for 
instance, before release of product for a clinical trial.  Such discrimination is necessary from 
a biopharmaceutics point of view, as it will enable detection of changes in product quality 
that may affect in vivo performance.129  
 
For dissolution tests of herbal products, component compounds found in the plant can be 
used for reference purposes. In such a case, they can be referred to as marker compounds 
because they can be used to characterise the product. Such markers /references can be 
used as the active (phyto) pharmaceutical ingredient (API or APPI) during dissolution testing. 
Therefore, in dissolution tests of herbal products, the dissolution of these compounds will 
be assessed. Such assessment needs a discriminating method that can be used to establish 
differences between formulations, subtle though such differences might be.  
 
Much as a discriminating method is desired, it may also be necessary to select a 
discriminating method for dissolution profiles comparison. The previous section described 
the considerable variation that may be encountered during dissolution testing of herbal 
materials using reference marker compounds, even with products from the same 
production batch.23,24 It then becomes important not only to develop a discriminating 
dissolution method, but to also compare dissolution profiles with a discriminating 
comparison method. Some of the dissolution profile comparison methods that have been 
proposed for their discriminating ability, especially for data that present considerable 
variation, will be discussed in the following section and may be employed for dissolution 
profiles comparison of marker compounds from herbal products.  
 
 
2.6  The dissolution profile and its applications  
2.6.1  What is a dissolution profile? 
A dissolution profile has been defined as the measured fraction (or percentage) of the 
labelled amount of drug released from a dosage unit at predetermined time points and 
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dissolved in the dissolution medium when tested in a dissolution apparatus.14,130 Dissolution 
profiles of an API from different formulations can be used to establish the similarity or 
otherwise of pharmaceutical dosage forms, to confirm dissolution specifications for a 
specific pharmaceutical dosage form and to predict in vitro in vivo correlations. Thus, it 
prevents the need for costly pharmacokinetic studies in humans as well as speeds up 
product development procedures. For dissolution profiles of herbal formulations, the 
release of the suspected active or marker compound is usually assessed.  
 
2.6.2  Methods for dissolution profiles comparison  
Dissolution profiles can be compared using one or a combination of graphical methods, 
statistical analysis, model dependent and model independent methods (Figure 2.6).120,131-133  
  
2.6.2.1   Graphical method 
The graphical methods plot the concentration of dissolved drug in solution as a function of 
time, and compare percentages of the drug in solution at each sampling point, as well as the 
shapes of the curves. Overlapping curves indicate some level of similarity between the 
curves and the difference between these curves can be assessed to evaluate the level of 
(dis)similarity. However, there is no knowledge of how small the difference has to be to 
indicate similarity, or how large it has to be to indicate dissimilarity.  
 
2.6.2.2   Statistical methods  
Statistical methods for dissolution profiles comparison include the student’s t-test, and the 
analysis of variance (ANOVA). The one sample t-test, paired or unpaired t-test can be 
employed in these cases, and t is calculated from the equation:      
 
   
        
  √ 
 
where X is the sample mean, N is the sample size, S is the standard deviation of the sample 
and µ is the standard deviation of the population. The calculated “t” value is compared to 
the tabulated “t” value and the null hypothesis rejected if the calculated exceeds the 
tabulated value. The ANOVA-based statistical methods are more commonly used than the t-
tests.  
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Figure 2.6:  Methods for dissolution profiles comparison  
 
For ANOVA-based methods, the variances within the reference and the test groups are 
calculated as shown in the equation below, and then compared to each other.  
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The F-value (ratio of the variance between the groups to the variance within the groups) 
calculated is compared to the tabulated (or expected) F-value at specific degrees of freedom 
and levels of significance. The variation between two profiles is considered insignificant (and 
hence the profiles declared similar) if the calculated is less than the tabulated F-value. The 
level of significance is the probability of obtaining a result as rare as the one actually 
observed, if the null hypothesis is true, and is usually 95 %. These statistical methods may 
seem good for dissolution profile comparison of active compounds from herbal materials, 
where within batch variations may be quite significant, as it takes note of the within-batch 
variation in analysed samples. However, statistical methods for dissolution profiles 
comparison are not ideal as each dissolution time point is treated as a separate entity, 
independent of other points, which is not necessarily so. As such, the difference in profiles 
may be significant at some points and not at others, making interpretation difficult.134 In 
addition, statistical methods for dissolution profiles comparison have been found to be 
over-discriminating from a biopharmaceutical point of view.135 Such limitations may be 
addressed with the use of model-dependent methods. 
 
 
2.6.2.3  Model-dependent methods 
Herbal medicinal products like S. frutescens are consumed for the prevention and treatment 
of ailments. As such, they can be viewed as drugs and dissolution processes of their active 
components can thus be modelled and analysed as is done for conventional drug 
formulations. Subsequently, the terms ‘API’ and ‘drugs’ will be used interchangeably.  
 
Majority of drugs are available as solid dosage forms. For such drugs to be absorbed and 
hence exert pharmacological action, they have to be released from the dosage form and 
dissolve in the appropriate section of the gastrointestinal tract.136 Model dependent 
methods for dissolution profile analysis and comparison attempt to determine the release 
of the active from a formulation by employing mathematical equations, which use fitted 
models to describe dissolution and the kinetics of drug release from a product in different 
areas of the gastrointestinal tract, each section signified by its appropriate dissolution 
medium. For instance, in the fasted state, the pH of the stomach is usually below 2. Soon 
after food intake, gastric pH increases to values between 4 and 7. Along the length of the 
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small intestine, the pH fluctuates between 6.5 and 7.5.137 Dissolution tests in media 
representative of these pH conditions can therefore be used to evaluate and model API 
release in various sections of the gastrointestinal tract.    
 
The release of an API from a drug product proceeds via a series of processes through which 
a drug is freed from its enclosing matrix, dissolves to form a homogenous phase, in order to 
be subjected to the pharmacokinetic processes of absorption, distribution, metabolism and 
excretion,138 and ranks as a very important process in development and consumption 
pharmaceutics. Advantage can be taken of an API’s release kinetics in order to produce a 
formulation with desired release characteristics, translating to optimum bioavailability and 
efficacy. Prediction of these desired release kinetics can be done by model-dependent 
methods of dissolution profile analysis via mathematical modelling.  
 
In mathematical modelling of drug release, abstract models are used to describe the 
processes involved in drug release. Many processes are involved in drug release, one of 
which may be drug dissolution. Dissolution, as defined by the IUPAC, is the mixing of two 
phases to form one homogenous phase, the solution. Dissolution occurs in a number of 
stages: the drug is initially wetted with water from the dissolution medium, breaking up 
solid state bonds in the drug and thereby enabling solvation of individual drug molecules. 
The individual drug molecules then diffuse through the unstirred boundary layer and 
eventually, are transferred by convection within the well-stirred bulk fluid.136 These 
processes can be represented with appropriate mathematical models. 
 
Drug dissolution is not synonymous with drug release from a matrix (Figure 2.7). 136 In Figure 
2.7 (a), the different processes involved in drug release are indicated, and how one process 
can influence and be influenced by other process(es). Figure 2.7 (b) differentiates drug 
release from drug dissolution, where the green circles represent the API present in the form 
of a solid particle, which on contact with the dissolution medium releases individualized 
drug molecules in solution (the green stars). The polymer matrix enclosing the drug (the 
shaded cylinder) may also undergo swelling to release some of the drug molecules into 
solution, well before complete disintegration of the drug product (Figure 2.7 (b): see API, i.e. 
green circle, still trapped within polymer matrix while some molecules are already in 
 
 
 
 
31 
 
solution, i.e. the green stars). Thus, various phenomena – such as water diffusion into the 
polymer enclosing the drug, drug dissolution and diffusion or swelling, dissolution and 
degradation of the polymer – may be involved in drug release.136,139 These mechanisms 
involved in drug release may in turn be affected by other processes such as polymer-drug 
interactions, pH of the dissolution medium, crystallization and pore closure such that the 
appropriate underlying mechanism may well involve a number of other processes140 as 
shown in Figure 2.7 (a).  
 
          
(a)        (b)  
Figure 2.7:    Graphics of drug dissolution showing (a) the mechanisms involved in release 
from matrix (author, not available) and (b) a comparison of drug dissolution to 
drug release from a matrix136  
 
Drug release kinetics and transport processes involved in drug release can be described with 
suitable mathematical models to estimate drug release from a formulation as well as to 
elucidate mechanisms involved in drug release.136,139,141,142 Such models give a good 
estimate of the geometry and dimensions of the required compound, and can thus be used 
to optimize drug delivery, and in regulatory settings to assess quality parameters.136,139,143,144 
 
It is pertinent to mention that there is no universally acceptable model for release of all 
drugs, and release data are usually fitted to various models in order to assess goodness of fit 
prior to selection of the best model. The accuracy of a mathematical model in predicting 
drug release increases with increasing model complexity, however, theoretical calculations 
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have to be compared with experimental results before the model of best fit can be selected. 
Model suitability may also be compromised by prevailing experimental conditions.139  
 
When modelling drug release, some equations serve to describe the release profile while 
some other equations can be used to predict the mechanism of drug release in addition to 
describing the release profile. Equations and models used to describe the release profile are 
referred to as empirical. They describe the overall shape of the release curve, not 
necessarily with any kinetic basis.145 On the other hand, semi-empirical models describe the 
shape of the curve as well as offer some explanations for the underlying drug release 
mechanism.145 Examples of semi-empirical models of drug /API release employed in this 
study are the Weibull, Peppas-Sahlin and Korsmeyer-Peppas models.  
 
The Weibull equation, previously criticized for the non-physical nature of its parameters and 
for having no kinetic basis,146 has subsequently had its model parameters re-evaluated and 
related to system geometry. It was documented that the creation of a concentration 
gradient close to the releasing boundaries of the Euclidian matrix, or the “fractal behaviour” 
attributed to the environment’s fractal geometry, was explained by the Weibull function.147 
Fractal behaviour is one that has a consistent pattern at every scale, whether scaled down 
or up. It is an integral part of fractal geometry which offers many options for the 
description, measurement and prediction of natural phenomena (such as may be 
encountered in dissolution studies) using mathematical equations.148,149 It can thus be 
applied to biological systems and processes which typically consist of many levels of 
substructure, with a consistent pattern at every scale.  
 
A third model classification, the mechanistic models of drug release, can be used to predict 
dissolution profiles without the need for conduction of dissolution tests. This is due to the 
fact that physical properties of the API such as solubility and density are components of the 
model equation.145 Semi-empirical or semi-mechanistic models are superior to either 
empirical or mechanistic models alone. This superiority of the semi-mechanistic model holds 
as long as the capacity for curve fitting and underlying process prediction is not 
endangered.150   
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Equations for the various models that can be employed to evaluate drug release are given in 
Table 2.1, and a brief description of each model follows. Descriptions of the parameters in 
the model equations are explained in Zhang et al.151 In all the model equations, F represents 
the fraction of drug (dissolved) in solution, Fmax represents the percentage of drug released 
at infinite time, t represents time and Tlag represents the time before onset of drug or API 
dissolution.    
 
Table 2.1:   Mathematical equations for models describing release of active 
pharmaceutical ingredient (API) from its matrix  
 
Model Equation Parameters  
Zero order         k0 
First order          (         ) k1 
Weibull_1 
         [      
(    )
 
 ] 
α, β, Ti 
Weibull_2          (      
  
 ) α, β 
Weibull_3         (    
   
 
 ) α, β, Fmax 
Weibull_4 
        [    
  
(    )
 
 ] 
α, β, Ti, Fmax 
Makoid-Banakar with Tlag        (       )
 
       (      )    kMB, n, k, Tlag 
Peppas-Sahlin 1 with Tlag      (      )
 
    (      )
  
 k1, k2, m, Tlag 
Logistic_2 
        
        ( )
           ( )
 
α, β, Fmax 
Logistic_3 
        
 
       (    )
   K, γ, Fmax 
Korsmeyer-Peppas         
  kKP, n 
Korsmeyer-Peppas with Tlag        (      )
 
  kKP, n, Tlag 
 
2.6.2.3.1   Zero order kinetics 
Release of active pharmaceutical ingredient (API) from a matrix that does not disintegrate, 
but releases the drug slowly over time can be described by zero order kinetics. The fraction 
of the API dissolved in time t is given by the equation:  
 
 
 
 
34 
 
        
where k0 is the zero order release constant. The same amount of API is released per unit 
time, and this model is ideal when the API is required to achieve prolonged pharmacological 
action.152 
 
                                                 
Graphical representation of zero order release model 
 
2.6.2.3.2   First order kinetics 
In first order release kinetics, the rate of API release is dependent on a concentration 
gradient set up between the concentration of the solute and its solubility in time, t. Release 
of API is concentration dependent, and can be given by the equation:153,154  
         (         ) 
    
where k1 is the first order release constant. 
       
Graphical representation of the first order release model 
 
2.6.2.3.3   The Weibull models  
This model was first described by Weibull in 1951 and later modified to suit the release 
process by Langenbucher.155 The equation for the Weibull model can be successfully applied 
to most release curves and is commonly encountered in dissolution studies.146 According to 
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this equation, the cumulative fraction of API released from dosage forms in solution, at time 
t, is given by:  
    [      
(    )
 
 ] 
 
The parameter, Ti, represents the lag time before onset of the release process and is usually 
zero. The shape parameter, represented by b, describes the release curve as exponential 
(b=1) (case 1); sigmoidal (b>1) (case 2), when the curve exhibits an S-shape with an upward 
curve followed by a turning point; or parabolic (b<1) (case 3), when the initial part of the 
curve is steeper than obtained with the exponential curve; while the scale parameter, α, 
describes the time scale of the process.  
 
                                               
 Graphical representation of Weibull release model 
 
This model has been criticised for being too empirical with little or no kinetic basis to explain 
API release.156 However, it usually gives very good fit for most dissolution data,146 and 
portions of the release curve obtained can be used to evaluate API release by modelling it to 
the desired semi-empirical model. At least four different modifications of the Weibull model 
are available for fitting API release data. These differ in terms of the presence or absence of 
the parameters, Ti and /or Fmax, and yield slightly different model parameter values for the 
same data set. The exponent of time, β, in the Weibull equations can serve as an indicator 
of release mechanism of a drug through a polymer matrix, according to the values below:147   
Interpretation of release mechanisms from polymeric systems using the Weibull function 
Time exponent, β Solute release mechanism 
β ≤ 0.75  Fickian diffusion in fractal or Euclidian spaces 
0.75 < β  < 1 Combined release mechanism 
β > 1 Complex release mechanism 
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2.6.2.3.4   The Makoid-Banakar with Tlag model 
This was developed by Dr.s Makoid and Banakar,157 both pharmaceutical scientists. The 
Makoid-Banakar function is represented by:  
       (       )
 
       (      )    
where kMB, n and k are empirical parameters of the model. These parameters are limited by 
the fact that total drug /marker compound dissolution must occur at the same time as the 
maximum value of the Makoid-Banakar function.157 The Makoid-Banakar with Tlag model 
differs from the original Makoid-Banakar model by the inclusion of the parameter, Tlag, 
which represents the time before onset of drug release.   
 
                                                 
Graphical representation of the Makoid-Banakar release model 
    
 
2.6.2.3.5   Peppas-Sahlin 1 with Tlag model  
Peppas and Sahlin (1989) proposed that:158 
 
     (      )
 
     (      )
  
 
According to the Peppas-Sahlin equation, drug release can be governed by diffusion or 
relaxation depending on the values of the parameters kd and kr, representing the release 
rates of polymer diffusion and relaxation respectively, and the coefficient, m, with values 
between 0 and 1 in most cases.151,158 Like the Makoid-Banakar with Tlag model, this model 
differs from the original Peppas-Sahlin model by the inclusion of the parameter, Tlag.   
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Graphical representation of the peppas-Sahlin release model 
 
2.6.2.3.6    The Logistic models  
These are also empirical models, and lack significant kinetic properties. These models are 
valid only when the value of t exceeds zero.159 Two of these models, Logistic_2 and 
Logistic_3 are represented by the respective equations:   
 
        
        ( )
           ( )
  
and    
        
 
       (    )
   
where α and β describe the scale factor and shape parameter respectively, k is the 
dissolution rate constant, and γ is the time at which     
    
 
 . 
 
     
 Graphical representation of the logistic release model 
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2.6.2.3.7   Korsmeyer-Peppas with Tlag model  
Korsmeyer et al. developed a relationship describing drug release from polymeric 
systems.160 It is widely used to describe the kinetics of drug release from formulations. For 
the Korsmeyer-Peppas relationship,  
  
  
      
 
where    
  
  
  = the fraction of drug released at time t,  
 k  = the rate constant  
      and n = the release exponent 
 
For this model to work effectively, the fraction of drug released at time t, Mt /M∞, to be 
fitted to the model, should not exceed 60 %. This is so as to clearly determine the principal 
mechanism of drug release before a combination of other mechanisms become involved, 
usually seen beyond the 60 % portion of the curve.   
                
              Graphical representation of the Korsmeyer-Peppas release model 
                  
With this model, the value of the release exponent (n) characterises release mechanism for 
the compound of interest, depending on the shape of the enclosing matrix. For cylindrical 
shaped systems, which we can assume are represented by cylindrical tablets and capsule 
dosage forms, release is according to the mechanisms outlined for the range of values given 
below. Release exponent values are slightly different for release from polymeric systems of 
a different shape, e.g. circular flat-topped tablets.  
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Interpretation of release mechanisms from polymeric systems of cylindrical shape, using the 
Korsmeyer-Peppas function 
 
Release exponent 
(n) 
Solute release mechanism Rate as a function 
of time 
0.45  Fickian diffusion  t-0.5 
0.45 < n < 0.89 Anomalous (non-Fickian) diffusion t n-1 
0.89 Case-II transport Zero order release 
n > 0.89 Super case-II transport t n-1 
 
No dissolution model is universal for all drug dissolution profiles, and so several models are 
usually fitted in order to select the model of best fit. Such selections are made after careful 
consideration of statistical criteria for evaluating a model’s goodness-of-fit. Such criteria 
include the coefficient of determination (R2), the adjusted coefficient of determination 
(R2adj), the Akaike Information Criterion (AIC), the mean square error (MSE) and the sum of 
squares (SS).  
 
2.6.2.4   Model independent methods 
Model independent methods have been described as the most suitable for dissolution 
profiles comparison when at least three to four dissolution time points are available.  They 
include the ratio tests, the difference and similarity factors (f1 & f2) which are also referred 
to as the pair wise procedures, and the multivariate confidence region procedure or 
bootstrap approach.126,146 
 
2.6.2.4.1 Ratio test procedures 
The ratio test procedures relate dissolution parameters between reference and test 
formulations. These parameters may include the percent dissolved at time t, the area under 
the dissolution /release curves (AUC) or the mean dissolution time (MDT).146 For the 
purposes of this study, the ratio test procedures were not employed in dissolution profiles 
comparison.   
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2.6.2.4.2   Pair wise procedures 
The pair wise procedures include the Rescigno index, the difference factor (f1) and the 
similarity factor (f2). These procedures calculate the similarity or difference between two 
dissolution profiles at different time points.146 To allow for the use of average data when the 
pair wise procedures are employed for dissolution profiles comparison, the percent 
coefficient of variation (% CV) should not be more than 20 % at earlier time points and not 
more than 10 % at other time points. With herbal medicinal products where the ratio of the 
actives may vary depending on a number of circumstances, maintenance of the % CV limit 
may pose a challenge. In such cases, where the % CV is more than 15 % within batches, a 
multivariate model independent procedure may be employed.126 For the purposes of this 
study, the Rescigno index was not employed in dissolution profiles comparison, and brief 
descriptions of the pair wise procedures so employed follow.   
 
2.6.2.4.2.1 The difference factor, f1 
The difference factor, f1, assesses the difference in percentage dissolved from the reference 
and test products at the sampled times, and can be mathematically computed using the 
equation:      
 
   {
∑        
∑   
 
   
}      
 
where Rt and Tt are the mean percent dissolved at each time point for the reference and 
test products, respectively, and n is the number of observations /dissolution sample times 
being considered for the computation. An f1 value between 0 and 15 indicates similarity of 
two dissolution profiles while values outside this range indicate dissimilarity.126 
 
2.6.2.4.2.2   The similarity factor, f2 
The similarity factor, f2, is defined as a logarithmic reciprocal square root transformation of 
the sum of squared error. Unlike the difference factor, the similarity factor is a 
measurement of the similarity in percent (%) dissolution between two dissolution curves.126 
The similarity factor is computed from the formula:  
 
 
1 
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(
 
   
√[  
 
  
∑   
 
    (     )
 ])
  
 
where the parameters, Rt, Tt and n are as described for the difference factor, f1. Because f2 
has been found to be more sensitive than the f1 for dissolution profile similarity, it is 
approved by the FDA for comparison of drug dissolution profiles.135 An f2 value between 50 
and 100 indicates similarity of two dissolution profiles while values less than 50 indicate 
dissimilarity.126 
 
The calculated value of either f1 or f2 depends on which of the formulations is considered 
the reference; on interchanging the test and reference formulations, different results may 
be obtained for the f1 
146 and most likely, the f2.   
 
2.6.2.4.2.3 Modifications and enhancements of the similarity factor proposed for study 
The similarity factor, though suitable for the comparison of dissolution profiles, is 
dependent on certain conditions: (1) identical sampling times are necessary, (2) only one 
time point can be considered after 85 % dissolution of one of the products, and (3) of crucial 
interest to herbal medicinal products, the coefficient of variation may not be greater than 
20 or 10 % at earlier and later time points, respectively. The last point has been observed 
with some herbal products,23,24 and when this condition is not met, the f2 value may not be 
successfully utilized for dissolution profiles comparison as the value obtained may be biased 
in favour of similarity. The f2 has also been found not to be discriminating enough, and 
rather too liberal in concluding similarity between dissolution profiles.146 Because of these 
limitations, several authors have proposed modifications to the f2 equation, and such 
modified f2 equations are proposed for dissolution profiles comparison in samples with 
variation beyond the limit stipulated for original f2 computation.
131,161-164     
 
A modified f2 method may use weighting factors to calculate the effect of variation on the 
similarity of two dissolution profiles, giving a value for similarity, just like the similarity 
factor.161,162,165 Such modifications which make accommodation for within sample variation 
may present better approaches for dissolution profiles comparison of reference marker 
2 
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compounds from herbal materials, where wide intra-batch variation has been noted as a 
limitation to the use and quality control of these products.23,24 Two of such proposed 
modifications employed in this study are briefly discussed below.  
 
2.6.2.4.2.3.1 Gohel’s f2 
Gohel et al. proposed and later modified an equation for the similarity factor.161,162 This 
modified equation incorporates a scheme which calculates weight to accommodate for the 
effect of within sample variability on f2 values.
161,162 According to this scheme:  
 
        
(
 
   
√[       ∑   
 
   (     )
 ]
)
  
 
where w t is the weight factor due to variability within samples, and is calculated thus:  
w t  = 1  +  {(%CV of Rt ) /(MCV E/L )}  +  {(%CV of Tt )/(MCV E/L )}  
% CV of Rt and %CV of Tt are the percentage coefficients of variation for reference and test 
products, respectively; MCV E/L is the maximum allowable % CV; and the percent coefficient 
of variation, % CV = (standard deviation /mean) x 100.  
 
2.6.2.4.2.3.2 Median f2 
In this study, we propose another as-yet undocumented modification of the similarity factor 
for dissolution profiles comparison, especially in cases where variation is beyond the limit 
stipulated for original f2 calculation. This modification is the median similarity factor which 
employs the median (as opposed to the mean) values of the percentages dissolved at each 
sampling point for dissolution profiles comparison. By virtue of being more robust than the 
mean to the presence of outliers, the median-f2 may give a more discriminating value of the 
similarity factor than the original f2 for samples with considerable within-batch variation. 
 
 
  
2.6.2.5    Principal Component Analysis (PCA) for dissolution data 
Principal Component Analysis (PCA) is a multivariate method of data analysis which assesses 
the underlying structure of a set of data in order to determine the direction(s) responsible 
2 
n 
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for most of the variation in the data. In PCA, multiple variables determined in a study can be 
reduced to a minimum number of variables, called principal components, which account for 
most of the variation in the data. The major aim of PCA is therefore to reduce data 
dimensionality by extracting the smallest number of components that explain most of the 
variation in the original multivariate data, summarizing the data with these components and 
with as little loss of information as possible. This simplifies data for easier interpretation.  
 
The results of a PCA are presented as loadings and scores plots. The loadings plot shows the 
relationship among variables, assessing the contribution of each variable to data variation; 
while the scores plot projects the data onto the hyperspace, showing the relationships 
among data samples. While variables with high correlation are close to each other on the 
loadings plot, variables with negative correlation are seen on opposite sides (Figure 2.8 a). 
On the scores plot, objects are clustered according to their attributes (Figure 2.8 b) and 
objects on one side, e.g. the right side of the score plot, are dominated by variables on that 
side (Figures 2.8 a & b). 
 
PCA can thus be employed for analysis of dissolution data, where the sampling times can be 
seen as multiple variables, each variable (sampling time) accounting for a different 
dimension to the data. As such, the contributions of the variables (different sampling points) 
to the dissolution profiles of materials can be assessed. Sampling times that are similar will 
cluster together and a decision can be made to select the most relevant time points from 
the sample cluster, thereby removing redundant variables (in this case, sampling times) 
from subsequent dissolution tests. From cluster analysis of the scores plot, the more 
influential factor determining API release, i.e. type of S. frutescens material or the physico-
chemical properties of the APIwill be projected.  
 
From literature, it can be seen that no single approach is universally accepted for the 
comparison of dissolution profiles,131,134,146 which may be applied to pharmaceutical 
products. The different methods discussed herein will all be used to analyse dissolution data 
of marker compounds of S. frutescens materials in order to explore the strength of each 
method, and to determine which of the methods is the most suitable for dissolution data 
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analysis. However, it is important to ascertain the level of discrimination required prior to 
selection of any comparison method.  
 
 
(a): A loadings plot of data after principal component analysis 
 
 
(b): A scores plot of data after principal component analysis 
Figure 2.8: Examples of loadings and scores plot of data after principal component analysis 
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2.7   Consideration aspects for dissolution tests of S. frutescens materials  
The drug dissolution test is an official quality control test designed to evaluate drug release 
and dissolution within the gastrointestinal tract. Generally, it is conducted according to 
specifications set out in the pharmacopoeia.120 These specifications may be modified as 
necessary, though such modifications need to be validated.121 Depending on the part of the 
GIT where the drug is expected to be dissolved, dissolution tests can be conducted using 
different media and conditions that mimic different sections of the gastrointestinal tract 
(GIT).83  
 
With dissolution testing, volumes of dissolution media between 500 and 1000 ml are 
commonly used, 900 ml being the most common volume. In cases where the label claim is 
less than 5 mg or if marker compounds have less absorbance at the selected wavelength, 
the dissolution volume can be reduced in order to enhance the sensitivity of the 
method.126,166 The appropriate volume of a dissolution medium to use is however defined 
based on sink conditions. The ultimate goal in the choice of medium volume for dissolution 
testing is to obtain a discriminative method, and this is usually done experimentally. 
Sometimes, the discriminative dissolution test may even be obtained by violating sink 
conditions.167  
 
For dissolution testing of S. frutescens materials, the common mode of use of this plant in 
traditional settings was considered. Traditionally, S. frutescens is used in the form of a tea. 
In a tea, the water soluble flavonoid glycosides would be more easily released than the non-
water soluble aglycones, and hence more abundant. In dissolution testing which imitates 
the traditional conditions of use by virtue of the dissolution medium which is aqueous, the 
flavonoid glycosides would presumably be more concentrated and hence more available 
than the flavonoid aglycones. As such, it is envisaged they will serve as better marker 
compounds than the aglycones, for quality control of herbals containing this plant.         
 
Four of these flavonoid glycoside compounds have been isolated and identified as possible 
markers for S. frutescens products.51 These are sutherlandins A, B, C and D (Figure 2.7). They 
contain the same 3-hydroxy-3-methylglutaroyl (HMG) moiety.51 The major differences are in 
the aglycone and sugar identities. Sutherlandins A and C are derived from 2 different 
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aglycones, quercetin and kaempferol, respectively; however, they possess the same sugar 
molecule attached to an HMG moiety. Similarly, sutherlandins B and D, derived from 
quercetin and kaempferol respectively, possess the same sugar molecule (though this is 
different from that of sutherlandins A and C) attached to an HMG moiety. Since the sugar is 
known to influence aqueous solubility and hence dissolution,168,169 we hypothesize that the 
dissolution profiles of sutherlandins A and C from the different S. frutescens materials will 
be similar. Likewise, the dissolution profiles of sutherlandins B and D from the S. frutescens 
materials will be similar, though different from that of sutherlandins A and C. Such 
differences may also translate to differences in in vivo pharmacokinetics, which may 
influence the outcome of the upcoming clinical trial of S. frutescens. As such, the 
pharmacokinetics of the marker compounds will also be briefly discussed.   
 
 
2.8        Pharmacokinetic models and pharmacokinetics of flavonoids  
Immediately after API release and subsequent dissolution in the appropriate dissolution 
medium, the API is absorbed, commencing its pharmacokinetic journey. Pharmacokinetics 
refers to the study of the factors that affect the amount and time course of a substance at 
its site of action. It encompasses the fate of such a substance, for instance, a drug substance 
in the body, from absorption to the irreversible loss of the drug or its metabolite via 
excretion.  The four pharmacokinetic processes are absorption, distribution, metabolism 
and excretion (ADME).170 Parameters representing these processes can be determined with 
the use of suitable in vitro in vivo correlation (IVIVC) models.  
 
The determination of pharmacokinetic parameters is an important part of any API product 
development study. Such pharmacokinetic parameters can be deduced from in vivo human 
studies such as the upcoming clinical trial of S. frutescens. However, in vivo studies can be 
time consuming, expensive (not only financially, but also in terms of human and animal life 
and health), and in some cases, ethically unjustifiable. Because of these limitations, the 
pharmaceutical industry is constantly on the lookout for effective alternatives for 
determination of pharmacokinetic parameters, so-called in vitro in vivo correlation tools.171  
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In vitro in vivo correlation is defined by the FDA (1997) as “a predictive mathematical model 
that describes the relationship between an in vitro property of a dosage form and an in vivo 
response”. Such models can be used to determine and assess parameters involved in drug 
/API absorption, as well as other pharmacokinetic processes. Knowledge gained from IVIVC 
studies can be employed in drug manufacturing, saving time during development and 
optimization studies.172 IVIVC is also seen as an alternative to in vivo bioequivalence studies. 
As such, it can be employed by drug regulatory agencies, such as the MCC of South Africa, in 
product regulation.172 As helpful as it may be, it is pertinent to mention that an IVIVC 
relationship is not an absolute correlation, and does not automatically imply causality 
between in vitro and in vivo data;171 it is merely a simulation. 
A simulation is an imitation of the operation of a real world process or system over time. 
The aim of a simulation is to predict expected outcomes, and to give insight into the working 
of a process that cannot easily be visualized or experienced. For a simulation to work and 
predict accurately, a model which represents the key characteristics of the process or 
system, is developed. Such models are designed based on theories that explain the process 
or system to be simulated. This saves considerable time and money when compared to 
performing replicate tests on a real life design over time. In addition, extensive details on 
the workings of a process or system can be obtained from simulations.173 
 
Recent simulations that can be used to predict expected pharmacokinetic outcomes in API 
product development studies are in vitro dissolution studies, the Biopharmaceutics 
Classification System (BCS) as well as various mathematical models and validated simulation 
programmes such as the Molecular Operating Environment (MoE).  
 
 
2.8.1 The Biopharmaceutics Classification System (BCS) 
The Biopharmaceutics Classification System (BCS), devised by Amidon et al., is a scientific 
framework for classifying drug substances based on their aqueous solubility and intestinal 
permeability (Figure 2.9).122 According to this system, APIs  are classified into one of four 
groups based on their solubility and permeability profiles. Class I compounds exhibit high 
aqueous solubility and high intestinal permeability while class IV compounds exhibit low 
aqueous solubility and low permeability. Between these two classes are the class II and III 
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compounds: class II compounds exhibit low solubility but high permeability while class III 
compounds show and high aqueous solubility and low intestinal permeability. 
   
Figure 2.9:  The Biopharmaceutics Classification System (BCS) 
 
The BCS finds extensive employment in drug development studies and has been widely 
recognised and accepted in academic, industrial and regulatory settings.177 In such settings, 
it serves as a guide for predicting intestinal drug absorption by estimation of the 
contributions of three major factors – dissolution, solubility and intestinal permeability – 
that affect oral drug absorption from immediate release (IR) solid oral dosage forms.178,179 
These factors (dissolution, solubility and intestinal permeability) can therefore be used to 
predict product bioavailability.  
 
With respect to bioavailability prediction, certain drug products can be considered for 
biowaivers, i.e. approving the product based on in vitro dissolution tests, rather than 
requiring bioequivalence (BE) studies in human subjects.180 This is because a product’s 
dissolution rate within the gastrointestinal tract is known to influence its absorption rate; 
therefore, the drug dissolution test can be used to highlight cases in which different 
formulations may not be bioequivalent.181 When using in vitro dissolution testing as a 
substitute for in vivo bioequivalence, two formulations are deemed therapeutically 
equivalent if their dissolution profiles are similar. Thus, for an immediate release (IR) orally 
administered formulation that is rapidly dissolving and contains a class I active 
pharmaceutical ingredient (API), a biowaiver may be granted for the generic product on the 
basis of acceptable dissolution data.123,127 A biowaiver has also been proposed for class III 
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compounds that do not contain excipients which may interfere with gastrointestinal transit 
or absorption.182  
 
 
2.8.2   The Molecular Operating Environment (MoE)   
Due to long held beliefs on its many reputed therapeutic properties, especially in the 
management of HIV infection,60 preparations are underway for a clinical trial to assess the 
efficacy of the popular South African herb, S. frutescens, in HIV patients. Prior to this, a 
phase I pharmacokinetic study of S. frutescens will be conducted to assess the level and 
profiles of appropriate reference and marker compounds in plasma. Previous studies 
identified flavonoid glycosides as appropriate markers for assessment of products 
containing this plant;51 however, the plant is also known to contain aglycones of these 
flavonoid glycosides, specifically quercetin and kaempferol.  
 
While extensive studies have been conducted on flavonoids and their pharmacokinetics 
especially with respect to absorption, controversies are still rife over which form of the 
flavonoid (glycoside, aglycone, both) is actually absorbed. Such absorption is necessary for 
the ‘active components’ of the plant to exert pharmacological and hence therapeutic 
activity. As a product with purported therapeutic effects, S. frutescens can be viewed as a 
pharmacological agent (a drug). Tests and procedures used to assess pharmacological 
activity, and tests used to assess drug pharmacokinetics can therefore be applied to 
products of this plant. Such tests can be used to evaluate the bioavailability of S. frutescens 
products. 
 
The oral bioavailabilty of drug candidates is a key parameter in assessing their likelihood to 
succeed in the drug development process, and recently, is now used to assess the ‘drug 
likeness’ of a molecule. For such assessments, chemoinformatics and computational 
resources are utilized to integrate ‘development’ activities into early stage drug discovery. 
Through modelling and simulation, drug candidates with possible theoretical bioavailability 
are selected for the drug discovery process, while drug candidates that do not meet the 
common criteria found in most successful drug molecules are withdrawn from the discovery 
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process, cutting costs and time, as well as reducing new drug molecule attrition rates in the 
pharmaceutical industry.183 
 
The Molecular Operating Environment (MoE) is one such chemoinformatic and 
computational resource for assessment of possible drug molecules. One of the drug 
properties that can be assessed by the MoE is the bioavailability of a substance under 
consideration as a new drug molecule. For bioavailability assessment, specific physico-
molecular characteristics of the compound of interest are calculated, and used to predict 
the bioavailability or otherwise of compounds. The desired physico-molecular 
characteristics for oral drug bioavailability were summed up by Lipinski et al. in their popular 
proposal, “The Rule of 5”.184 According to this rule, successful new drug candidates for oral 
administration should not violate more than one of the following criteria:  
- Not more than 5 hydrogen bond donors (the total number of nitrogen-hydrogen and 
oxygen-hydrogen bonds) 
- Not more than 10 hydrogen bond acceptors (all nitrogen or oxygen atoms) 
- A molecular mass of less than 500 Daltons 
- An octanol-water partition coefficient, log P, not greater than 5 
 
This rule has also given rise to other extensions. An example of such an extension is “The 
Rule of 3” proposed by Congreve et al.185 The Rule of 3 proposes that for new drug 
candidates to succeed in the drug development process, they should possess the following 
characteristics:185  
- Molecular weight not more than 300 
- Hydrogen bond donors not more than 3 
- Hydrogen bond acceptors not more than 3   
- C log P value of not more than 3 
 
The desired characteristics so-listed by Lipinski and others can be calculated from the 
structural formula of each compound by MoE and used to predict in vivo pharmacokinetics 
(e.g. bioavailability) of selected marker compounds such as the flavonoids from S. 
frutescens.  
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2.8.3   General  ADME  profiles of flavonoids 
Extensive studies have been conducted on flavonoid absorption; however, controversies are 
still rife over which form of the flavonoid (glycoside, aglycone, both) is actually absorbed. 
Gastrointestinal absorption is thought to be dependent on intestinal microflora, which 
hydrolyse glycosides into readily absorbable aglycones.111,186 While it has been a long held 
belief that flavonoid aglycones are more readily absorbed, unlike the flavonoid glycosides 
which are poorly so, some reports have indicated otherwise and even reported that the 
sugar moiety, to a great extent, determines the absorption of dietary flavonoid glycosides in 
man.187,188  
Animal studies and in vitro studies suggest that flavonoid glycosides and aglycones are 
rapidly and intensively metabolized. Phase I metabolic reactions are likely, however, 
conjugation reaction with sulphate and /or glucuronic acid seem to be the most common 
metabolic reaction for flavonoid metabolism.94,189  
 
Very low amount of flavonoids have been recovered in the urine of animals after 
administration, indicating extensive metabolism to other compounds, while suggesting that 
the renal route is not a major pathway for excretion of intact flavonoids.190  
 
2.8.4   Pharmacokinetics of flavonoids present in S. frutescens 
The flavonoid aglycones under study, quercetin and kaempferol, belong to the subclass of 
flavonoids called the flavonols. These two compounds exhibit low solubility in aqueous-
based solvents.191,192 Due to their amphipathic nature, flavonoids can partition into or bind 
lipid layers;193 kaempferol is known to exhibit good permeability, driven by concentration 
gradient, across the membranes in Caco-2 studies while quercetin has its permeation 
limited only by extensive intestinal and /or hepatic glucuronidation.194-197 With their low 
solubility and high permeability, they may be classified as BCS class II agents.  
 
The flavonoid glycosides, on the other hand, exhibit high solubility, possibly due to the 
presence of the sugar molecule attached to the aglycone. These compounds are thought to 
be transported paracellularly. This may account for their low permeability, as most 
flavonoids are known to be transported transcellularly, either by passive diffusion or carrier-
mediated flux. Furthermore, the addition of a sugar moiety increases the molecular size and 
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number of hydroxyl groups, hindering flavonoid glycoside transport across cell 
membranes.198,199 With their high solubility and low permeability, the flavonoid glycosides 
may be classified as BCS class III agents. In the presence of fast-dissolving or uncritical 
excipients, it is envisaged that they will readily penetrate membranes.182 However, the 
different matrices within which the flavonoids are trapped in different S. frutescens 
formulations (i.e. leaf powder, spray-dried and freeze-dried aqueous extract) may affect 
their candidature for class III BA/BE waiver.  
 
 
In summary, herbal medicinal products have contributed to new drug discovery, both in the 
past and recently. As such, their use in the treatment and management of human ailments 
is becoming more popular. One of such products is the popular South African medicinal 
plant, S. frutescens, which has been used for over a century in South Africa for a wide range 
of illnesses. Its use has been boosted by in vitro studies that validate its use in treatments as 
well as in vivo studies that have reportedly shown no undue toxic effects from its 
consumption. Due to its many reputed benefits, arrangements are underway for a clinical 
trial to assess its efficacy. However, it is necessary to be able to assess and compare the 
quality of different S. frutescens materials in order to find the most appropriate one to be 
used in such a trial, therefore, the need to develop quality control tests and specifications 
for S. frutescens products. Such quality assessment will also be of use in setting regulatory 
specifications for S. frutescens materials. The theories behind such quality control tests have 
been presented in this chapter. The next chapters detail the rationale for each test chosen 
and how these will be conducted.  
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CHAPTER THREE 
 
PLAN OF WORK 
 
In this chapter, the main research question(s) and specific objectives that are to be pursued, 
as well as the hypotheses to be tested are presented. The study approach to be followed is 
also discussed.   
 
3.1  The main research questions 
Various forms of Sutherlandia frutescens materials, e.g. leaf powder, aqueous extracts, gels 
and tonics to mention a few, are commercially available and popularly used for the 
treatment of many ailments. Despite its popularity, not much is known about the quality 
and stability of its various forms available in commercial settings. The quality and stability 
may also have a marked influence on the content, release and in vitro dissolution of actives 
and subsequent performance of its various forms. The different forms of the plant contain 
flavonoids which might contribute to the possible pharmacological activities of the plant, 
and hence can be used to assess quality and by extension, efficacy.   
The primary research questions for which answers are needed are as follows:  
 
- Would the flavonoids be suitable marker compounds for assessment of S. frutescens 
quality?  
- Can the quality of different S. frutescens materials be assessed or compared based 
on the flavonoid content and release /dissolution of such flavonoids?  
 
To answer these questions, a suitable assay which can be used to assess flavonoids in S. 
frutescens materials and in dissolution media would be required. A major objective in the 
assay development is the isolation and identification of non-commercially available 
flavonoid glycosides which can serve as markers for products of this plant. In addition, there 
exists a need for a suitable dissolution test which can differentiate between S. frutescens 
materials. A suitable dissolution test in this context refers to the actual dissolution test itself 
as well as the methods employed for analysis of dissolution data. There is also a need to 
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predict oral bioavailability of selected flavonoids as a means of assessing bioequivalence of 
different S. frutescens products.   
 
3.2 Study aims and objectives 
The overall aim of the study was to develop quality control tests which can be employed in 
regulatory settings for assessment of S. frutescens materials. The specific objectives of the 
study were:  
- to isolate and identify non-commercially available flavonoid glycoside compounds 
for S. frutescens assay, 
- to develop and validate an HPLC assay for flavonoids in S. frutescens, 
- to determine and compare flavonoid levels in different S. frutescens materials (leaf 
powder or extract, also called active herbal ingredient [AHI] or active phyto-
pharmaceutical ingredient [APPI]), 
- to compare dissolution profiles and underlying release mechanisms of flavonoids 
from different S. frutescens materials, and  
- to predict in vivo bioavailability of flavonoids. 
 
3.3 Hypotheses 
The following specific hypotheses are postulated: 
a. Flavonoid content: The percentage content of the flavonoid glycosides will be more 
than that of the flavonoid aglycones in each S. frutescens material.  
  
b. Flavonoid dissolution:  
i. Irrespective of the S. frutescens material, the flavonoid glycosides will have a 
higher dissolution rate than the flavonoid aglycones, i.e.  
Q75
 (flavonoid glycosides)   <   Q75 
(flavonoid aglycones)    
ii.  With respect to the S. frutescens materials, flavonoid dissolution rate from 
the extracts (SDAE and FDAE) will be higher than flavonoid dissolution rate 
from the LP material, i.e. 
Q75
SDAE   =   Q75
FDAE   <   Q75
LP 
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c. Mechanism of flavonoid release prior to dissolution: This will depend more on the S. 
frutescens material than on the physicochemical properties of the flavonoid marker 
compounds, i.e. from each S. frutescens material, release of different flavonoid 
marker compounds will be by the same mechanism irrespective of the 
physicochemical properties of each specific marker compound.  
  
3.4:   Study approach and justification 
3.4.1 Selection of different S. frutescens materials 
 What materials and why those? 
The different materials chosen were the leaf powder (LP), spray-dried aqueous extract 
(SDAE) and freeze-dried aqueous extract (FDAE) materials. These were selected because 
they were produced by different methods and hence constitute part of the different S. 
frutescens materials that are commercially available. The material to be used for the 
upcoming clinical trial will also be selected from one of these.  
 
3.4.2 Selection of marker compounds to monitor  
 Why flavonoids?  
Flavonoids were chosen because some of the biological effects of S. frutescens, especially 
the antioxidant effects, have been attributed to flavonoid compounds.16,200,201 As such, they 
can be seen as active components of S. frutescens, and have the potential to serve as 
marker compounds for its products.16,17,51 Both the glycosidic and aglycone forms of 
flavonoids are known to exist in this plant. Because of differences in flavonoid glycoside and 
aglycone chemistry, they can be said to be representative of the different forms under 
which active components of S. frutescens might occur in different conditions, e.g. storage 
and environmental conditions, and so can serve as appropriate references for quality, 
stability and efficacy assessment.  
 
 Which flavonoids were chosen? Why were these flavonoid compounds chosen?  
A total of nine flavonoid compounds were selected for assay development. Five of the 
compounds (the glycosides: rutin, kaempferol-3-O-rutinoside, quercitrin; and the aglycones: 
quercetin and kaempferol) were purchased commercially. Three of these five compounds 
(rutin, kaempferol-3-O-rutinoside and quercitrin), though not yet conclusively identified in S. 
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frutescens, were selected because they are glycosides of the aglycones present in S. 
frutescens and so may also be present in the plant. The other four compounds selected 
were the flavonoid glycosides, sutherlandins A to D, which though not yet commercially 
available, have been isolated and identified from S. frutescens material as possible quality 
control markers.51  
 
 What did these choices entail (e.g. also required isolation of marker compounds)? 
The flavonoid glycosides, sutherlandins A to D, were isolated from S. frutescens SDAE. 
Isolation of flavonoid glycosides for analytical studies has not always been common practice 
in herbal product analysis. Flavonoid glycosides arise from a limited number of flavonoid 
aglycones; however, the flavonoid glycosides derived from the few aglycones are varied and 
extensive in number. Because of their large number, it is not always possible to obtain 
commercial quantities of the flavonoid glycosides for analytical purposes. To address this 
shortcoming, previous studies usually quantified flavonoid glycosides in terms of their 
corresponding aglycones, to which the glycosides have been acid-hydrolysed for such 
purpose.87,95 Such hydrolysis reduces the number and variety of flavonoid compounds 
available, simplifying analysis.202  
 
However, plant material may be adulterated with pure flavonoid glycoside or aglycone 
compounds, or even other flavonoid-containing plant materials, which may not be detected 
following acid hydrolysis of flavonoid glycosides. Acid hydrolysis of flavonoid glycosides may 
also result in degradation of other phenolic compounds present, with the result that the 
true flavonoid content and arrangement in plant materials may be misrepresented.107,203 In 
addition, acid removal following hydrolysis of flavonoid glycosides to aglycones may pose 
considerable challenges. These limitations of flavonoid glycoside assay via the flavonoid 
aglycones therefore behoves us to identify and quantify individual flavonoid glycosides and 
not just the flavonoid aglycones present in plant samples, as a means of assessing quality of 
the plant materials.204  
 
An ideal approach may therefore be to isolate and purify the appropriate glycosides from 
the plant, and then use these for quantification purposes. This would also be a better option 
especially for aqueous-based quantification studies where the flavonoid glycosides are more 
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concentrated than the aglycones in the extracting solvent and so may be easier to detect, 
making them more suitable marker compounds for reversed phase high performance liquid 
chromatographic (HPLC) analysis. 
 
 Why HPLC (and what criteria should  the HPLC method comply with)? 
For this study, an assay that will separate flavonoid glycosides from aglycones and all 
detectable flavonoids from each other had to be developed. It should be noted that as 
different formulations and dosage forms of S. frutescens are commercially available, so also 
are their matrices. Because of this, conditions have to be selected and optimized in order to 
allow for separation of the compounds of interest in the presence of other chemical 
constituents. The HPLC assay technique was employed due to its ability to separate and 
analyse multiple components present in plant matrices.18  
 
A good HPLC method for S. frutescens materials should be simple and reproducible. It 
should be able to separate all nine selected compounds as this will result in good separation 
in plant material where other yet unknown compounds may also be present in the plant 
matrix.  
 
3.4.3 Determination of content levels and dissolution profiles of marker flavonoids from 
different S. frutescens materials  
 Why content levels?  
Flavonoid glycosides and aglycones possess different structures and chemistries. In plant 
material, most flavonoids exist in the glycosidic form with a sugar molecule attached to the 
flavonoid aglycone structure. In unstable conditions, e.g. exposure to acid, heat or light, the 
flavonoid glycosides may be degraded or converted to the aglycones.21 Therefore, 
assessment of flavonoid glycosides and aglycones, and their levels in products, will give an 
indication of the stability of a plant product. 
 
 Why dissolution (and the selected method thereof)? 
For this study, dissolution tests for three different S. frutescens materials (LP, SDAE and 
FDAE 1) were conducted in three different dissolution media at pH 1.2, 4.5 and 6.8, to 
simulate conditions obtained in different sections of the gastrointestinal tract. Even though 
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all the products are presumably derived from one source, there are subtle differences in 
appearance, processing methods and processing dates. The three products used for 
dissolution were therefore selected in order to assess the discriminating power of the 
dissolution method.  
 
For the dissolution tests, the standard USP basket method, with modifications, was 
employed. The first modification was in the volume of the dissolution medium which was 
reduced to 450 ml. The second modification was in the number of dosage units to be 
employed which was increased to two capsules containing each plant material. This was 
done to increase flavonoid concentration in the dissolution medium and so enhance 
detection.   
 
 How were profiles to be compared and interpreted? Why that way? 
Dissolution profiles of flavonoids from the different materials were compared using Q-
release values. Q-values give an indication of the time taken for the specified percentage of 
actives to dissolve in the dissolution medium. Q-75 % and Q-85 % were evaluated for each 
flavonoid marker compound at different pH conditions in order to characterise each 
flavonoid as rapidly dissolving or otherwise from the plant material. Although there are no 
pharmacopoeial specifications for S. frutescens materials, the acceptance criterion 
employed for this study was arbitrarily set at a minimum of 75 % flavonoid dissolution in 45 
minutes. A Q-value of 75 % in 45 minutes suggests that the marker compound exhibits the 
characteristics of immediate release from its enclosing material. Immediate release 
formulations may be further classified as rapidly dissolving (Q-value of ≥ 85 % dissolution in 
≤ 30 minutes) or very rapidly dissolving (Q-value of ≥ 85 % dissolution in ≤ 15 minutes). This 
parameter (Q 85 %) was also assessed for the flavonoid markers from the S. frutescens 
materials.  
 
Dissolution data were further compared using the original similarity factor, f2. Because the 
data had percent coefficient of variation (% CV) in excess of 20 % at earlier time points (≤ 15 
minutes) and 10 % at later time points (> 15 minutes), and to assess the suitability of original 
f2 use, the dissolution profiles were also compared using a modification of the original f2 
proposed for dissolution profiles comparison in cases of extensive variation.161,162 
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We also propose another as-yet undocumented modified method for dissolution profiles 
comparison: the median-f2. This is considered  because the median value, being more robust 
to the presence of outliers, may be expected to give a more accurate value of the f2 than the 
original f2 method which uses mean values of percentages dissolved for f2 calculation, in 
cases where samples present with extensive variation.   
 
Finally, to determine the minimum crucial number of sampling points necessary for 
flavonoid dissolution from S. frutescens materials, as well as to assess the relationship 
between dissolution data from different materials, dissolution data was further subjected to 
principal component analysis (PCA). As a data reduction tool, PCA analyses data by 
extracting the smallest number of components to explain most of the variation in the 
original data. 
 
 Why dissolution data modelling (e.g. to compare release mechanisms)? 
It was also of interest to determine if the dissolution mechanisms were different for 
flavonoid markers form different S. frutescens materials. Therefore, to describe the release 
and elucidate the underlying mechanism of release for each flavonoid marker compound, 
dissolution data was fitted to various mathematical models. The release of an API from its 
enclosing material occurs in dissolution media prior to API dissolution, and is a prerequisite 
for such dissolution. Such release can be described using appropriate mathematical models. 
The dissolution data was thus fitted to various models in order to obtain the mathematical 
models of best fit which can be used to describe the dissolution curve mathematically as 
well as to elucidate the kinetics of marker compound release. 
 
Three semi-empirical models – Weibull, Peppas-Sahlin and Korsmeyer-Pepas models – were 
utilized in order to characterise the release mechanisms of markers from different S. 
frutescens materials. The Weibull model describes release by diffusion or a complex 
mechanism depending on the value of the time exponent, β; the Peppas-Sahlin model 
describes API release as governed by diffusion or polymer relaxation depending on the 
values of kd and kr while the Korsmeyer-Peppas model describes API release as via diffusion 
or a complex mechanism according to the value of the release exponent, n.  
 
 
 
 
 
60 
 
For Korsmeyer-Peppas modelling, the fraction of drug released at time t (Mt /M) utilised for 
modelling should not be more than 60 % in order to appropriately elucidate release 
mechanism before complete dissolution of the dosage form, by which time other 
mechanisms not involved in release may contribute to a wrong inference.160 A minimum of 
three data points are required for Korsmeyer-Peppas modelling.160 For all the sutherlandins, 
the portion of the curve Mt/M ≤ 60 % did not have enough sampled data points for the 
analysis especially for glycosides from the LP and SDAE; where in some cases close to 100% 
had been released by the second or third time point. To obtain enough data to fit Mt/M ≤ 
60 %, the predicted values from the empirical model of best mathematical fit, for each 
flavonoid glycoside, which generated more data points before the portion of the curve 
Mt/M ≤ 60 %, were used for fitting to the Korsmeyer-Peppas equation.  
 
3.4.4 Prediction of in vivo bioavailability of S. frutescens flavonoids  
 Why was this done? How (and why that way)? 
The essence of this section is to evaluate a selection of marker compounds in order to 
predict the ones that would most likely be bioavailable. For the upcoming clinical trial on S. 
frutescens, an analytical test has to be developed and validated for proposed marker 
compounds (flavonoids) in plasma and other biological fluids. However, prior to such assay 
development, possible markers need to be evaluated in order to select the ones most likely 
to be bioavailable. This was done using the molecular properties of each marker compound 
and the computational resource, Molecular Operating Environment, MoE. An assay will then 
be developed for the bioavailable marker compounds in plasma since these are the 
compounds that are likely to be detected. Prediction of in vivo bioavailability offers 
advantage over the conduction of several experiments to determine such as it saves time 
and resources, and removes the need for ethical justification of possible in vivo studies. 
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CHAPTER   FOUR 
 
MATERIALS   AND   METHODS 
 
In this chapter, the materials, equipment and procedures used to determine the 
comparative levels of flavonoids in, and their dissolution from, a selection of S. frutescens 
materials are presented. Included among the procedures explained are those for the 
selection and isolation of the relevant flavonoids, development and validation of a suitable 
HPLC assay, conduct of dissolution studies and the analysis of dissolution data. In addition, 
the methods employed for modelling of in vitro release using computerized software, and 
the prediction of in vivo bioavailability from molecular properties, are also presented.  
 
4.1  Materials 
The following herbal and chemical materials were sourced and used:  
 S. frutescens-containing products, i.e. leaf powder (LP, batch number: E16794, 
Afriplex, Paarl);  spray-dried aqueous extract (SDAE, batch number: Ferl-DST/001-
1210; CSIR,Bellville); freeze-dried aqueous extract 1 (FDAE 1, batch number: 1674, 
Ferlot Manufacturing & Packaging Pty (Ltd)); freeze-dried aqueous extract 2 (FDAE 
2, batch number: E62265, Afriplex, Paarl); freeze-dried aqueous extract 3 (FDAE 3, 
batch number: E63067, Afriplex, Paarl). The certificates of analysis (CoA) for the 
different products are available in Appendix 1.  
 
 Reference compounds: Commercially available reference standards, with purity as  
indicated in the manufacutrer’s CoA, and source, in parantheses: rutin (≥ 94 %) 
(Sigma Aldrich); quercetin dihydrate (≥ 99 %), quercitrin (≥ 98.5 %), kaempferol-3-O-
rutinoside (≥ 98 %), kaempferol (≥ 99 %) (Extrasynthese, Genay Cedex, France);   
and non-commercially available marker compounds: flavonoid glycosides isolated 
from S. frutescens SDAE (as described in section 4.3.1), with purity determined by 
HPLC analysis as ≥ 98.9 %, ≥ 89.7 %, ≥ 99.6 % and ≥ 98.6 % for sutherlandins A, B, C 
and D, respectively.  
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 Solvents and reagents: Acetonitrile, methanol (Sigma Aldrich); formic acid, 
concentrated hydrochloric acid (Merck (Pty) Ltd); butanol (Associated Chemicals 
Enterprises, Johannesburg, RSA); distilled water (Millipore, Milford, MA); sodium 
hydroxide pellets, potassium dihydrogen orthophosphate, di-sodium hydrogen 
orthophosphate (Merck, SA); monobasic potassium phosphate (Sigma Aldrich, USA); 
distilled water (Millipore, Milford, MA, USA).  
 
 HPLC and other consumables: Strata™ 1 ml C18 solid phase extraction (SPE) 
cartridges, Luna® C18 preparative column (250 x 10 mm, 10 µm), Luna® C18 analytical 
column (250 x 4.6 mm, 5 µm), Kinetex® C18 analytical column (150 x 2.1 mm, 5 µm)  
(Phenomenex, Torrance, CA, USA); Discovery C18 preparative column (250 x 10 mm, 
10 µm), Discovery® C18 analytical column (250 x 10 mm, 5 µm), Discovery® C18 guard 
column (1 cm x 10 mm, 5 µm) (Supelco, Bellefonte, PA, USA); HPLC vials (1.8 ml, AA 
Tech, CT, RSA); latex gloves, nose masks, pipettes – 20, 200 & 1000 µl (Lasec, SA); 
pipette tips - 200 & 1000 µl (Bio-smart Scientific, London, UK); nylon 0.45 µm syringe 
filters (25 mm, StarLab Scientific); 0.45 µm membrane filters (Millipore, Ireland);  
parafilm (Pechiney Plastic Packaging, Chicago, IL-60631); syringe needles (Avacare, 
Sunray Medical Co., China); eppendorf tubes (Eppendorf, Germany); centrifuge 
tubes (Biologix, USA). 
 
4.2  Equipment  
 The following equipment were used:  
 Centrifuge (Digicen 21, Orto alresa, United Scientific); rotary evaporator (Büchi, 
Labotec, SA); -86°C upright ultralow freezer (NU-9668E, NuAire, USA), dissolution 
apparatus (VanKel VK 700, USA).  
 
 Chromatographic equipment: HPLC-DAD analyses using an Agilent 1200 series HPLC 
system, equipped with an in-line degassing system (G1322A, Japan); quaternary 
pump (G1311A, Germany); auto loading sampler (G1329A, Germany); 
thermostatted column compartment (G1316A, Germany) and photodiode array 
detector (G1315B, Germany);  
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and LC-MS and LC-MS/MS analyses using a Waters Synapt G2 quadrupole time-of-
flight mass spectrometer (Milford, MA, USA).  
 
 NMR spectrometer (Bruker Avance IIID Nanobay, Bruker BioSpin GmbH, 
Rheinstetten, Germany).       
 
 Small scale instruments: Weighing balance (max 210 g, Ohaus, NJ, USA); vacuum 
pump (Rocker, Singhla Scientific, Haryana, India); heater (MS7-H550-Pro, 
DragonLAB); Vortex mixer (VM-400, Gemmy Industrial Corp., Taiwan), pH meter 
(Model PL-700PV, Taipei, Taiwan), size 0 capsule filler (Cap.M.Quik™, S L Sanderson 
& Co., Berry Creek, CA, USA).    
   
 Computer modelling software: OpenLAB™ CDS ChemStation edition HPLC data 
acquisition software (Agilent Technologies, Palo Alto, CA, USA); LatentiX© data 
analytical software (Version 2.12, www.latentix.com, Latent5, Copenhagen, 
Denmark); DDSolver (Microsoft Excel add-in program, Zhang et al., 2010); 
Molecular Operating Environment (MoE) (Chemical Computing Group Inc., 
Montreal, Canada).  
 
4.3  Methods  
The methods involved in this study are shown in the flow diagram (Figure 4.1) and discussed 
in this sub-section.  
 
4.3.1 Acquisition and isolation of flavonoid compounds from S. frutescens  
Briefly, nine reference marker compounds (two flavonoid aglycones and seven of their 
corresponding glycosides) were selected for suitability assessment as marker compounds 
for S. frutescens (1a and 1b). Five of these compounds, viz. rutin, kaempferol-3-O-rutinoside, 
quercitrin, quercetin and kaempferol were purchased, while the other four, viz the flavonoid 
glycosides, sutherlandins A to D, were not commercially available and had to be isolated 
from S. frutescens plant material (1b). An HPLC assay for the flavonoid reference compounds 
in S. frutescens solution was developed and validated (2a and 2b) and used for the 
quantification of the reference compounds in the different S. frutescens materials (3).  
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Figure 4.1: Flow diagram of step-wise approach to determine flavonoid content, dissolution 
characteristics and in vivo bioavailability of flavonoids in S. frutescens phytomedicinal 
materials 
 
KEY:  SA: sutherlandin A          SB: sutherlandin B SC: sutherlandin C 
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SD: sutherlandin D         R: rutin                   K-3-O-rut: kaempferol-3-O-rutinoside 
Qctr: quercitrin           Q: quercetin      K: kaempferol 
A dissolution test was also developed and validated for the S. frutescens materials (4) and 
the flavonoids released in dissolution media were detected and quantified using a valildated 
HPLC method. Dissolution profiles of marker compounds were compared using standard 
and modified methods (5), modelled to determine release characteristics of flavonoid 
markers from different S. frutescens materials (6) and the in vivo bioavailability of selected 
marker compounds predicted (7).  
 
4.3.1.1  Flavonoid extraction and pre-separation (solid-phase extraction) 
Powdered S. frutescens SDAE material was washed, first with hexane, and then with ethyl 
acetate. The ethyl acetate fraction was partitioned by liquid-liquid extraction into butanol, 
and the butanol extract concentrated using the rotary evaporator under reduced heat to 
obtain a dark viscous product.  
 
The crude butanol extract was subjected to reversed phase column chromatography using 
C18 Strata™ solid phase extraction (SPE) cartridges for the isolation of flavonoid fractions. 
First, the SPE cartridge was conditioned with 100 % acetonitrile followed by water 
containing 0.01 % formic acid. The butanol fraction (dissolved in 50 % acetonitrile in water) 
was applied uniformly to the SPE cartridges and the column eluted using a five step gradient 
elution with water: acetonitrile mixtures (0.01 % formic acid) of decreasing polarity (0 to 
100% acetonitrile). Six major fractions were obtained (Figure 4.2). Fraction 3 was found to 
contain the sutherlandins (Figure 4.2), identified using UV-spectroscopy, and was further 
fractionated using the methods discussed below.  
 
 4.3.1.2 Pre-separation of flavonoids by semi-preparative HPLC  # 1 
Fraction 3 obtained from SPE gradient elution was subjected to HPLC, using a Supelco® 
Discovery semi-preparative C18 column (250 x 10 mm, i.d. 10 µm) with a compatible guard 
column, both maintained at 45°C. The mobile phase consisted of water (0.01 % formic acid) 
(A) and acetonitrile (0.01 % formic acid) (B), and was filtered through a 0.45 µm filter and 
degassed prior to use. The flow rate of the mobile phase was 3 ml /min, injection volume 
50 µl and peaks were separated according to the following linear gradient elution:  
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Figure 4.2:  Flow diagram showing step-wise approach to isolation of marker compounds (sutherlandins A, B, C and D) from S. frutescens 
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0 to 1 min, 82 % A/ 18 % B; 1 to 15 min, 82 % A/ 18 % B to 75 % A/ 25 % B; 15 to 20 min, 
75 % A/ 25 % B to 65 % A/ 35 % B; 20 to 25 min, 65 % A/ 35 % B to 40 % A/ 60 % B; 25 to 26 
min, 40 % A/ 60 % B to 82 % A/ 18 % B; followed by an equilibration with 82 % A/ 18 % B 
from 26 to 35 minutes. The eluent was monitored at several wavelengths over a range from 
250 to 380 nm, the specific wavelength of interest being 370 nm.  
 
Preliminary identification of the four flavonoid glycosides for collection during isolation was 
based on retention times and UV-spectral characteristics.  
 
Preliminary quantities obtained for the semi-pure compounds were as follows:  
Fraction 3:  Sutherlandin A ?:  15.0 mg 
Fraction 4:   Sutherlandin B ?:    6.4 mg 
Fraction 7:   Sutherlandin C ?:  12.1 mg 
Fraction 8b+9a:  Sutherlandin D ?:  16.2 mg 
 
Fractions 4, 8 and 9 were further subjected to HPLC using the same method described above 
(semi-preparative HPLC # 1) to further separate component compounds. Fraction 4 yielded 
two different compounds, viz. 4a and 4b and fraction 8 two different compounds, i.e. 8a and 
8b, while compounds 9a and 9b were obtained from fraction 9. Further HPLC separation and 
purification of fractions 3, 4b, 7, 8b and 9a was carried out using the method described 
below (semi-preparative HPLC # 2).  
 
 4.3.1.3 Sample clean-up (semi-preparative HPLC # 2)  
Portions of fractions 3, 4b, 7, 8b and 9a above were subjected to HPLC for further clean up, 
using the Phenomenex Luna® semi-preparative column (250 mm x 10 mm, i.d. 10 m) with 
a compatible guard column, both maintained at 45°C. The other method parameters were 
the same as in HPLC # 1 with the exception of the injection volume which was 100 µL. 
 
The isolated compounds were identified based on retention times and UV-spectral 
characteristics, and their percentage purity calculated based on analytical HPLC. The final 
isolated products were dried, weighed and stored in amber coloured vials at 4°C until LC-
MS/MS and NMR analysis to confirm their identities.  
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4.3.1.4  Identification of isolated compounds  
LC-MS and LC-MS/MS analyses were conducted using a Waters Synapt G2 quadrupole time-
of-flight mass spectrometer, connected to a Waters Acquity ultra-performance liquid 
chromatograph (UPLC) and photo diode array (PDA) detector. For the LC analysis, a Waters 
UPLC BEH C18 column (100 x 2.1 mm, 1.7 μm) and gradient elution was used. The mobile 
phase, consisting of water (1.0 % formic acid) (A) and acetonitrile (B), was filtered and 
degassed prior to use. The flow rate of the mobile phase was maintained at 0.35 ml/min, 
and peaks representing the different marker compounds were separated according to the 
following gradient elution prior to a holding period of 0.5 minute: 0 to 0.5 min, 95 % A/ 5 % 
B; 0.5 to 20 min, 95 % A/ 5 % B to 56 % A/ 44 % B; 20 to 21 min, 56 % A/ 44 % B to 0 % A/ 
100 % B; 21 to 22 min, 0 % A/ 100 % B to 0 % A/ 100 % B; 22 to 23 min, 0 % A/ 100 % B to 
95 % A/ 5 % B; followed by an equilibration with 95 % A/ 5 % B from 23 to 26 minutes. The 
injection volume was 3 µL and MS data was acquired via high resolution electrospray 
ionisation (HR-ESI) performed in the positive ion mode with nitrogen gas as nebulizer, using 
further details of the method described by Albrecht et al.19 to generate LCMS 
chromatograms and fragmentation data of the marker compounds.  
 
The 1H-NMR spectra were recorded in methanol-d4 (CD3OH) using a Bruker Avance IIID 
Nanobay 400 MHz NMR spectrometer equipped with a 5 mm broadband observe (BBO) 
probe, and chemical shifts were recorded in parts per million (ppm).   
 
 4.3.2   HPLC assay method for quantification of flavonoids in S. frutescens   
An HPLC assay for nine flavonoid compounds was developed and validated (Figure 4.1,  
2a & 2b).  
 
4.3.2.1  HPLC system and conditions.  
The HPLC system used for the acquisition of chromatograms and UV spectra was an Agilent 
1200 series HPLC system, equipped with an in-line degassing system, quaternary pump, 
auto loading sampler, thermostatted column compartment and photodiode array detector. 
Chromatographic separation was obtained using a Phenomenex Luna® C18 column (25 cm x 
4.6 mm, 5 µm i.d.) with a compatible guard column, both maintained at 45°C. The mobile 
phase, consisting of water (0.01 % formic acid) (A) and acetonitrile (0.01 % formic acid) (B), 
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was filtered through a 0.45 µm filter and degassed prior to use. The flow rate of the mobile 
phase was maintained at 0.8 ml/min, injection volume was 20 µl, and peaks were separated 
according to the following linear gradient elution: 0 to 1 min, 82 % A/ 18 % B; 1 to 15 min, 
82 % A/ 18 % B to 75 % A/ 25 % B; 15 to 20 min, 75 % A / 25 % B to 65 % A/ 35 % B; 20 to 25 
min, 65 % A/ 35 % B to 40 % A/ 60 % B; 25 to 26 min, 40 % A/ 60 % B to 82 % A/ 18 % B; 
followed by an equilibration with 82 % A/ 18 % B from 26 to 35 minutes. The eluent was 
monitored at several wavelengths over a range from 250 to 380 nm, the specific wavelength 
of interest at 370 nm. Samples were collected based on retention times and UV-spectral 
characteristics of compounds. Data acquisition and processing was carried out using the 
OpenLAB™ CDS ChemStation Edition software.  
 
4.3.2.2  Validation of HPLC assay 
The following parameters were determined to validate the HPLC assay according to ICH 
guidelines.205  
 
For linearity assessment, stock solutions for the calibration curves and quality control assays 
were prepared by weighing out specific amounts of the nine reference and marker 
compounds, which were dissolved in methanol: water (50:50) to achieve concentrations 
between 0.5 and 2 mM. The linearity of the calibration curve for each of the reference and 
marker compounds was assessed in triplicate over a six sample concentration range, and 
calibration curves constructed by a linear regression of plots of peak area against 
concentration.  
 
The limit of detection (LOD) is defined at a signal-to-baseline ratio of 3:1, and is taken as the 
lowest concentration of standard, which under the described HPLC conditions, will  produce 
a peak height at least three times higher than the base line noise, while the limit of 
quantification (LOQ) is defined at a signal-to-baseline ratio of 10:1.205 For the LOD and LOQ 
determination, the peak area was used as the signal response and, the mean baseline noise 
was 0.4 mAU (n = 3).  
   
For stability assessment, samples of the reference and marker compounds were subjected 
to a variety of conditions (acid /base hydrolysis, freeze /thaw cycles, ambient light and heat 
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exposure) and injected into the HPLC system to assess the analyte in the presence of any 
degradants which may arise under these conditions. For acid /base hydrolysis, reference 
and marker compounds were treated with 2 M solution of hydrochloric acid or sodium 
hydroxide, respectively, heated in a water bath at 60°C for 60 minutes (for acid hydrolysis), 
or left at room temperature for two hours (for basic hydrolysis), and reaction products 
observed. Freeze-thaw cycles were conducted by five consecutive freezing (at –80°C for 30 
minutes) and thawing (at room temperature for 30 minutes) sessions.  For ambient light 
analysis, the reference and marker compounds were exposed to sunlight for one month; 
while for assessment of heat stability, the reference standards were heated for 3 hours at 
60°C.   
 
The precision of the analytical method was determined by assaying six spiked samples at the 
lower and upper limits of the concentration range studied for each of the reference or 
marker compounds. The accuracy of the method was determined by the mean 
concentrations obtained for the replicates and the percentage difference. Samples were 
prepared by dilution of the stock solutions with solvent for each standard. The relative 
standard deviations (% RSD) were then calculated for the reference and marker standard 
samples at the lower and upper limits of the concentration range. 
 
Evaluation of HPLC method robustness was considered in the mobile phase development. 
The robustness and ruggedness of the method were investigated by varying 
chromatographic parameters such as the flow rate and temperature. 
 
Finally, system suitability parameters206 were calculated from the chromatograms obtained 
for each of the reference and marker compounds during the studies. The Agilent 
ChemStation software was used to calculate these parameters thus:  
Capacity factor:     
  
  
  ,  where ta is the retention time from the time of injection 
to the time of the elution of the peak maximum and tb is the elution 
time of the void volume or non-retained compounds. Peaks should be 
well resolved from the void volume and k’ > 2 is acceptable.  
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Resolution, Rs:         
(     )
(     )
, where t2 and t1 are retention times of the two 
components, and W1 and W2 are corresponding widths of the bases of 
the peaks, obtained by extrapolating the sides of the peaks to the 
baseline. Rs > 2 between the peak of interest and the closest potential 
interfering peak is desirable.  
Tailing factor, T:     
      
  
   , where f is the distance from the front edge of the  
peak to a perpendicular line drawn from the peak maximum to the 
baseline. T < 2 is acceptable.  
 
     
4.3.3 Determination of presence and levels of reference and marker compounds in 
selected S. frutescens materials 
 
Five S. frutescens products were selected for analyses. These materials were the leaf 
powder, spray-dried aqueous extract (SDAE) and three freeze-dried aqueous extract 
materials described in Section 4.1.   
 
Samples of the five S. frutescens materials selected were prepared thus: about 100 mg of 
each S. frutescens material, i.e. leaf powder (LP), spray-dried aqueous extract (SDAE), 
freeze-dried aqueous extract 1 (FDAE 1), freeze-dried aqueous extract 2 (FDAE 2) and 
freeze-dried aqueous extract 3 (FDAE 3), was vortexed in 2 ml of 50 % aqueous methanol, 
sonicated for 30 minutes and then centrifuged at 3500 rpm for 15 minutes. The extraction 
procedure was repeated thrice, respective supernatants combined and the final volume 
adjusted to 8 ml with 50 % aqueous methanol and mixed thoroughly. Prior to injection, 
appropriate dilutions were made, and the final solution filtered using a 0.45 µm nylon 
membrane filter. Aproximately 1.0 ml of filtrate was discarded and the remaining volume 
collected in an LC sample vial. Triplicate sample solutions of each S. frutescens material were 
made, injection volume was 50 µl and samples were analysed using the validated HPLC 
method already described under section 4.3.2. The average peak areas of the flavonoids of 
interest in each sample were used to quantify and determine concentration of the sample 
from the calibration curve and flavonoid content in the different S. frutescens materials 
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were compared. Data was presented as average percentage content (mg flavonoid x 
minimum purity of flavonoid reference /mg plant material) ± SD (n = 3).  
 
4.3.4 Dissolution test for S. frutescens materials 
Three S. frutescens materials (i.e. LP, SDAE and FDAE 1) were selected for the dissolution 
tests conducted in three different dissolution buffers at pH 1.2, 4.5 and 6.8. The selected S. 
frutescens materials were filled into size 0 capsules using Cap.M.Quik™ size 0 capsule filler. 
A hundred capsules of each material were prepared, and the capsules weighed before and 
after filling in order to determine the uniformity of weight in compliance with USP 
guidelines.  
 
The USP basket apparatus method was used to determine the dissolution of the flavonoids 
from the S. frutescens-containing capsules in the following media – 0.1 N hydrochloric acid 
(pH 1.2), acetate buffer (pH 4.5) and phosphate buffer (pH 6.8). Standard procedures were 
used to prepare the media and the final pH confirmed using a calibrated pH meter. Initially, 
1 or 2 or 3 capsules were immersed in 900 ml of dissolution medium for the test. Due to the 
low content of the flavonoids in plant material (< 5mg /capsule) as well as to improve the 
sensitivity of the method by increasing marker compound concentration, the dissolution 
medium was reduced to 450 ml, maintained at 37 ± 0.5 °C. Two capsules containing the 
appropriate S. frutescens material were placed in each dissolution vessel basket, and vessel 
contents stirred at 100 rpm. Apart from the change in volume and number of dosage units, 
all other conditions were in accordance with standard USP guidelines.  
 
At predetermined time intervals (5, 10, 15, 20, 30, 45, 60, 90 and 120 minutes), 3 ml of 
sample was withdrawn from each vessel through a 0.45 µm nylon membrane syringe filter. 
The samples were filtered during withdrawal to prevent continuation of dissolution, and 
replaced with an equal volume of the same pre-warmed medium in order to maintain 
constant volume and temperature. The filtered withdrawn samples were analysed using the 
validated HPLC method reported in 4.3.2 and the amount and percentage of reference 
compounds dissolved calculated from the peak area response of the HPLC chromatograms, 
using the highest peak response obtained from each vessel as the 100 % value. Data was 
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plotted as percentage dissolved ± standard deviation versus dissolution time, and Q-release 
values were determined for the flavonoid marker compounds of interest. 
The samples were filtered during withdrawal to prevent continuation of dissolution, and 
replaced with an equal volume of the same pre-warmed medium in order to maintain 
constant 
 
As a category III analytical procedure, i.e. analytical procedure for determination of 
performance characteristics, the dissolution test method was validated for precision by 
means of repeatability.207 The precision was evaluated for repeatability by analysing six 
individual samples (six replicates) collected from the dissolution apparatus at a time of 60 
minutes (pH 1.2), and expressed as relative standard deviation (% RSD) between samples.  
 
Principal component analysis (PCA) was conducted using LatentiX version 2.12. Dissolution 
data was uploaded and autoscaled and the PCA model for the data calculated. The loadings 
and scores plots were generated from the calculated PCA model and used to assess the 
relationship between different sampling times and the relationship between dissolution of 
marker compounds from the different materials. Clustering of variables in PCA analysis 
indicates that all the variables in the cluster provide the same information, and this was 
applied to identify redundant variables.      
 
4.3.5  Comparison of flavonoid glycoside dissolution profiles from different S. frutescens 
materials 
To compare dissolution profiles of flavonoids from the different S. frutescens materials in 
three different dissolution media, three methods were employed. These were the original 
similarity factor and two modifications of this: Gohel et al.’s similarity factor and a new 
method which we propose, the median similarity factor. The objective of comparing 
dissolution profiles with these different methods was to assess how the modifications 
compared to the original similarity factor, and to determine which method was the most 
discriminating for the profiles. The most discriminating method for dissolution profiles 
comparison is the one which gives the lowest f2 value.  
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4.3.5.1  Similarity factor, f2 method 
For each combination of product dissolution profiles (e.g. LP versus SDAE, etc.), the 
similarity factor (f2) was calculated using the equation: 
        
(
 
   
√[     ∑(     )
 ]
)
  
where Rt and Tt are the average percentages dissolved at each time point for the reference 
and test products, respectively; and n is the number of observations. An f2-value between 
50 and 100 indicates similarity of two dissolution profiles while values below 50 indicate 
dissimilarity179, and this criterion was used to compare the product profiles.  
 
4.3.5.2  Gohel’s modified similarity factor method 
The similarity factor was calculated using the equation: 
        
(
 
   
√[  
 
  
∑   
 
    (     )
 ])
  
 
which includes a weight factor proposed by Gohel et al.161,162 This weight factor was 
calculated using the following equation:  
 
weight, wt  =  1   +   {(% CV of Rt ) /(MCV E/L )}   +   {(% CV of Tt )/(MCV E/L )}  
 
where wt is weight; % CV of Rt and % CV of Tt are the percentage coefficient of variation of 
reference and test products, respectively; MCV E/L is the maximum allowable % CV and co-
efficient of variation was calculated thus: % CV = (standard deviation /mean) × 100. All 
other symbols are as represented in the original similarity factor, f2, equation.  
  
Again, if the f2 values are between 50 and 100, it indicates similarity of two dissolution 
profiles while values below 50 indicate dissimilarity179, and this criterion was used to 
compare the product profiles. 
n 
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4.3.5.3  Median similarity factor  
The median similarity factor, median f2, was calculated, using the same equation used for 
ordinary f2 calculation: 
        
(
 
   
√[     ∑(     )
 ]
)
  
 
 
All symbols are as represented in the original similarity factor equation with the exception 
of Rt and Tt, which represent the median percent dissolved at each time point for the 
reference and test products, respectively. As in the previous cases, a median f2-value 
between 50 and 100 indicates similarity of two dissolution profiles while values below 50 
indicate dissimilarity, and this criterion was used to compare the product profiles.  
 
4.3.6 Determination of release characteristics 
For this, the methods used to fit release data for description of release curves, as well as 
semi-empirical model fitting for release mechanism elucidation are presented.  
 
4.3.6.1   Model fitting for description of flavonoid release from S. frutescens materials 
From dissolution data of S. frutescens LP, SDAE and FDAE in three different dissolution 
buffers, reference and marker compound release were assessed by different mathematical 
models of API release in order to select the model of best fit. Data was fitted to various 
models using DDSolver. For fitting drug dissolution models to non-transformed data, 
DDSolver determines the parameter values that minimize the sum of squares (SS) or the 
weighted sum of squares (WSS) by use of the non-linear least-squares curve-fitting 
technique: 151 
    ∑  
 
   
  (             )
 
 
where n is the number of observations; wi is the weighting factor; yi_obs refers to the ith 
observed y value and  yi_pre refers to the ith predicted y value. Mathematical expressions 
describing these models are as summarized in Table 2.1.  
 
 
 
 
 
76 
 
First, in order to determine the best mathematical equation for description of flavonoid 
glycoside release from different S. frutescens materials, dissolution data was fitted to 
different models. Descriptions of the parameters in the model equations are explained in 
literature.151 Goodness of fit was analysed for the models and the best mathematical model 
for flavonoid release from S. frutescens material was chosen after careful consideration of 
the coefficient of determination (R2) and the adjusted coefficient of determination (R2adj). 
For release models with the same number of parameters, the R2 value was used to 
determine the model of best fit (with higher R2 value indicating better fit) while for release 
models with different number of parameters, R2adj was used to select the best model  (with 
higher R2adj  value indicating better fit).
151 In cases of over fitting, R2adj may decrease, giving 
an indication of model suitability, while R2 will always increase or remain constant as more 
parameters are included in a model.146 
 
Although there are no specifications for modelling of flavonoid glycoside release from S. 
frutescens, the specification for goodness of fit of a model was arbitrarily set at a minimum 
value of 0.98 for R2. Besides R2 and R2adj, model suitability was also confirmed by assessment 
of the Akaike Information Criterion (AIC), Model Selection Criterion (MSC), mean square 
error (MSE) and sum of squares (SS) values.  
 
4.3.6.2  Evaluation of flavonoid release mechanisms from S. frutescens materials 
To determine the mechanisms involved in flavonoid release from the different S. frutescens 
materials, dissolution data were fitted to three semi-empirical models: Weibull, Peppas-
Sahlin and the Korsmeyer-Peppas models. Release mechanisms were determined according 
to values of the time exponent (β) for the Weibull model (as discussed in Section 2.6.2.3.3).  
 
To assess if release was via diffusion or relaxation, dissolution data was fitted to the semi-
empirical equation proposed by Peppas and Sahlin:158  
 
      (      )
 
      (       )
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The parameters, kd and kr, represent the release rates of polymer diffusion and relaxation, 
respectively.158 A higher value of kd than kr implies that API release is more by diffusion than 
relaxation, and vice versa.  
For fitting to the Korsmeyer-Peppas model, the first 60 % or less of the release data was 
fitted to the Korsmeyer-Peppas equation and release mechanism determined by the value 
of the release exponent.  
  
4.3.7  Prediction of flavonoid in vivo bioavailability   
For the prediction of in vivo bioavailability of the flavonoid compounds employed in this 
study, the chemoinformatic and computational software, MoE, was used. Structural 
formulae of the reference or marker compounds employed were exported to the operating 
environment. Values were generated for different molecular properties such as molecular 
weight, number of hydrogen bond acceptors, octanol-water partition coefficient, rotatable 
bonds, to mention a few. Such molecular properties enabled the characterisation of each 
compound’s bioavailability according to documented literature theories proposed by 
Lipinski et al. and Congreve et al.184,185   
 
In the next chapter, results obtained after application of these methods are discussed.  
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CHAPTER FIVE 
 
RESULTS AND DISCUSSION 
 
In this chapter, the results obtained in isolation of marker compounds (sutherlandins) from 
S. frutescens material, development and validation of HPLC assay for flavonoid compounds 
in solution, assessment of marker compound profiles and levels in different S. frutescens 
materials, and dissolution testing and dissolution profiles comparison of flavonoids from 
different S. frutescens materials, are presented. In addition, flavonoid dissolution and 
molecular properties were modelled for release mechanism elucidation and in vivo 
bioavailability prediction, respectively, and results from these are also presented and 
discussed.    
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5.1   Isolation and identification of sutherlandins A, B, C and D from S. frutescens  
The use of flavonoid glycosides as marker compounds for plant materials is usually limited 
by their commercial non-availability. This section reports on the isolation of four flavonoid 
glycosides (sutherlandins A, B, C and D) from S. frutescens material and their subsequent 
identification by appropriate analytical techniques. 
 
5.1.1  Isolation of sutherlandins A, B, C and D  
Fractionation of the crude butanol extract yielded six fractions eluted with varying 
acetonitrile-water concentrations. The UV spectra of the six fractions (Appendix 2, Figures   
A 2.1 to A 2.4) were compared and fraction 3 (Chapter 4, Figure 4.2, green highlight) was 
found to be rich in flavonoid compounds. The other fractions did not contain much of the 
flavonoid glycoside compounds as can be seen from the quantities reflected on the y-axis of 
their HPLC chromatograms (Appendix 2, Figures A 2.1 to A 2.4).  
 
5.1.2  Identification of sutherlandins A, B, C and D 
The component compounds in fraction 3 were further separated and samples cleaned up 
using semi-preparative HPLC. Use of a photodiode array detector (PDA) in HPLC analysis 
enabled the acquisition of the UV/Vis spectral data for the sutherlandins. The four marker 
compounds contained in 40 % ACN solution (Figure 4.2, green highlight) were isolated; 
preliminary identification while they were still in solution was via UV-spectral characteristics 
as shown in the spectrum index plot (Figure 5.1.1). These matched those previously 
reported for the same compounds.20 
 
The isolated compounds were irregularly shaped, non-crystalline and yellow to peach 
coloured. Final quantities obtained for sutherlandins A, B, C and D were 1.8 mg, 1.2 mg, 2.7 
mg and 1.5 mg, respectively. Minimum values for percentage purity (as assessed by 
analytical HPLC) were 98.9 %, 89.7 %, 99.6 % and 98.6 % for sutherlandins A, B, C and D, 
respectively.  
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Figure 5.1.1: Spectrum index plot of HPLC-PDA analyses of isolated compounds, sutherlandins A, B, C and D, isolated from S. frutescens 
 
Sutherlandin A 
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Sutherlandin B 
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Sutherlandin C 
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Sutherlandin D 
 
 
 
 
84 
 
To confirm the identity of the isolated compounds, they were analysed using mass 
spectrometry (MS), and the MS data is shown in Figure 5.1.2. High-resolution electrospray 
ionisation mass spectrometry (HR ESI-MS) analysis provided the [M+H]+ molecular ions of 
the respective compounds in the positive ion mode. The protonated species [M+H]+, similar 
to those previously reported,20 were therefore observed at m/z 741.1862, 741.1857, 
725.1900 and 725.1913 atomic mass units (amu), corresponding to and confirming the 
molecular identities of sutherlandins A, B, C and D, respectively (Figure 5.1.2 and Table 
5.1.1).  
 
The isolated compounds were further characterized using the fragmentation patterns 
observed in the mass spectrum. Sutherlandins A and B showed characteristic fragments at 
m/z 609.1487 ([M+H-sugar]+, i.e. [M+H-132]+) and 303.0484 (base peak, quercetin), while 
sutherlandins C and D showed characteristic fragments at m/z 593.1472 ([M+H-sugar]+, i.e. 
[M+H-132]+) and 287.0554 (base peak, kaempferol) (Table 5.1.1). These ions reflect the loss 
of sugar from the flavonoid glycoside skeleton, and confirm the identity of the isolated 
compounds as sutherlandins A, B, C and D.    
 
Table 5.1.1:  LC-ESI-MS of isolated compounds identified using positive ion mode and key 
fragment analysis 
 
Reference 
compound 
Exact mass 
(amu) 
[M+H]+ 
(amu) 
[M+H-sugar]+  
(amu) 
Key fragment 
(amu) 
Sutherlandin A 740.1800 741.1862 609.1487 303.0484 
Sutherlandin B 740.1800 741.1857 609.1448 303.0498 
Sutherlandin C 724.1851 725.1900 593.1472 287.0545 
Sutherlandin D 724.1851 725.9130 593.1486 287.0554 
 
 
In addition to HPLC-DAD and LC-ToF-MS, 1H NMR was also performed to ensure structural 
elucidation of the isolated compounds. The results are shown in Appendix 3: the chemically 
distinct hydrogens are shown downfield to the left while the sugar moieties of the isolated 
sutherlandins are upfield to the right in the 1H NMR spectra.         
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Figure 5.1.2: Mass spectra of sutherlandins A to D, isolated from S. frutescens (separation 
of the reference standards was on a Waters UPLC BEH 1.7 μm C18 column 
with dimensions 100 x 2.1 mm, using gradient elution and flow rate of 0.35 
ml/min. Mobile phases A and B were water (1% formic acid) and acetonitrile 
respectively, injection volume was 3 µL and total run time was 26 minutes). 
The protonated species [M+H]+ were observed at m/z 741.1862, 741.1857, 
725.1900 and 725.1913 amu, for sutherlandins A to D respectively.   
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5.1.3 Conclusions  
A crucial part of this study was the isolation of non-commercially available marker 
compounds (sutherlandins A, B, C and D) for S. frutescens assay. Chromatographic purity of 
the isolated compounds were found to be 98.9 %, 89.7 %, 99.6 % and 98.6 % for 
sutherlandins A, B, C and D, respectively.  Based on the described experiments and results 
obtained, these compounds were qualified for use as reference standards to estimate 
concentrations of sutherlandins A, B, C and D in various S. frutescens products.  
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5.2      Development and validation of HPLC assay for flavonoid compounds in S. frutescens  
This section reports the development and validation of a reversed phase HPLC method to 
assess content and dissolution of reference and marker compounds in S. frutescens 
products. Nine flavonoid compounds (consisting of seven flavonoid glycosides: 
sutherlandins A, B, C and D, rutin, kaempferol-3-O-rutinoside and quercitrin; and their two 
corresponding flavaonoid aglycones: quercetin and kaempferol) were selected for assay 
development and validation.  
 
5.2.1  HPLC method development 
To assess the profiles and levels of flavonoid glycosides and aglycones in S. frutescens plant 
materials, an assay was required. For this purpose, an HPLC assay was developed and 
validated for flavonoid analysis. The assay method involved a reverse phase HPLC separation 
with PDA detection, and the nine reference compounds earlier mentioned were used for the 
assay.  
 
Different HPLC conditions were analysed in order to identify conditions with satisfactory 
resolution of chromatograms within the shortest possible time. Final chromatographic 
conditions selected are as described in Section 4.3.2.1. The use of acetonitrile-water was 
suitable for satisfactory resolution of the chromatograms, and the addition of 0.01 % formic 
acid to both solvents improved peak separation. The reference and marker compounds 
were separated by isocratic followed by gradient elution, and this was found to be suitable 
for the analysis of flavonoid glycosides and their corresponding aglycones in S. frutescens 
materials. Ultraviolet (UV) radiation was employed for the detection of the flavonoids due 
to the presence of flavonoid chromophores that absorb UV-light,107 as well as the 
availability of UV-detection systems. Although absorption maximum was 350 nm for the 
selected compounds, 370 nm was the preferred wavelength due to its greater selectivity for 
the flavonoid compounds of interest. The reference compounds were separated within 30 
minutes by HPLC-DAD technique. Chromatograms of standards and an S. frutescens sample 
are depicted in Figure 5.2.1 a and b. The glycosides eluted between 11 and 19 minutes, and 
the aglycones between 26 and 29 minutes.  
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(a) Typical HPLC chromatogram of a mixture of the nine reference and marker 
compounds in 50 % aqueous methanol solution 
 
 
 
(b) Typical HPLC chromatogram showing reference and marker compounds in S. 
frutescens plant material  
 
Figure 5.2.1: HPLC chromatograms of reference and marker compounds in (a) 50 % 
aqueous methanol and  (b) plant material, measured at λ = 370 nm. Retention 
times for rutin, sutherlandin A, sutherlandin B, kaempferol-3-O-rutinoside, 
sutherlandin C, sutherlandin D, quercitrin, quercetin and kaempferol were 
11.9, 12.7, 13.8, 15.3, 16.2, 17.0, 18.0, 26.2 and 28.1 minutes, respectively. 
Separation of the reference and marker compounds was achieved at 45°C on 
a Phenomenex Luna® 5 µm C18 column with dimensions 250 x 4.6 mm, using 
gradient elution and a flow rate of 0.8 ml/min. Mobile phases A and B were 
acetonitrile (0.01 % formic acid) and water (0.01 % formic acid), respectively, 
injection volume was 20 µL and total run time was 35 minutes. 
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5.2.2  HPLC assay validation  
The following are the results of the HPLC assay validation for flavonoids in solution.  
 
5.2.2.1  Calibration curves and linear concentration range 
To determine linearity, various concentrations of the reference compounds were set up and 
calibration curves analysed. The equations for calibration curve analyses are presented in 
Table 5.2.1. The (six point calibration) curves for the nine reference compounds showed a 
linear correlation, i.e. R2 > 0.99, between concentration and peak area of the detector 
response (Table 5.2.1). 
 
Table 5.2.1: Summary of selected calibration parameters for reference and marker 
compounds by HPLC-DAD method 
 
Analyte Regression equation Linearity range 
(μg/ml) 
R2 LOD 
(μg/ml) 
LOQ 
(μg/ml) 
Sutherlandin A y = 22.252x – 9.5909 4.0 to 180.0 0.9998 2 4 
Sutherlandin B y = 14.543x + 13.149 4.0 to 200.0 0.9996 4 4 
Sutherlandin C y = 17.890x + 11.763 4.0 to 200.0 0.9990 4 15 
Sutherlandin D y = 17.45x - 1.5755 4.0 to 180.0 0.9996 2 4 
Quercetin  y = 108.51x + 104.95 4.0 to 120.0 0.9967    < 2 9 
Kaempferol y = 91.752x + 140.98 4.0 to 120.0 0.9983 2 9 
Rutin  y = 27.88x + 35.835 4.0 to 120.0 0.9988    < 2 15 
Quercitrin y = 27.472x - 12.148     0.4 to   60.0 0.9998 5 10 
K-3-O-rutinoside y = 26.729x + 54.301 4.0 to 200.0 0.9991    < 2 9 
 
5.2.2.2  Limit of detection (LOD) and limit of quantitation (LOQ) 
For this assay, the limit of detection (LOD) was defined at a signal-to-baseline ratio of 3:1 
and the limit of quantitation (LOQ) at a signal-to-baseline ration of at least 10, with 
acceptable accuracy and precision (< 10 % for each criterion).205 Values for the LOD and LOQ 
are presented in Table 5.1.2. The LOD was lowest for quercetin, rutin and kaempferol-3-O-
rutinoside, and highest for quercetin. The LOQ was lowest for sutherlandins A, B and D, and 
highest for Sutherlandin C and rutin. 
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These values showed some similarity to those from another study with different flavonoid 
compounds.208 However, they are higher than the results obtained with a few other 
flavonoid studies,209,210 possibly due to the wavelength chosen for analysis, 370 nm. This 
wavelength, though not the absorption maxima for the flavonoids, was chosen in order to 
enhance selectivity for the flavonoid compounds of interest at the expense of other non-
flavonoid compounds that may be present in plant material. The LOD and LOQ values 
obtained are therefore deemed suitable for this assay. Some other studies on flavonoids in 
plant material have also reported higher LOD and LOQ values than were obtained in this 
study.211,212   
 
5.2.2.3  Stability 
Stability assessment involved acid-base hydrolysis, consecutive freeze-thaw cycles and 
exposure to ambient light and heat.  
 
5.2.2.3.1 Acid /base hydrolysis 
The results of acid-base hydrolysis are presented in Figure 5.1.4. The original chromatogram 
of each unhydrolysed compound showed only one noticeable peak (in green) in the 
flavonoid glycoside region for all seven flavonoid glycosides and in the aglycone region for 
the aglycones. On hydrolysis, the flavonoid glycosides were hydrolysed to the corresponding 
flavonoid aglycones (in purple), identified by comparison of their retention times and UV 
spectra with those of reference flavonoid aglycone compounds.  
 
A wide range of flavonoid glycosides are available in nature. Because of their abundance, 
quantification of each and every flavonoid glycoside in samples will present a Herculean 
task. These flavonoid glycosides are however derived from a very small number of flavonoid 
aglycones; therefore, the starting point for most analytical reactions involving flavonoid 
glycosides is the identification of the flavonoid aglycone. For this, acid is used to cleave the 
sugar from the aglycone.107 Clearly, all the flavonoid glycosides of interest in this study are 
sensitive to acid hydrolysis, confirming their identity as O-glycosides. They can thus serve as 
markers for quality control as their reactions under acid-base conditions can indicate 
instability of S. frutescens products.  
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As expected, the flavonoid aglycones were not affected by acid hydrolysis.  Alkaline 
hydrolysis of the flavonoid glycosides led to the production of the deacylated flavonoid 
glycosides (navy traces, Figure 5.2.2).  
 
 
 
Figure 5.2.2: HPLC chromatograms (at 370 nm) of reference and marker compounds before 
and after acid or base hydrolysis 
 
           KEY:    SA: sutherlandin A     SD: sutherlandin D  R: rutin             
       SB: sutherlandin B    Q: quercetin  Qr: quercitrin   
      SC: sutherlandin C    K: kaempferol Ko: kaempferol-3-O-rutinoside  
 
 
5.2.2.3.2 Freeze-thaw cycle  
The results of the freeze-thaw cycle after five consecutive freezing (at -80°C) and thawing (at 
room temperature) exercises are presented in Figure 5.2.3. The reference standards showed 
relative stability to five successive freezing and thawing cycles, as signified by the retention 
times and peak sizes before and after the freeze-thaw cycle.  
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Figure 5.2.3: HPLC chromatograms (at 370 nm) of reference and marker compounds before 
and after undergoing five consecutive freeze-thaw cycles 
 
KEY:     SA: sutherlandin A         SD: sutherlandin D    R: rutin             
SB: sutherlandin B        Q: quercetin    Qr: quercitrin   
               SC: sutherlandin C        K: kaempferol    Ko:kaempferol-3-O-rutinoside 
 
An exception was quercetin, exhibiting instability, shown by decrease in peak size, and 
formation of other products. This was in contrast to previous studies that demonstrated 
quercetin stability to freeze-thaw cycles, though the said studies evaluated quercetin 
stability in biological fluids,213,214 and not in aqueous-based solutions as presented here.  
Since this study utilized plant samples containing mostly flavonoid glycosides, the samples 
can be stored for prolonged periods in the freezer prior to analysis as their stability on 
thawing has been demonstrated. This however may not be ideal if quercetin is to be used as 
a marker as it is prone to instability under freeze-thaw conditions as investigated herein, 
and may also be formed in cases of product instability.  
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5.2.2.3.3 Ambient light exposure 
HPLC chromatograms of samples subjected to sunlight exposure for one month are shown 
in Figure 5.2.4. The traces indicate that the flavonoid glycosides (sutherlandins A, B, C and D) 
showed relatively good stability with respect to the retention times (i.e. still eluted at 
previous retention times observed prior to sunlight exposure). However, the peak response 
for all seven glycosides decreased to between 45 and 97 % of the original.  
 
 
 
Figure 5.2.4:  HPLC chromatograms (at 370 and 250 nm) of reference and marker 
compounds after sunlight exposure for one month 
 
SA: sutherlandin A           SD: sutherlandin D     R: rutin             
  SB: sutherlandin B          Q: quercetin      Qr: quercitrin   
  SC: sutherlandin C          K: kaempferol     Ko: kaempferol-3-O-rutinoside  
 
The flavonoid aglycones on the other hand were not stable, and additional peaks 
representing other compounds were observed. These other compounds were probably 
degradation products of the aglycones, and were observed in the chromatograms for 
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quercetin and kaempferol. The actual peaks representing quercetin and kaempferol were 
however not detected after light exposure (Figure 5.2.4), implying that these compounds 
had been degraded, possibly due to photo-oxidation.215 The stability of flavonoids to light is 
known to depend on the nature of the hydroxyl group attached to C3 of the flavonoid 
structure (please see Figure 2.2, Chapter 2), where the absence or glycosylation of the 
hydroxyl group confers some degree of stability not seen in flavonoid molecules with a 
hydroxyl group at C3 as is the case with quercetin and kaempferol.
216 The seven flavonoid 
glycosides under study are all glycosylated at position C3 (please refer to flavonoid 
structures in Figure 2.2, Chapter 2), conferring on them some degree of photostability not 
obtained with the non-glycosylated flavonoid aglycones, quercetin and kaempferol. This 
may explain why the flavonoid glycosides, though affected by ambient light exposure which 
served to reduce the peak response, were affected to a lesser degree than the flavonoid 
aglycones of lower photostability due to the presence of a free hydroxyl group at C3. The 
‘lower-stability’ flavonoid aglycones underwent degradation to such an extent that their 
peaks were not detected in the chromatograms obtained following ambient light exposure. 
The lower phtostability of the flavonoid aglycones is ascribed to a greater triplet state 
population cum higher singlet oxygen reactivity.216 
  
All the compounds exhibited instability on exposure to light; ideally, samples containing 
these compounds should not be exposed to ambient light conditions as tested here. This 
also shows that the flavonoid compounds are susceptible to light and can therefore be used 
as markers to monitor quality and stability of S. frutescens products exposed to light.  
 
5.2.2.3.4 Heat exposure 
After exposure to heat (for 3 hours at 60°C), all the flavonoid glycosides and aglycones were 
still observed at their respective retention times (Figure 5.2.5), indicating that heat did not 
cause exhaustive degradation of the compounds. The peak response was however reduced 
to between 4 and 84 % of the original for the flavonoid glycosides and aglycones under 
study. This is in line with a study by Manach et al. 217 which reported a 60 % loss of quercetin 
in apple juice stored for 9 months at 25°C.   
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Figure 5.2.5:  HPLC chromatograms (at 370 and 250 nm) of reference and marker 
compounds after heat exposure for 3 hours at 60oC   
 
   SA: sutherlandin A  SD: sutherlandin D  R: rutin             
  SB: sutherlandin B             Q: quercetin  Qr: quercitrin   
  SC: sutherlandin C             K: kaempferol  Ko: kaempferol-3-O-rutinoside  
 
The flavonoid glycoside, kaempferol-3-O-rutinoside, where peak response increased to 
106.8 % after heat exposure was an exception from the other flavonoids in the group, 
though such increase can also be viewed as being due to some form of instability or an 
indication of compromised quality. Ideally, samples containing these compounds should not 
be exposed to heat conditions as tested here. The flavonoid compounds, having shown 
susceptibility to heat, can therefore be used as markers for quality and stability assessment 
of S. frutescens products exposed to heat. 
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5.2.2.4  Precision and accuracy  
Precision and accuracy data for the reference and marker compounds are shown in Tables 
5.2.2 and 5.2.3. The RSD for the compounds ranged from 1.01 to 5.75 % but were less than 
3 % for most of the compounds (Table 5.2.2). Precision data less than 5 % RSD is 
acceptable,218 more so for herbal materials where variation in actives may be quite 
considerable.24,186 This suggests that the proposed method is sensitive enough for the assay 
of flavonoid glycosides in S. frutescens. Results of intra-day and inter-day assays were 
consistent, with RSD less than 1 % for all reference and marker compounds (Table 5.2.3). 
The precision and accuracy data are therefore within acceptable limits for S. frutescens 
assay.  
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Table 5.2.2:  Precision and accuracy data for quantification of reference and marker 
compounds (λ = 370 nm) 
 
 Reference compound % RSD 
Lower conc. (µg/mL): 15 µg/mL Sutherlandin A 2.01 
Higher conc. (µg/mL): 33 µg/mL Sutherlandin A 2.54 
   
Lower conc. (µg/mL): 15 µg/mL Sutherlandin B 5.75 
Higher conc. (µg/mL): 35 µg/mL Sutherlandin B 2.83 
   
Lower conc. (µg/mL): 15 µg/mL Sutherlandin C 3.80 
Higher conc. (µg/mL): 35 µg/mL Sutherlandin C 2.14 
   
Lower conc. (µg/mL): 15 µg/mL Sutherlandin D 2.36 
Higher conc. (µg/mL): 33 µg/mL Sutherlandin D 2.29 
   
Lower conc. (µg/mL): 8 µg/mL Quercetin  2.84 
Higher conc. (µg/mL): 35 µg/mL Quercetin 1.28 
   
Lower conc. (µg/mL): 9 µg/mL Kaempferol 2.13 
Higher conc. (µg/mL): 35 µg/mL Kaempferol 0.85 
   
Lower conc. (µg/mL): 9 µg/mL Rutin 2.39 
Higher conc. (µg/mL): 35 µg/mL Rutin 2.21 
   
Lower conc. (µg/mL): 9 µg/mL Quercitrin 2.01 
Higher conc. (µg/mL): 33 µg/mL Quercitrin 1.01 
   
Lower conc. (µg/mL): 9 µg/mL Kaempferol-3-O-rutinoside 3.20 
Higher conc. (µg/mL): 35 µg/mL Kaempferol-3-O-rutinoside 1.63 
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Table 5.2.3: Intra- and inter-day precision analyses for reference and marker compounds 
(λ = 370 nm) 
 
Reference/ marker 
compound 
 
Ave 
 
% RSD 
Intra-day 
(Ave) 
Intra-day 
(% RSD) 
Inter-day 
(Ave) 
Inter-day 
(% RSD) 
Sutherlandin A 1325.99 0.998 1341.60 0.061 1328.03 0.442 
Sutherlandin B 916.62 0.442 933.47 0.469 909.18 0.818 
Sutherlandin C 1167.74 0.111 1130.98 0.452 1136.91 0.629 
Sutherlandin D 1085.46 0.205 1087.62 0.056 1087.89 0.959 
Quercetin 7134.14 0.146 7063.00 0.433 6987.52 0.327 
Kaempferol 5952.61 0.242 5967.14 0.090 5989.19 0.494 
Rutin 1836.46 0.738 1861.07 0.161 1853.79 0.355 
Quercitrin 1646.19 0.045 1659.16 0.048 1662.54 0.457 
Kaempferol-3-o-rutinoside 1759.65 0.019 1761.84 0.204 1782.92 0.502 
 
 ‘Ave’ represents average peak area in mAU 
 
5.2.2.5  Robustness and ruggedness freezer 
Evaluation of method robustness was considered when the suitability of the mobile phase 
was assessed. The robustness and ruggedness of the method were investigated by varying 
chromatographic parameters such as the flow rate and temperature, and the results 
obtained are given in Figures 5.2.6 and 5.2.7.  
 
A decrease in the flow rate of the mobile phase (from 0.8 to 0.5 ml/minute) resulted in an 
increase in the retention time for all the reference compounds (Figure 5.2.6). A decrease in 
flow rate generally increases the retention time of eluting compounds. In this case, the 
increase in retention time was significant. A significant increase in retention times may 
result in peak broadening, and lead to compromised chromatographic output. While a faster 
flow rate generally results in decreased retention times and sharper peaks for the eluted 
compounds, this is not always the case. Faster is not always better; a faster flow rate may 
result in insufficient time for the analyte to interact with the stationary phase, and so the 
best (optimal) flow rate for optimal separation of the analytes of interest is usually sought. 
For this study, the optimal flow rate was 0.8 ml/minute. 
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Figure 5.2.6:  HPLC chromatograms for a mixture of the nine reference and marker 
compounds, demonstrating the effect of variation in flow rate: (a) 0.5 ml/min  
(b) 0.8 ml/min 
 
As shown in Figure 5.2.7 below, changing the temperature of the column compartment 
from 40°C to room temperature did not cause significant changes in the peak sizes and 
retention times, showing that the developed method is robust to temperature changes.  
 
 
Figure 5.2.7:  HPLC chromatograms for a mixture of the nine reference and marker 
compounds demonstrating the effect of variation in column temperature 
(a) 
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5.2.2.6  System suitability testing 
The Agilent ChemStation® software was used to calculate system suitability parameters and 
results obtained are summarized in Table 5.2.4. Values of the capacity factor (k’) ranged 
from 30 to 71, resolution (Rs) from 49 to 245 and tailing factor (T) from 1.0574 to 1.2563. 
The suitability of the chromatographic system in terms of column efficiency, resolution and 
precision, for flavonoid analysis in S. frutescens is therefore assured.  
 
Table 5.2.4: HPLC retention times and selected system suitability parameters for the 
reference and marker compounds 
 
Compound k’ Rs T 
Sutherlandin A (SA) 31.5870 81.594 1.0714 
Sutherlandin B (SB) 34.4686 83.906 1.0574 
Sutherlandin C (SC) 40.6013 61.483 1.1421 
Sutherlandin D (SD) 42.6056 48.999 1.0843 
Quercetin (Q) 66.3686 244.577 1.1981 
Kaempferol (K) 71.2636 - 1.2563 
Rutin (R) 29.7370 85.084 1.1117 
Kaempferol-3-O-rutinoside (Ko) 38.3600 97.067 1.1065 
Quercitrin (Qr) 45.3070 97.910 1.0903 
 
 
5.2.3 Conclusions  
To date, analysis of flavonoid glycosides, together with their corresponding flavonoid 
aglycones, which can be used for the assay of S. frutescens materials, has not yet been 
investigated. There are many flavonoids in this plant which may be used for development of 
its HPLC assay. For this assay, we chose nine flavonoids (seven flavonoid glycosides and two 
corresponding flavonoid aglycones) which were all found to be suitable for the assay. The 
marker and reference compounds were well separated, resulting in good separation of 
component flavonoids in plant materials. The developed assay employed a combination of 
isocratic and gradient elution systems, with DAD-detection, and provided a simple method 
with relatively good linearity, accuracy and robustness, which can be suitably employed for 
the assay of S. frutescens materials.     
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5.3    Profiles and levels of flavonoid compounds in different S. frutescens materials 
For this section of the study, a validated HPLC method was employed for the analysis of 
reference and marker compounds in samples of different S. frutescens materials. The 
chromatograms obtained were analysed for the presence of any flavonoid compounds and 
specifically the marker compounds, sutherlandins A, B, C and D, in different S. frutescens 
materials viz LP, SDAE and FDAE.  
 
5.3.1  Quantification of reference compounds in plant materials 
The HPLC separation of reference and marker compounds in the different S. frutescens 
materials analysed is presented in Figure 5.3.1. The flavonoid glycosides, sutherlandins A, B, 
C and D, represented by peaks 1, 2, 3 and 4, respectively, were detected in all the samples 
assayed. The flavonoid aglycones, quercetin and kaempferol, represented by peaks 5 and 6, 
respectively, were only detected in two of the FDAE materials and not in the LP or SDAE 
materials. Three of the nine compounds, rutin, quercitrin and kaempferol-3-O-rutinoside 
were not conclusively identified in the plant materials assayed. While peaks with similar 
retention times and UV-spectra as these three compounds were detected in some of the S. 
frutescens materials assayed, they were not isolated and so their identities could not be 
conclusively confirmed by further analytical techniques.  
 
The percentage content (w/w) of the reference and marker compounds detected in the 
different S. frutescens materials is shown in Table 5.3.1. The average peak area was used to 
quantify each compound in each of the five S. frutescens materials. Of the two possible 
forms in which the flavonoids can exist in plant materials (glycoside and aglycone), the 
flavonoid glycosides were more abundant than the flavonoid aglycones in each of the 
assayed materials, in support of our first hypothesis (Section 3.3). 
 
The flavonoid aglycone content (0.01 to 0.21 %) was found to be lower than that of the 
flavonoid glycosides (0.07 to 1.58 %), and in some cases, below the quantification limit. The 
freeze-dried extracts contained 0.01 to 0.20 % of the flavonoid aglycones, while these 
compounds were not detected in either the LP or SDAE samples. This suggests that the 
flavonoid aglycone content may be increased by processing parameters, such as is used in 
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the preparation of the freeze-dried extracts. However, no collaboration of this was found in 
existing literature.  
 
 
Figure 5.3.1: HPLC chromatograms of the five S. frutescens materials in 50 % aqueous 
methanol solution. The numbers 1 to 6 represent sutherlandin A, sutherlandin 
B, sutherlandin C, sutherlandin D, quercetin and kaempferol, respectively.  
 
In all the plant materials assayed, sutherlandin C was found to have the highest abundance, 
and so can be assayed for in all the S. frutescens materials. The least abundant flavonoid 
glycoside was not the same in all the plant samples assayed, with different materials 
showing non-uniformity in the flavonoid of least abundance. In the LP and SDAE materials, 
the flavonoid glycosides of least abundance were sutherlandin B and sutherlandin D, 
respectively, while in all the freeze-dried materials, the flavonoid glycoside of least 
abundance was sutherlandin A. 
 
Neither the LP nor SDAE material contained detectable levels of the aglycones, quercetin 
and kaempferol. In the freeze-dried materials, kaempferol content was more than quercetin 
content for FDAE 1 and FDAE 3, and below quantifiable limits for FDAE 2. The sum of the 
analysed flavonoids in the plant materials exceeds that obtained in other studies of total 
flavonoids219,220,221 and suggests that the flavonoid content in the S. frutescens materials is 
sufficient for flavonoid use as marker compounds. Overall, the levels of the flavonoid 
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glycosides and aglycones in the different S. frutescens materials assessed varied significantly 
(p < 0.001). The assessment of flavonoid glycoside (sutherlandin A, B, C and D) content can 
therefore be used to differentiate between S. frutescens products.  
 
Table 5.3.1: Percentage (w/w) of reference and marker compounds found in 50 % aqueous 
methanol extracts of the different S. frutescens materials. Results are 
presented as percentage content (w/w) 
 
Reference 
compound 
LP SDAE FDAE 1 FDAE 2 FDAE 3 
SA 0.526 ± 0.005 0.579 ± 0.011 0.200 ± 0.002 0.647 ± 0.022 0.072 ± 0.001 
SB 0.450 ± 0.034 0.597 ± 0.006 0.760 ± 0.005 1.004 ± 0.018 0.560 ± 0.002 
SC 1.576 ± 0.009 1.204 ± 0.002 1.084 ± 0.000 1.343 ± 0.032 1.110 ± 0.013 
SD 0.513 ± 0.018 0.442 ± 0.001 0.701 ± 0.018 0.777 ± 0.036 0.662 ± 0.020 
Q  ND  ND 0.024 ± 0.000 < LOQ 0.014 ± 0.000 
K  ND  ND 0.210 ±0.000 < LOQ 0.055 ± 0.000 
 
Each value is expressed as average percentage content (mg flavonoid x minimum 
purity of flavonoid reference/mg plant material) ± SD (n = 3). Means within a row for 
each flavonoid compound are significantly different (p < 0.001).  
 
Key:   SA: sutherlandin A  SC: sutherlandin C  Q: quercetin               
SB: sutherlandin B              SD: sutherlandin D  K: kaempferol 
             ND: not detected        < LOQ: less than LOQ  
 
In addition, the levels of the flavonoid aglycones (quercetin and kaempferol) in the analysed 
samples were quite low and in some cases, absent, thus making quantification of these 
compounds a challenge. The ratio of the flavonoid glycosides to the total flavonoids 
(glycoside + aglycone) was at least 90 % in the samples studied. Therefore, the use of the 
flavonoid aglycones (and not the glycosides) as markers for quality control and stability 
assessment of S. frutescens LP, SDAE or FDAE materials may not be justifiable or feasible 
using  the specific assay employed in the present study. This however, can be expected in 
samples extracted using more polar solvents like methanol and water.  It may well be that 
extraction with less polar solvents would yield more of the aglycones than the glycosides. 
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5.3.2   Conclusions 
The validated HPLC-DAD method previously reported in Section 5.2 was found to be 
appropriate for separation and quantification of flavonoid glycosides and their 
corresponding aglycones in different formulations of S. frutescens. The LP, SDAE and FDAE 
materials all contained all four marker compounds, i.e. sutherlandins A, B, C and D, with 
sutherlandin C being the most abundant in all the five materials. The two flavonoid 
aglycones, quercetin and kaempferol, were detected in two of the FDAE materials, and not 
in the LP or SDAE material. There were more flavonoid glycosides than aglycones in all the 
plant materials, suggesting that the former may be more suitable as marker compounds. 
The use of the flavonoid glycosides as markers is therefore recommended for assessment of 
S. frutescens materials.  
 
The aglycones can also be used as marker compounds because their presence, as products 
of flavonoid glycoside breakdown, can indicate instability of the plant materials. However, 
use of the flavonoid aglycones levels alone, without the flavonoid glycosides levels as well, is 
not recommended. Assay of all six flavonoids employed here is preferred to the assay of a 
single flavonoid as it gives the profiles and levels of the flavoniods in the different materials. 
This in turn can indicate quality status of different S. frutescens products.  
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5.4  Comparison of flavonoids dissolution in S. frutescens materials  
The objective of this section was to assess if dissolution studies of S. frutescens can be done, 
how they can be done and the suitability of dissolution testing for assessment and 
comparison of S. frutescens materials. The USP basket method was used with modifications, 
and dissolution profiles of the marker compounds were compared using standard and 
modified methods.  
 
5.4.1 Characteristics of S. frutescens materials and packed capsules used for analysis 
For this study, the materials investigated were S. frutescens LP, SDAE and FDAE packaged in 
capsules. The S. frutescens materials (LP, SDAE and FDAE) complied with set specifications 
such as plant material appearance, odour and taste, foreign matter, moisture and 
microbiology at the time of delivery. Details of their specifications are presented in the 
Certificates of Analyses (CoA) in Appendix 1. The LP was a coarsely-milled, free-flowing, light 
green powder with light green stalk bits. The extracts (SDAE and FDAE),  of a smaller particle 
size than the LP, were homogenous and hygrocopic materials. The SDAE was a light brown 
colour while the FDAE was a darker shade of brown.  
 
Three of the five S. frutescens materials used for quantification studies in Section 5.3 viz LP, 
SDAE and FDAE 1, were selected for dissolution tests of S. frutescens materials. The three 
materials were filled into size 0 capsules, which were weighed before and after filling in 
order to assess uniformity of weight. The weights obtained for the LP, SDAE and FDAE 
materials were 322.5 ± 8.7 mg, 324.9 ± 7.6 mg and 322.5 ± 8.5 mg, respectively, which 
complied with the USP requirements for weight uniformity, i.e. between 85 and 115 % of 
the mean.  
 
5.4.2  Validation of dissolution method 
To validate the dissolution method as a category III procedure, i.e. analytical procedure for 
determination of performance characteristics, six individual samples (six replicates, each 
containing the SDAE material) collected from the dissolution apparatus at a time of 60 
minutes (pH 1.2) were analysed to validate method precision by repeatability, and the 
values expressed as relative standard deviation (RSD) between samples.206 For sutherlandins 
A, B and C, the RSD values were 4.4, 4.8 and 2.7 % respectively, all within specified criterion 
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of ≤ 5 %.218 This suggests that the dissolution method described herein can be used for 
dissolution of sutherlandins A, B and C from different plant materials. The RSD for 
sutherlandin D was however 17.0 %, outside the specification limits, possibly due to 
degradation of this marker compound at different rates in the different vessels containing 
the acidic dissolution medium (please see Appendix 4, Figure A 4.2, pH 1.2: SDAE). This 
suggests that sutherlandin D may not be a good marker compound for analysis of plant 
samples at pH 1.2. Nevertheless, this does not necessarily negate its use for assessment at 
other pH conditions.  
 
5.4.3 Dissolution of flavoniod compounds from S. frutescens materials 
The Q-release values for flavonoids dissolution from different S. frutescens materials are 
presented in Tables 5.4.1 to 5.4.6. Although there are no pharmacoepoeial specifications for 
dissolution of S. frutescens materials, the acceptance criterion employed for this study was 
arbitrarily set at a minimum of 75 % flavonoid dissolution in 45 minutes. For comparison 
using the similarity factor (original similarity factor and its modifications), the acceptance 
criterion was f2 < 50. Following are the results of Q-release and dissolution profiles 
comparison for flavonoids from S. frutescens LP, SDAE and FDAE at different pH conditions. 
In the figures and tables, ‘NA’ refers to not available, ‘f2‘ is the original similarity factor, ‘wt 
f2’ refers to the similarity factor modified to allow for impact of within batch variability on f2, 
and ‘f2-median’ refers to the similarity factor calculated using median values of the 
percentages dissolved at each sampling point.  
 
 
5.4.3.1  Dissolution profiles of sutherlandin A  
The dissolution profile of sutherlandin A from different S. frutescens materials, at three pH 
conditions, is shown in Figure 5.4.1. A perusal of the profiles at pH 1.2 shows that the 
dissolution curves for sutherlandin A are different from the three different materials at each 
specific pH, suggesting that release of this marker compound is different from all three 
materials.  
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Figure 5.4.1: Dissolution profiles of sutherlandin A from different S. frutescens materials at 
pH 1.2, 4.5 and 6.8. Data is presented as mean ± SD 
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The Q-values for 75 % and 85 % release were attained at different times from the three 
materials (Table 5.4.1), implying different dissolution characteristics. Dissolution from the LP 
and SDAE materials were immediate while dissolution of the marker from the FDAE 
displayed a lag period of about 15 minutes. This trend was also noticed at pH 4.5 and 6.8; 
the dissolution profiles for sutherlandin A were all different as judged by the shape of the 
curves and the Q-75 and Q-85 release values.  
 
The dissolution profiles of sutherlandin A from all three materials were compared using the 
original f2 equation. The results obtained for comparison of any two of the three materials 
were all below 50, indicating dissimilarity of all profiles, therefore implying differences in 
the dissolution of the different materials (Table 5.4.2).  
 
Table 5.4.1:  Classification of sutherlandin A in S. frutescens materials by dissolution rate 
 
  
Plant material 
& pH  
Q = 75 % 
(minutes) 
Dissolution 
characteristic 
Q = 85 % 
(minutes)  
Dissolution 
characteristic 
Suth A 
1.2 
LP 45 Immediate release  60 Delayed dissolution  
SDAE 10 Immediate release 20 Rapidly dissolving  
FDAE 90 Not immediate release 90 Delayed dissolution  
            
4.5 
LP 20 Immediate release 30 Rapidly dissolving  
SDAE 15 Immediate release 20 Rapidly dissolving  
FDAE 90 Not immediate release 90 Delayed dissolution  
            
6.8 
LP 45 Immediate release 120 Delayed dissolution  
SDAE 15 Immediate release 15 
Very rapidly 
dissolving 
FDAE 90 Not immediate release 90 Delayed dissolution  
 
The variances obtained with the dissolution data were however beyond that stipulated for 
use of the original f2 equation and therefore, dissolution data were also compared using 
Gohel’s modified f2 and the median f2. Comparison of sutherlandin A dissolution profiles at 
pH 4.5 and 6.8 for LP versus SDAE, LP versus FDAE and SDAE versus FDAE materials gave 
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original and modified f2 values as shown in Table 5.4.2. The results confirm dissimilarity of 
sutherlandin A dissolution from all three S. frutescens materials, i.e. f2 < 50.  
 
Table 5.4.2: Comparison of f2-values for sutherlandin A dissolution profiles at pH 1.2, 4.5 and 6.8  
(a) LP (reference) versus SDAE materials  
pH  f2 Wt f2  f2-median 
1.2 34.7 22.3 32.8 
4.5 47.2 33.6 43.3 
6.8 37.3 24.3 36.7 
 
(b) LP versus FDAE materials 
pH f2 Wt f2  f2-median 
1.2 16.4 -9.2 15.4 
4.5 12.7 -12.2 12.5 
6.8 35.6 18.0 14.1 
  
(c) SDAE versus FDAE materials 
pH  f2 Wt f2  f2-median 
1.2 11.6 -15.7 9.8 
4.5 10.6 -15.3 10.2 
6.8 8.7 -5.9 8.5 
 
The dissolution of sutherlandin A is therefore clearly different from the three materials at 
pH 1.2, 4.5 and 6.8. As such, the dissolution test can be used for quality control of S. 
frutescens materials at any of the three pH conditions as it can distinguish between different 
materials.   
 
 
5.4.3.2      Dissolution profiles of sutherlandin B  
The dissolution profiles of sutherlandin B from different S. frutescens materials, at three 
different pH conditions, are shown in Figure 5.4.2.  
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Figure 5.4.2:  Dissolution profiles of sutherlandin B from different S. frutescens materials at 
pH 1.2, 4.5 and 6.8. Data is presented as mean ± SD 
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The shapes of the profiles show differences in sutherlandin B dissolution from the different 
materials at the three pH conditions. However, dissolution characteristics overlapped for 
some of the materials; the times to attain Q-values of 75 % and 85 % were the same for the 
LP and FDAE materials at pH 1.2, but differed for all three materials at pH 4.5 and 6.8 (Table 
5.4.3). This implies that Q-release values of sutherlandin B may not be ideal for 
distinguishing between the S. frutescens materials at pH 1.2, though the reverse may well be 
obtained at pH 4.5 and 6.8.  
 
Table 5.4.3:  Classification of sutherlandin B in S. frutescens materials by dissolution rate 
 
  
Plant material & 
pH  
Q = 75 % 
(minutes) 
Dissolution 
characteristic 
Q = 85 % 
(minutes)  
Dissolution 
characteristic 
Suth B 
1.2 
LP 90 Not immediate release 90 Delayed dissolution  
SDAE 20 Immediate release > 120 Delayed dissolution  
FDAE 90 Not immediate release 90 Delayed dissolution  
            
4.5 
LP 30 Immediate release 45 Delayed dissolution  
SDAE 15 Immediate release 20 Rapidly dissolving  
FDAE 90 Not immediate release 90 Delayed dissolution  
            
6.8 
LP 45 Immediate release 45 Delayed dissolution  
SDAE 15 Immediate release 15 Very rapidly dissolving 
FDAE 90 Not immediate release 120 Delayed dissolution  
 
From the SDAE, the dissolution curve of this marker compound displayed a downward trend 
after peak dissolution, which was not observed with the LP or FDAE materials. The 
downward trend may possibly be due to degradation of this marker compound in the SDAE 
material at pH 1.2. As was obtained with sutherlandin A, dissolution of sutherlandin B from 
the FDAE showed a lag period, with Q-75 % not attained till the 90-minute sampling point.  
 
Comparison of dissolution profiles of sutherlandin B from any two of the three materials 
gave f2 values less than 50 for all combinations (Table 5.4.4), indicating that the dissolution 
profiles of sutherlandin B from all three materials were different. While Q-values may not 
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differentiate between materials at pH 1.2, values of f2 and its modifications can be 
employed to differentiate between the S. frutescens materials at any of the three pH 
conditions assessed.  
 
In addition, for differentiation between S. frutescens materials using sutherlandin B as a 
marker compound, the Q-values at pH 4.5 and 6.8 are preferred to the Q-value at pH 1.2 as 
the latter may not be able to differentiate between the LP and the SDAE materials.  
 
 
Table 5.4.4:  Comparison of f2-values for sutherlandin B dissolution profiles at pH 1.2, 4.5 
and 6.8  
 
(a) LP (reference) versus SDAE materials   
pH  f2 Wt f2  f2-median 
1.2 35.3 19.2 31.1 
4.5 46.1 32.9 44.6 
6.8 35.4 21.1 35.3 
 
(b) LP versus FDAE materials 
pH f2 Wt f2  f2-median 
1.2 15.5 -12.6 16.1 
4.5 14.6 -6.7 15.2 
6.8 38.5 -6.0 17.0 
 
(c) SDAE versus FDAE materials 
pH  f2 Wt f2  f2-median 
1.2 10.6 -16.3 9.0 
4.5 11.5 -10.4 12.6 
6.8 10.4 -11.7 10.5 
 
5.4.3.3   Dissolution profiles of sutherlandin C  
The dissolution profiles of sutherlandin C from different S. frutescens materials, at three 
different pH conditions, are shown in Figure 5.4.3.  As with dissolution of sutherlandins A 
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and B, the shapes of the profiles looked different for the three materials at each of the three 
pH conditions.  
 
Figure 5.4.3: Dissolution profiles of sutherlandin C (from S. frutescens materials) at pH 1.2, 
4.5 and 6.8.  Data is presented as mean ± SD 
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The dissolution characteristics were the same as with sutherlandin A; however, the time to 
attain 75 % dissolution from the SDAE at pH 1.2 and 85 % dissolution from the LP at pH 6.8 
differed for the two marker compounds: sutherlandins A and C (Table 5.4.5). The times to 
attain the specified Q-values were different for sutherlandin C from all three materials at all 
three pH conditions, even though the dissolution characteristics overlapped for some of the 
materials.  
 
Dissolution profiles comparison using the f2 and its modifications returned values below 50 
for any two of the three materials at all three pH conditions (Table 5.4.6), indicating that the 
dissolution profiles were not similar. Therefore, for assessment and comparison of S. 
frutescens materials using sutherlandin C as a marker compound, the times to attain 
specified Q-values for sutherlandin C dissolution as well as the f2 can be used to 
differentiate between S. frutescens materials.  
 
Table 5.4.5:  Classification of sutherlandin C in S. frutescens materials by dissolution rate 
 
  
Plant material 
& pH  
Q = 75 % 
(minutes) 
Dissolution characteristic 
Q = 85 % 
(minutes)  
Dissolution 
characteristic 
Suth C 
1.2 
LP 45 Immediate release 60 Delayed dissolution  
SDAE 15 Immediate release 20 Rapidly dissolving  
FDAE 90 Not immediate release 90 Delayed dissolution  
            
4.5 
LP 20 Immediate release 30 Rapidly dissolving  
SDAE 15 Immediate release 20 Rapidly dissolving  
FDAE 90 Not immediate release 90 Delayed dissolution  
            
6.8 
LP 45 Immediate release 45 Delayed dissolution  
SDAE 15 Immediate release 15 Very rapidly dissolving 
FDAE 90 Not immediate release 90 Delayed dissolution  
 
 
 
 
 
 
 
 
 
115 
 
Table 5.4.6:  Comparison of f2-values for sutherlandin C dissolution profiles at pH 1.2, 4.5 
and 6.8  
 
(a) LP (reference) versus SDAE materials  
pH  f2 Wt f2 f2-median 
1.2 33.9 21.6 30.6 
4.5 47.6 33.1 45.0 
6.8 37.9 25.3 34.6 
 
(b) LP versus FDAE materials 
pH f2 Wt f2  f2-median 
1.2 16.7 -1.7 16.6 
4.5 13.6 -8.9 13.0 
6.8 16.0 -6.8 15.2 
  
(c) SDAE versus FDAE materials 
pH  f2 Wt f2  f2-median 
1.2 11.7 -7.2 11.5 
4.5 11.9 -10.8 11.8 
6.8 10.0 -11.6 9.3 
 
 
5.4.3.4      Dissolution profiles of sutherlandin D  
The graph of cumulative percent dissolved over time for marker compound, sutherlandin D, 
is shown in Figure 5.4.4. As with sutherlandins A, B and C, the shapes of the dissolution 
curves looked different for the different materials, and the dissolution characteristics 
overlapped for some of the materials (Table 5.4.7).  
With the exception of sutherlandin D dissolution from the LP and FDAE materials at pH 1.2, 
the time to attain specified Q-values were different for all the materials at all pH conditions. 
This is a similarity to the case obtained with sutherlandin B dissolution. 
 
 
 
 
 
116 
 
 
Figure 5.4.4: Dissolution profiles of sutherlandin D from different S. frutescens materials at 
pH 1.2, 4.5 and 6.8. Data is presented as mean ± SD 
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As with sutherlandin B, Q-release values of sutherlandin D cannot be used to differentiate 
between different S. frutescens materials at pH 1.2, but can be used at pH 4.5 and 6.8. The 
dissolution of this marker compound from the SDAE, as with sutherlandin B, displayed a 
downward trend in the SDAE at pH 1.2. As suggested with sutherlandin B dissolution, it is 
possible that this marker compound is not stable for prolonged periods at pH 1.2. The two 
marker compounds (sutherlandins B and D) are also known to contain the same sugar 
moiety, which perhaps influences their dissolution. Because the same trend was not noticed 
for the LP and FDAE materials, such instability may perhaps be enabled by properties of the 
SDAE material. As with sutherlandins A, B and C, dissolution of sutherlandin D from the 
FDAE material displayed a characteristic lag, with with Q-75 % not attained till the 90-
minute sampling point. 
 
Table 5.4.7:  Classification of sutherlandin D in S. frutescens materials by dissolution rate 
 
  
Plant material & 
pH  
Q = 75 % 
(minutes) 
Dissolution 
characteristic 
Q = 85 % 
(minutes)  
Dissolution 
characteristic 
Suth D 
1.2 
LP 90 Not immediate release 120 Delayed dissolution  
SDAE 15 Immediate release > 120  Delayed dissolution  
FDAE 90 Not immediate release 90 Delayed dissolution  
            
4.5 
LP 20 Immediate release 45 Delayed dissolution  
SDAE 15 Immediate release 20 Rapidly dissolving  
FDAE 90 Not immediate release 120 Delayed dissolution  
            
6.8 
LP 45 Immediate release 60 Delayed dissolution  
SDAE 15 Immediate release 20 Rapidly dissolving  
FDAE 90 Not immediate release 90 Delayed dissolution  
 
Comparison of sutherlandin D dissolution profiles between any two S. frutescens materials 
at all three pH conditions using the f2 and its modifications returned values indicative of 
dissimilarity of profiles (Table 5.4.8). As with sutherlandin B, Q-values at pH 4.5 and 6.8 (but 
not at pH 1.2, with respect to the LP and FDAE materials) and f2 values at any of the three 
pH conditions can be used to differentiate S. frutescens materials. 
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Table 5.4.8:  Comparison of f2-values for sutherlandin D dissolution profiles at pH 1.2, 4.5 
and 6.8  
 
(a) LP (reference) versus SDAE materials  
pH  f2 Wt f2  f2-median 
1.2 33.1 17.0 27.8 
4.5 45.6 11.8 46.5 
6.8 40.0 22.0 35.6 
 
(b) LP versus FDAE materials 
pH f2 Wt f2  f2-median 
1.2 17.5 -15.1 20.1 
4.5 14.3 -35.2 13.6 
6.8 15.4 -16.2 15.0 
  
(c) SDAE versus FDAE materials 
pH  f2 Wt f2  f2-median 
1.2 10.5 -20.4 9.3 
4.5 13.9 -10.7 13.6 
6.8 10.4 -19.5 9.4 
 
 
5.4.3.5  Dissolution profiles of quercetin  
The graph of cumulative percent dissolved over time for the reference compound, 
quercetin, from S. frutescens materials is shown in Figure 5.4.5. There was no dissolution of 
quercetin from the LP material, at any of the three pH conditions. This supports the data 
from the study on flavonoid content, which showed no detectable peaks for the flavonoid 
aglycone, quercetin, in the LP material. 
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Figure 5.4.5: Dissolution profiles of quercetin from different S. frutescens materials at pH 1.2  
  and 4.5. Data is presented as mean ± SD 
 
From the SDAE materials, there was a dissolution profile of this compound only at pH 1.2, 
characterised by very wide deviations, and no dissolution of quercetin at pH 4.5 and 6.8. The 
study on flavonoid content also showed no presence of quercetin from the SDAE material; 
however, it is possible that a very acidic pH enhances its dissolution, resulting in the profile 
observed at pH 1.2. This marker compound is known to be sparingly soluble and chemically 
unstable in aqueous-based gastrointestinal fluids. Acidic conditions are reported to offer 
quercetin some protection from degradation, while its chemical instability increases as the 
condition becomes more alkaline.222 These may explain the dissolution of quercetin from 
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the SDAE at pH 1.2, albeit with wide deviations, and the absence of any detectable levels at 
pH 4.5 and 6.8. Such deviations and the non-detection of quercetin from the LP material and 
in the dissolution media at pH 4.5 and 6.8 also indicate that this compound may not be a 
good marker compound for dissolution tests of S. frutescens materials. 
 
Dissolution of quercetin from the FDAE also showed some variation, though not as extensive 
as that obtained with the SDAE. A lag time of 10 minutes was noticed before the detection 
of peaks at the 15-minute sampling time. Even though the dissolution characteristics were 
similar for the SDAE and FDAE materials at pH 1.2 (Table 5.4.9), their f2 values were below 
50; original f2, Gohel’s f2 and the median f2 values were 21.3, -6.8 and 14.4, respectively, 
indicating dissimilarity of dissolution profiles.  
 
Table 5.4.9: Classification of quercetin in S. frutescens materials by dissolution rate 
  
Plant material & 
pH  
Q = 75 % 
(minutes) 
Dissolution characteristic 
Q = 85 % 
(minutes)  
Dissolution 
characteristic 
Quercetin 
1.2 
LP NA NA NA NA 
SDAE > 120 Not immediate release > 120  Delayed dissolution  
FDAE > 120  Not immediate release > 120  Delayed dissolution  
            
4.5 
LP NA NA NA NA 
SDAE NA NA NA NA 
FDAE 120 Not immediate release 120 Delayed dissolution  
            
6.8 
LP NA NA NA NA 
SDAE NA NA NA NA 
FDAE NA NA NA NA 
 
Thus, the Q-values cannot be used to differentiate between the SDAE and FDAE materials, 
while the f2 values showed differences in dissolution profiles of quercetin from the two 
materials. At a pH of 4.5, dissolution of quercetin was detected only from the FDAE material. 
This reference compound cannot therefore be used to differentiate between the S. 
frutescens materials employed in this study as it is not common to all.  
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5.4.3.6         Dissolution profiles of kaempferol  
The graph of cumulative percent dissolved over time for the reference compound, 
kaempferol, from S. frutescens materials is shown in Figure 5.4.6. There was no dissolution 
of kaempferol from the LP at any of the three pH conditions. From the SDAE material, 
dissolution of kaempferol was detected at only one of the pH conditions assessed (pH 1.2), 
with wide deviations, such as was seen for quercetin. Dissolution of kaempferol was also 
detected from the FDAE material at pH 1.2, though there was a lag time, with the first peak 
only detected at the 30-minute sampling time.  
 
 
Figure 5.4.6:  Dissolution profiles of kaempferol from different S. frutescens materials  at pH  
             1.2 and 4.5.  Data is presented as mean ± SD 
The Q-release values and dissolution characteristics were mostly similar for the two 
materials, i.e. the SDAE and the FDAE at pH 1.2 (Table 5.4.10) and so cannot be used to 
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differentiate S. frutescens materials when the reference compound is kaempferol. At pH 4.5, 
kaempferol dissolution was observed only from the FDAE material.  
 
Comparison of dissolution profiles of kaempferol from the SDAE and FDAE materials using 
the original f2, Gohel’s f2 and median f2 returned values of 16.2, -4.1 and 27.3, respectively, 
indicating dissimilarity of dissolution profiles. However, this marker compound may not be 
as good as the flavonoid glycosides for differentiating S. frutescens materials as it was not 
detected in some of the materials and at some pH conditions.  
 
Table 5.4.10: Classification of kaempferol in S. frutescens materials by dissolution rate 
 
  
Plant material & 
pH  
Q = 75 % 
(minutes) 
Dissolution characteristic 
Q = 85 % 
(minutes)  
Dissolution 
characteristic 
Kaempferol 
1.2 
LP NA NA NA NA 
SDAE 90 Not immediate release > 120 Delayed dissolution  
FDAE > 120 Not immediate release > 120 Delayed dissolution  
            
4.5 
LP NA NA NA NA 
SDAE NA NA NA NA 
FDAE 120 Not immediate release 120 Delayed dissolution  
            
6.8 
LP NA NA NA NA 
SDAE NA NA NA NA 
FDAE NA NA NA NA 
 
The findings from the dissolution tests indicate that flavonoid glycosides are better marker 
and differentiating compounds than the flavonoid aglycones for dissolution studies of S. 
frutescens materials; they were detected in the different dissolution media and also 
projected different dissolution properties for different S. frutescens materials. Glycosylation 
of a flavonoid decreases its reactivity while improving its water solubility,223,224 enhancing its 
dissolution in aqueous-based media. This may serve to explain the dissolution of the 
flavonoid glycosides, to different degrees, in the dissolution media assessed. The flavonoid 
aglycones, on the other hand, are not ideal as marker compounds for dissolution tests but 
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may be used to monitor instability as they are sometimes formed as degradation products 
of the glycosides.  
The Q-release values for the flavonoid aglycones, though not available in all instances, were 
more than the Q-release values for the flavonoid glycosides, supporting the first of our 
second hypotheses (Chapter Three, Section 3.3, b (i)), which states that flavonoid glycoside 
dissolution will proceed faster than flavonoid aglycone dissolution. The second part of our 
second hypotheses, b(ii), states that flavonoid dissolution from the two extracts (SDAE and 
FDAE) will be the same but faster than flavonoid dissolution from the LP material. We had 
reasoned that being aqueous extracts, the SDAE and FDAE materials will be fully soluble in 
the aqueous-based dissolution media, and release their flavonoid content faster than the 
LP, which in its aqueous-unextracted from would be less soluble. However, the dissolution 
rates of the SDAE and FDAE did not match and the FDAE material was found to have the 
slowest dissolution rate as seen from the Q-values (Tables 5.4.1 , 5.4.3, 5.4.5, 5.4.7, 5.4.9 
and 5.4.10). Dissolution seemed fastest from the SDAE material but was equally matched by 
the rate obtained from the LP material, while the freeze-dried aqueous extract presented 
with the slowest release. This may stem from its processing parameters which will be 
investigated in further studies.  
   
To conduct dissolution studies and differentiating tests on S. frutescens materials therefore, 
any of the four flavonoid glycosides but not the flavonoid aglycones may be used in any of 
the three media assessed as their Q-release and f2 values are differentiating of the 
materials. However, the use of sutherlandin D at pH 1.2 is not recommended as its precision 
under dissolution conditions did not meet validation specifications.  
 
It is interesting to note that in the SDAE material, sutherlandin B and D displayed a 
downward trend after attaining maximum dissolution, while this was not the case for 
sutherlandins A and C. Sutherlandins B and D are different in that they are flavonoid 
glycosides of the aglycones, quercetin and kaempferol respectively, while the presence of 
the apiofuranosyl group, is a similarity. It is very likely that the breakdown of the sugar 
moiety within the SDAE material is responsible for the decrease in percentage observed 
after peak dissolution. Likewise, sutherlandins A and C are different in that they are 
flavonoid glycosides of the aglycones, quercetin and kaempferol respectively, while the 
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presence of the xylopyranosyl group, is a similarity. It is also very likely that the resistance of 
sutherlandins A and C to breakdown in the dissolution medium, especially at pH 1.2, can be 
attributed to this similarity – the xylopyranosyl group. This downward trend in dissolution 
profiles of sutherlandins B and D was not the case for the LP and FDAE material though. It 
seems that while the similarity in the sugar group may be the reason for the decrease in 
cumulative amount of sutherlandins B and D dissolved over time, the SDAE material also 
provided an enabling environment for this to occur.  
 
The dissolution characteristics of each flavonoid compound from the different S. frutescens 
materials, reported in Tables 5.4.1 , 5.4.3, 5.4.5, 5.4.7, 5.4.9 and 5.4.10, show that the same 
flavonoid glycoside may not necessarily be released at the same rate from different 
materials. Thus, the dissolution test reported here has established differences in flavonoid 
dissolution from different materials, and so can be used as a tool for quality control.  
 
 
5.4.4  Analysis of dissolution data using Principal Component Analysis (PCA)  
The results of PCA analysis of dissolution data are presented in Figures 5.4.7 to 5.4.10. The 
loadings plot of dissolution data for S. frutescens LP, SDAE and FDAE materials are presented 
in Figure 5.4.7. It can be seen from the cluster that sample collection at 20, 30, and 60 
minutes does not make much difference to the results, and one of these time points can be 
selected in order to save time and resources. The sampling time at 120 minutes was 
different at all the pH conditions, however, sampling at 5 and 10 minutes may not be 
necessary and only one of the two sampling times may suffice. At all the pH conditions 
assessed, a total of 4 to 6 sampling points can therefore be adequately used to construct a 
dissolution profile of flavonoid glycoside release from any of the three S. frutescens 
materials.  
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Figure 5.4.7:    PCA loadings for the dissolution of sutherlandins A, B, C, D, from three S.  
          frutescens materials (LP, SDAE and FDAE)  at (A) pH 1.2  (B) pH 4.5 and  
(C) pH 6.8 
B:  
C:  
 
 
A 
 
 
 
 
B 
 
 
 
 
 
C 
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The scores plot of dissolution data for S. frutescens LP, SDAE and FDAE materials are 
presented in Figures 5.4.8 to 5.4.10. The scores plot of a PCA portrays the relationship 
between observations, and observations that are similar cluster more than observations 
that exhibit significant differences. The scores plots projected show that dissolution of 
flavonoid glycosides from S. frutescens materials at pH 1.2, 4.5 and 6.8 depends mainly on 
the S. frutescens material and less on the pH of the dissolution medium or the properties of 
the flavonoid glycoside itself. Note the clustering of S. frutescens materials (LP, SDAE or 
FDAE) in the highlighted sections of Figures 5.4.8 a, 5.4.9 a and 5.4.10 a. Such clustering 
shows similarity in dissolution of different marker compounds from the same material, 
while the non-clustering observed in the highlighted sections (of Figures 5.4.8 b, 5.4.9 b and 
5.4.10 b) indicates that the pH of the medium or characteristics of the marker compounds 
contribute less than the S. frutescens material in the dissolution characteristics of the 
markers from S. frutescens materials.  
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Figure 5.4.8 (a):  PCA scores plot of marker compounds dissolution from S. frutescens 
materials at pH 1.2, with highlights on the different materials: (I) LP 
material,   (II) spray-dried aqueous extract material, and   (III) freeze-
dried aqueous extract material 
 
 
 
 
      
  
 
 
Figure 5.4.8 (b): PCA scores plot of marker compounds dissolution from S. frutescens 
materials at pH 1.2, with highlights on the different marker 
compounds:  (A) sutherlandin A, (B) sutherlandin B,  (C) sutherlandin C, 
and  (D) sutherlandin D  
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Figure 5.4.9 (a): PCA scores plot of marker compounds dissolution from S. frutescens 
materials at pH 4.5, with highlights on the different materials: (I) LP 
material,   (II) spray-dried aqueous extract material, and   (III) freeze-
dried aqueous extract material 
 
 
 
  
  
 
 
Figure 5.4.9 (b): PCA scores plot of marker compounds dissolution from S. frutescens 
materials at pH 4.5, with highlights on the different marker 
compounds:  (A) sutherlandin A,  (B) sutherlandin B,  (C) sutherlandin 
C, and  (D) sutherlandin D 
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Suth C LP-SD-FD at pH 4.5
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PCA Scores [Model 1]
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  4.5 SDB: i
  4.5 LPD: c
  4.5 LPD: h
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  4.5 LPB: b
  .  : b
  4.5 LPD: a
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  4.5 LPD: e
  4.5 LPA: d
  4.5 LPA: h
  4.5 SDB: g
  4.5 SDD: g
  4.5 LPA: b  4.5 LPC: b
  4.5 LPB: e
  4.5 SDD: b
  .  : a
  4.5 LPB: c
  4.5 SDD: c
 4.5 LPA: e
  4.5 LPC: c
  4.5 LPB: g
  4.5 LPA: a
  4.5 LPC: h
 4.5 SDA: c
  4.5 SDC: g
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  4.5 SDA: g
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  4.5 SDB: k
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  4.5 SDA: a
  4.5 LPA: k
  4.5 SDC: h
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  4.5 SDA: f
  4.5 SDB: f
  4.5 LPC: k
  4.5 LPD: i
  4.5 LPA: j
  4.5 SDD: f
  4.5 LPC: i
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  4.5 SDB: j
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Suth D LP-SD-FD at pH 4.5
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Figure 5.4.10 (a):  PCA scores plot of marker compounds dissolution from S. frutescens 
materials at pH 6.8, with highlights on the different materials: (I) LP 
material,   (II) spray-dried aqueous extract material, and   (III) freeze-
dried aqueous extract material 
 
 
 
          
  
 
Figure 5.4.10 (b):  PCA scores plot of marker compounds dissolution from S. frutescens 
materials at pH 6.8, with highlights on the different marker 
compounds:  (A) sutherlandin A,  (B) sutherlandin B,  (C) sutherlandin 
C, and  (D) sutherlandin D 
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LP ABCD at pH 6.8
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5.4.5 Conclusions 
A dissolution test was developed and utilized for S. frutescens materials, with selected 
flavonoid glycosides as marker compounds. The flavonoid glycoside compounds were 
soluble in aqueous-based media, enabling the assessment of dissolution profiles at three 
different pH conditions. The dissolution profiles for each flavonoid glycoside marker 
compound were found to differ in all three S. frutescens materials.  
 
For quality control and regulation of S. frutescens products then, the flavonoid glycosides, 
along with their Q-release and f2-values can be employed as differentiating tools in 
dissolution tests of different materials. The dissolution test as well as the profile comparison 
methods here reported can be applied to the quality control and bioequivalence assessment 
of S. frutescens products using the flavonoid glycosides as marker compounds. The same can 
also be applied in the quality control of other herbal materials containing flavonoid 
glycosides provided suitable marker compounds are selected for such materials. The 
flavonoid aglycones, on the other hand, could not be detected in some of the materials and 
so may not be ideal for quality control studies by dissolution tests.   
 
The differences observed in the dissolution of each flavonoid glycoside marker compound 
from the different materials may be due to differences in their release from the enclosing 
material, a prerequisite for API dissolution. This shall be explored in the next section.  
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5.5 Modelling of flavonoid glycoside release from different S. frutescens materials 
To elucidate the mechanisms behind release of flavonoid glycoside marker compounds from 
S. frutescens materials, dissolution data of flavonoid glycosides from different S. frutescens 
materials were fitted to mathematical models. This section describes the results obtained 
from mathematical modelling of marker compound release from the different materials.  
 
 
5.5.1  Release profiles and kinetics of flavonoid glycosides from S. frutescens materials 
(LP, SDAE and FDAE) 
 
5.5.1.1      Release profiles and kinetics at pH 1.2 
From the leaf powder (LP) material at pH 1.2, release profile of sutherlandins A and B best 
fit the Weibull_1 model (R2 = 0.9818 and 0.9818, respectively), while the best fit for 
sutherlandins C and D (R2 = 0.9845 and 0.9871, respectively) was obtained with the 
Weibull_4 model (Figure 5.5.1, and Appendix 6: Table A 6.1). Although there is no 
universally acceptable empirical model for dissolution curves, the Weibull model has been 
found to fit most dissolution data curves.151 The β-values of the Weibull function were 1.827 
± 1.453, 2.434 ± 1.757, 1.509 ± 1.517 and 2.384 ± 1.540 for sutherlandins A, B, C and D, 
respectively. Based on the β-values, release of sutherlandin A from the LP material at pH 1.2 
is by a complex mechanism.  
 
From the spray-dried aqueous extract (SDAE), the in vitro release data for sutherlandins A to 
D did not fit any of the assessed models. The models of best fit were the Peppas-Sahlin and 
Makoid-Banakar models (Figure 5.5.2); however, the R2 values were only between 0.4000 
and 0.8000, and so the profiles were not deemed good enough for fitting to the Korsmeyer-
Peppas model for release mechanism elucidation.  
 
For release of the reference standards from the FDAE material, the plot showed  relatively 
good R2 values, with goodness of fit for the Weibull models, as well as the Makoid-Banakar 
with Tlag, Peppas Sahlin 1 and Logistic models. Based on the R
2 and R2adj values, the 
Weibull_4 model for sutherlandins A (R2 = 0.9902) and C (R2 = 0.9909), and the Makoid-
Banakar model for sutherlandin B (R2 = 0.9949) were selected as the models of best fit 
(Figure 5.5.3). 
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Figure 5.5.1:  Models of best fit for in vitro release of sutherlandins A–D from S. frutescens 
LP at pH 1.2. Results are Mean ± SD. Equations are for models of best fit for 
release of marker compounds from S. frutescens material. 
 
 
 
 
Figure 5.5.2:  Models of best fit for in vitro release of sutherlandins A–D from S. frutescens 
SDAE at pH 1.2. Results are Mean ± SD. Equations are for models of best fit 
for release of marker compounds from S. frutescens material. 
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Values of β in the Weibull models for sutherlandins A and C release were all above 1 
(Appendix 4: Table 1), suggesting a complex release mechanism. The release of sutherlandin 
D from the FDAE showed best fit for the Peppas-Sahlin 1 with Tlag model (R
2 = 0.9714) 
though such fit did not meet the minimum acceptable criterion of 0.9800 for R2, and so 
could not be fit to the Korsmeyer-Peppas model for release mechanism elucidation (Figure 
5.5.3 and Appendix 4: Table 1).      
 
 
 
Figure 5.5.3:  Models of best fit for in vitro release of sutherlandins A–D from S. frutescens 
FDAE at pH 1.2. Results are Mean ± SD. Equations are for models of best fit 
for release of marker compounds from S. frutescens material. 
 
The Korsmeyer-Peppas release exponent, n, for sutherlandin A, B, C and D in the LP material 
at pH 1.2 were 1.183 ± 0.727, 1.183 ± 0.727, 1.145 ± 0.654 and 1.594 ± 0.890, respectively 
(Appendix 6: Table A 6.1). From the FDAE materials at pH 1.2, values of n were 1.455 ± 
0.853, 1.709 ± 2.252 and 1.663 ± 0.588 for sutherlandins A, B and C, respectively (Appendix 
4, Table 1). Such values indicate that release of the marker compounds from the two 
materials was due to polymer relaxation as a result of gel swelling, so-called super case-II 
transport.225 This also seems to agree with the β values obtained from the Weibull models 
for marker compounds release from the LP and FDAE materials, which were above 1 and 
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indicated that release of the reference standards was not by diffusion but rather by a 
complex mechanism. For the release of reference standards from the SDAE material at pH 
1.2, and sutherlandin D from the FDAE at pH 1.2, empirical mathematical models of good fit 
could not be obtained, and so these were not modelled to the Korsmeyer-Peppas equation 
for release mechanism elucidation.   
 
The release of an API in the gastrointestinal tract (GIT), a prerequisite for API dissolution, 
usually takes place in the acidic gastric region, hence the use of dissolution data obtained at 
pH 1.2. However, because some marker compounds exhibited delayed dissolution at some 
pH conditions, as seen in the previous section (Tables 5.4.1 , 5.4.3, 5.4.5, 5.4.7, 5.4.9 and 
5.4.10), which may be due to their delayed release, release profiles and kinetics were also 
assessed at pH 4.5 (representing gastric pH soon after food intake, which may cause delayed 
release and dissolution) and 6.8 (representing intestinal pH), and are here presented.     
 
 
5.5.1.2  Release profiles and kinetics at pH 4.5  
At pH 4.5, release profiles of sutherlandins A to D from the LP material did not meet the set 
requirement for model assignment (i.e. R2 ≥ 0.9800). The models of best fit were the 
Weibull_3 model for sutherlandins A, C and D (R2 = 0.9702, 0.9720 and 0.9581, respectively) 
and the Weibull_4 model for sutherlandin B (R2 = 0.9729) (Figure 5.5.4, and Appendix 6: 
Table A 6.2). Because none of these models met the minimum specification set for R2, they 
were not fit to the Korsmeyer-Peppas model for elucidation of release mechanism.  
 
From the SDAE material, release profiles of the marker compounds (sutherlandins A to D), 
like that from the LP material, did not meet the minimum specifications set for the R2 value. 
As such, they were not fitted to the Korsmeyer-Peppas model for release mechanism 
elucidation. The model of best fit for the reference standards was the Weibull_3 model, 
with R2 values of 0.9623, 0.9599, 0.9598 and 0.9448 for sutherlandins A, B, C and D 
respectively, (Figure 5.5.5).  
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Figure 5.5.4:  Models of best fit for in vitro release of sutherlandins A–D from S. frutescens 
LP at pH 4.5. Results are Mean ± SD. Equations are for models of best fit for 
release of marker compounds from S. frutescens material. 
 
 
 
 
 
Figure 5.5.5:  Models of best fit for in vitro release of sutherlandins A–D from S. frutescens 
SDAE at pH 4.5. Results are Mean ± SD. Equations are for models of best fit 
for release of marker compounds from S. frutescens material. 
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From the FDAE material at pH 4.5, most of the models assessed were good fits for 
description of marker compound release. With the exception of the zero and first order 
models, all the other models assessed showed almost perfect fit (R2 ≥ 0.9900) for the 
release of the four marker compounds (Appendix 6: Table A 6.2). The mathematical models 
of best fit selected for marker compounds release are shown in Figure 5.5.6, and were the 
Peppas-Sahlin_1 with Tlag model for sutherlandin A (R
2 = 0.9982), the Makoid-Banakar with 
Tlag model for sutherlandin B (R
2 = 0.9983) and the Weibull_4 model for sutherlandins C (R2 
= 0.9988) and D (R2 = 0.9932).  
 
 
 
Figure 5.5.6:  Models of best fit for in vitro release of sutherlandins A–D from S. frutescens 
FDAE at pH 4.5. Results are Mean ± SD. Equations are for models of best fit 
for release of marker compounds from S. frutescens material. 
 
The Peppas-Sahlin model can be seen as semi-empirical since in addition to describing the 
shape of the curve, it also gives some information on the underlying mechanism of API 
release. The vakues of kd and kr represent the extent of API release by polymer diffusion and 
polymer relaxation, respectively.158  
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For sutherlandin A release from the FDAE material, which was best described by the Peppas-
Sahlin model, the values of kd and kr were 5.562 ± 29.21 and 7.135 ± 12.41, respectively. 
These values are significantly different (p < 0.05), suggesting that they differ for sutherlandin 
A release from the FDAE material. The value of kr is higher than the value of kd, suggesting 
that release of sutherlandin A from the FDAE material may be more by polymer relaxation 
and less by polymer diffusion; however, with the wide deviations in the values of kd and kr, it 
may well be by a combination of both mechanisms.  
 
Sutherlandin B release from the FDAE material was best described by the Makoid-Banakar 
with Tlag model. Model description for sutherlandins C and D release from the FDAE material 
was best with the Weibull_4 model (Figure 5.5.6). The β-values (1.688 ± 0.386 and 2.420 ± 
1.681 for sutherlandins C and D, respectively) indicate that release is governed by a complex 
mechanism. Even though the Weibull models were not the models of best fit for 
sutherlandins A and B from the FDAE material, they can also be used to model and describe 
sutherlandin A and B release from this material as they proved to fit these models (R2 > 
0.9900). The value of β from the Weibull models (greater than 1 in all cases) suggests a 
complex release mechanism for all the marker compounds from the FDAE material at pH 
4.5.   
 
The Korsmeyer-Peppas release exponents for sutherlandins A, B, C and D from the FDAE 
were 1.059 ± 1.011, 1.681 ± 0.718, 1.647 ± 0.770 and 2.044 ± 1.049, respectively (Appendix 
4, Table 2), indicating that release of the reference standards from the FDAE material at pH 
4.5 was by super case-II transport, a confirmation of the inference drawn from the β values 
in the Weibull models of good fit which suggested a complex release mechanism.  
 
5.5.1.3          Release profiles and kinetics at pH 6.8  
For release profiles of sutherlandins A to D from the LP material at pH 6.8, none of the 
models assessed fit well enough (R2 was less than 0.9800) to be selected as a good fit for 
describing API or marker compound release, and so dissolution data of these markers were 
not fit to the Korsmeyer-Peppas model for elucidation of release mechanism. The models of 
best fit were the Makoid-Banakar with Tlag model for the release of sutherlandins A, B and D 
(R2 = 0.9245, 0.9189 and 0.9389, respectively; Appendix 4, Table 3) and the Peppas-Sahlin 1 
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with Tlag model for the release of suterhlandin C (R
2 = 0.9376). These models are shown in 
Figure 5.5.7.  
 
 
 
Figure 5.5.7:  Models of best fit for in vitro release of sutherlandins A–D from S. frutescens 
LP at pH 6.8 . Results are Mean ± SD. Equations are for models of best fit for 
release of marker compounds from S. frutescens material. 
 
From the SDAE material, release profiles of the marker compounds (sutherlandins A to D), 
like that from the LP material, did not meet the minimum specifications set for the R2 value. 
The models of best fit for marker compounds release were the Weibull_4 model for 
sutherlandins A and C (R2 = 0.9448 and 0.9399, respectively), the Weibull_3 model for 
sutherlandin B (R2 = 0.9163), and the Peppas-Sahlin 1 with Tlag model for sutherlandin D    
(R2 = 0.8889) (Figure 5.5.8). Due to the low R2 values, dissolution data from the SDAE at this 
pH were not fit to the Korsmeyer-Peppas model for release mechanism elucidation. 
 
The FDAE material showed good fit to many of the assessed models (R2 > 0.9800) for the 
release of three out of the four marker compounds (sutherlandins A, B and C) at pH 6.8. The 
release of the markers was best described by the Makoid-Banakar with Tlag model for 
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sutherlandins A, B and D (R2 = 0.9979, 0.9938 and 0.9955, respectively) and the Weibull_4 
model for sutherlandin C (R2 = 0.9948). 
 
 
 
Figure 5.5.8:  Models of best fit for in vitro release of sutherlandins A–D from S. frutescens  
SDAE at pH 6.8. Results are Mean ± SD. Equations are for models of best fit 
for release of marker compounds from S. frutescens material. 
 
For the release of sutherlandins A, B and C, the Weibull models also met the required 
minimum R2 value (i.e. 0.9800) for good model selection. Values of β for this model were all 
above 1 for sutherlandin A, B and C release from the FDAE material, implying that their 
release is by a complex mechanism. Release was however best described by the Makoid-
Banakar model for sutherlandins A, B and D and by the Weibull_4 model for sutherlandin C 
(Figure 5.5.9).  
 
Values of the Korsmeyer-Peppas release exponent for sutherlandins A, B, C and D were all 
above 0.89 (Appendix 4, Table 3), suggesting that release of these compounds from the 
FDAE material at pH 6.8 was neither via diffusion nor zero order kinetics but possibly by 
super case-II transport, a complex release mechanism.  
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Figure 5.5.9:  Models of best fit for in vitro release of sutherlandins A–D from S. frutescens  
FDAE at pH 6.8. Results are Mean ± SD. Equations are for models of best fit 
for release of marker compounds from S. frutescens material. 
 
 
The results of curve-fitting studies suggest that the Weibull and Makoid-Banakar models are 
good mathematical models for describing sutherlandin release from S. frutescens materials, 
even in cases where the coefficient of determination (R2) did not meet the minimum 
specifications set. Release characteristics of the marker compounds from the LP material at 
pH 4.5 and 6.8, and from the SDAE material at all three pH conditions, did not fit optimally 
to any of the models assessed and so could not be described.   
 
The three pH conditions – 1.2, 4.5 and 6.8 – can be said to represent the prevailing pH 
conditions in the stomach prior to feeding, in the stomach after feeding and in the small 
intestine, respectively. As such, they give an indication of the release mechanisms in these 
regions of the gastrointestinal tract and how pH affects such release.  
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5.5.2      Conclusions 
This section reports on the mechanism of release for the marker compounds, sutherlandins 
A to D, from S. frutescens LP, SDAE and FDAE materials. Generally, the empirical models for 
release description of each marker compound at a specific pH differed in the different S. 
frutescens materials. However, the release mechanisms were not Fickian but ranged from 
combined to complex mechanisms that could all be described by super-case II transport. 
The results showed that release was similar for different markers from the same material, in 
support of our third postulated hypothesis, and further confirming results of the PCA 
analysis reported in the previous section.   
 
Based on the elucidated mechanisms of release, the marker compounds were all released 
from the different materials via a complex mechanism. It may thus be concluded that such 
release studies can be used in the analysis and verification of products that claim to contain 
S. frutescens. To differentiate S frutescens materials however, it may be necessary to 
determine the model of best fit as this, unlike the release mechanism, differed for different 
materials. Such differences may further serve to explain the differences in Q-release values 
and dissolution profiles of markers from different S. frutescens materials, and may likely 
translate to a difference in in vivo bioavailability and efficacy of formulations containing 
different materials. There may therefore be a need to implement tests such as these for 
quality control, especially in the formulation stages of S. frutescens products, in order to 
obtain products with desired release characteristics.  
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5.6  Prediction of in vivo bioavailability of selected flavonoids  
The objective of this section was to assess the likelihood of flavonoid absorption after oral 
administration in humans. Chemical structures of reference and marker compounds 
employed in this study, and the computational resource, Molecular Operating Environment 
(MoE), were utilized to generate molecular properties which were assessed by Lipinski’s 
Rule of 5 and the Rule of 3 in order to predict each reference or marker compound’s 
expected bioavailability.184,185 Such predictions will be compared to actual in vivo results 
obtained from the upcoming clinical trial.  
 
5.6.1    Molecular properties of flavonoids 
Table 5.6.1 depicts the molecular properties of S. frutescens reference and marker 
compounds, which can be used to assess their bioavailability following oral administration.  
 
The first four flavonoid glycosides (sutherlandins A, B, C and D) have 11 to 12 hydrogen 
bond donors, 17 to 18 hydrogen bond acceptors, molecular weights greater than 500 
Daltons, and log P values less than 5. They can be seen to have violated more than one 
criterion in the Rule of 5, which makes them unlikely candidates for new drug development. 
Even with log P values less than 5, more than one rule has been violated and so these 
compounds may not be likely drug candidates. In any case, the said log P values for all the 
flavonoid glycosides are negative, indicating that they did not actually meet the criterion set 
for log P (≤ 5); compounds with negative log P values are too hydrophilic and unable to pass 
through membranes, since they hardly enter the hydrophobic interior (exemplified by the 
octanol phase in the octanol /water system) of the lipophilic lipid bilayer.226 The three other 
flavonoid glycosides (rutin, quercitrin and kaempferol-3-O-rutinoside) also have molecular 
properties in excess of the specifications set by Lipinski et al.184 The glycoside, quercitrin, 
even though it complied with the molecular mass and log P values, may not be bioavailable 
as more than one criteria of the Rule of 5 has been violated.  
 
The flavonoid aglycones, on the other hand, have 4 to 5 hydrogen bond donors, 5 to 6 
hydrogen bond acceptors, molecular mass of less than 500 Daltons and log P values less 
than 5, which makes them likely candidates for new drug development according to the 
Rule of 5.  
142 
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Table 5.6.1:  Molecular properties of reference and marker compounds 
 
Compound
H-bond 
donors
H-bond 
acceptors
Molecular 
mass (Da) log P
Rotatable 
bonds
Total polar 
surface area
Bioavailability 
status
Sutherlandin A
12 18 740.62 -1.85 11 0
Not 
bioavailable 
Sutherlandin B
12 18 740.62 -1.90 12 0
Not 
bioavailable 
Sutherlandin C
11 17 724.62 -1.57 11 0
Not 
bioavailable 
Sutherlandin D
11 17 724.62 -1.63 12 0
Not 
bioavailable 
Rutin 
10 16 612.54 -1.35 6 0
Not 
bioavailable 
Quercitrin 
7 11 450.4 0.57 3 0
Not 
bioavailable 
Kaempferol-3-O -rutinoside
9 15 596.54 -1.08 6 0
Not 
bioavailable 
Quercetin 
5 6 302.24 2.03 1 0 Bioavailable
Kaempferol
4 5 286.24 2.3 1 0 Bioavailable
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Applying the Rule of 3 for oral bioavailability assessment, all seven flavonoid glycosides can 
also be seen to have violated the rule in terms of the listed characteristics, while the 
flavonoid aglycones did not.   
 
While the flavonoid glycosides have been shown to be good markers for content and 
dissolution studies of S. frutescens, they may not be orally bioavailable. This means that in 
plasma samples analysed during the forthcoming clinical trial, the flavonoid glycosides may 
not be detected. However, flavonoid glycosides can be converted to the aglycones on 
hydrolysis, contributing to the plasma profiles of the bioavailable aglycones. We can 
therefore hydrolyse flavonoid glycosides to aglycones, and determine the equivalent level of 
flavonoid aglycones represented by the flavonoid glycosides in each S. frutescens material. 
This can be compared to the actual levels of flavonoid aglycones detected in plasma in order 
to calculate the percentages of the marker compounds that are absorbed.   
 
 
5.6.2     Conclusions 
Identification of lead molecules with drug-like properties is still a major challenge in drug 
discovery settings. A computerised model incorporating various guidelines for drug 
discovery can assist in the identification of lead molecules with favourable properties early 
on in drug discovery, minimizing the chances of misses, and perhaps by-passing the need for 
in vivo tests. From the results obtained, the flavonoid aglycones of S. frutescens (quercetin 
and kaempferol), but not the flavonoid glycosides (sutherlandins A, B, C and D) met the Rule 
of 5 and the Rule of 3 criteria for in vivo bioavailability of orally administered compounds. 
They (the flavonoid aglycones) can thus be employed as marker compounds for in vivo 
studies of S. frutecens products. While the flavonoid glycosides may not be orally 
bioavailable, they can be quantified from flavonoid aglycone levels in hydrolysed samples.    
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CHAPTER SIX 
 
CONCLUSIONS & RECOMMENDATIONS 
 
Various formulations of the popular South African medicinal plant, Sutherlandia frutescens, 
are commercially available, with no documentation for their quality assessment. This study 
set out to develop quality control measures that can be employed in the control and 
regulation of S. frutescens products.  
 
The objectives of this study were:  
 
- to isolate and identify flavoniod glycosides (sutherlandins A, B, C and D) as marker 
compounds for S. frutescens, 
- to develop and validate an HPLC assay for flavonoids in S. frutescens,  
- to compare flavonoid content of different S. frutescens materials, 
- to compare in vitro dissolution profiles and release mechanisms of flavonoids from 
different S. frutescens materials, and  
- to predict in vivo bioavailability of S. frutescens flavonoids. 
 
From the results obtained, the following findings were made: 
 
 Sutherlandins A, B, C and D were successfully isolated from S. frutescens SDAE 
material, with percentage purity approximately 99 % for sutherlandins A, C and D, 
and 90 % for sutherlandin B, as determined from HPLC analysis. These compounds 
can be used for HPLC method development, as well as for quantification studies of 
sutherlandins in different materials.     
 
 An HPLC assay was successfully developed and validated for flavonoid glycosides and 
their corresponding aglycones in S. frutescens materials. The developed HPLC 
method is simple, precise and robust, and was further applied for flavonoid 
quantification in different S. frutescens materials. Validation parameters for the 
developed HPLC method were within acceptable limits. The flavoniod glycosides 
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were found to be good marker compounds for S. frutescens materials, and their 
levels were more than the levels of the flavonoid aglycones in the materials 
assessed, supporting our proposed hypothesis that flavonoid glycoside content 
exceeds flavonoid aglycone content. The percentages of the flavonoid glycosides 
were at least 0.5  % in all the samples assayed with the exception of sutherlandin A 
content in FDAE 1 and FDAE 3 which were 0.203 ± 0.002 % and 0.073 ± 0.00  %, 
respectively. The difference in content of each flavonoid compound in the different 
materials was found to be statistically significant (p < 0.001), and so flavoniod 
content levels can be used to differentiate S. frutescens materials.     
 
 A dissolution test was utilized for S. frutescens materials, with the flavonoids as 
marker compounds. A Q-value of 75 % was attained within 45 minutes for all the 
flavonoid glycosides from the LP and SDAE materials, implying that release and 
dissolution from these materials was immediate. From the FDAE sample, a Q-value 
of 75 % was attained in 90 minutes at the earliest, implying delayed release and 
dissolution from this material. The f2 values for each flavonoid glycoside compound 
from the different materials were all below 50, thus implying dissimilarity of 
dissolution profiles. The flavonoid aglycones, on the other hand, could not be 
detected in some of the materials and so may not be ideal markers for S. frutescens 
dissolution studies. The dissolution test established differences in flavonoids 
dissolution from different S. frutescens materials and so can be employed for their 
quality control.  
 
 Different mathematical models described the release of each flavonoid glycoside 
(sutherlandin) from the different S. frutescens materials. Release mechanisms also 
differed for each sutherlandin in the different S. frutescens materials, but were 
similar for different sutherlandins from the same material. This indicates that release 
of the flavonoid glycosides depends more on the S. frutescens material than on the 
characteristics of the marker compounds. Therefore, release mechanisms of all four 
sutherlandins (A, B, C and D) can be employed for identification of S. frutescens 
materials as they will be similar in all S. frutescens materials. Following such 
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identification, the mathematical model of best fit for any of the sutherlandins can be 
used to differentiate between S. frutescens materials.  
 
 The flavonoid aglycones of S. frutescens (quercetin and kaempferol), but not the 
flavonoid glycosides (sutherlandins A, B, C and D, rutin, quercetrin and kaempferol-3-
O-rutinoside) met the criteria for in vivo bioavailability of orally administered 
compounds. This shows that the flavonoid aglycones, rather than the flavonoid 
glycosides, will be orally bioavailable. In S. frutescens samples, bioavailability of the 
flavonoid glycosides can thus be assessed by hydrolysing such flavonoid glycosides to 
their corresponding flavonoid aglycones.  
 
Overall, this study provides methods and valuable preliminary data that can be used for 
quality assessment of S. frutescens materials. In line with our findings, the following are 
recommended:  
 
- For quality assessment of S. frutescens materials, the HPLC method here reported 
can be employed as it is sensitive enough to detect differences in S. frutescens 
materials.  
- The dissolution test so reported also establishes differences between different S. 
frutescens materials, and gives an indication of the release mechanisms of flavonoid 
marker compounds from these materials. As such, it can be employed for the quality 
control of S. frutescens materials.  
 
The problems encountered with quality control and assessment of S. frutescens materials 
are however not peculiar to S. frutescens alone, but can be experienced with any other 
herbal material or product. Therefore, the HPLC and dissolution methods herein described 
for flavonoids in S. frutescens can be employed for the quality assessment and control of 
other flavonoid-containing herbal materials. Flavonoids are known to be very common in 
plant materials and so such methods and tests as reported here will assist to a great extent 
in herbal product quality control and regulation, thereby improving the quality and efficacy 
of such products.  
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Appendix 1: Certificates of analysis (CoA) for S. frutescens materials 
 
 
 
Figure A 1.1:  Certificate of analysis for leaf powder (LP) material, batch number: E 16794 
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Figure A 1.2: Certificate of analysis for spray-dried aqueous extract (SDAE) material, batch 
number: Ferl-DST/001-1210 
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Figure A 1.3:  Certificate of analysis for freeze-dried aqueous extract (FDAE) material 2, batch 
number: E 62265 
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Figure A 1.4:  Certificate of analysis for freeze-dried aqueous extract (FDAE) material 3, batch number: E 
63067 
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Appendix 2: UV spectra of the first four fractions from S. frutescens material  
 
Figure A 2.1: Fraction 1; 0% acetonitrile 
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Figure A 2.2: Fraction 2; 20% acetonitrile 
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Figure A 2.3: Fraction 3; 40% acetonitrile 
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Figure A 2.4: Fraction 4; 60% acetonitrile   
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Appendix 3:  NMR spectra of flavonoid glycosides isolated from S. frutescens matrerials 
 
Figure A 3.1:  NMR spectrum of sutherlandin  A in methanol-d4 (CD3OH) 
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Figure A 3.2:   NMR spectrum of sutherlandin  A in methanol-d4 (CD3OH) 
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Figure A 3.3:   NMR spectrum of sutherlandin  A in methanol-d4 (CD3OH) 
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Figure A 3.4:  NMR spectrum of sutherlandin  B in methanol-d4 (CD3OH) 
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Figure A 3.5:   NMR spectrum of sutherlandin  B in methanol-d4 (CD3OH) 
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Figure A 3.6:   NMR spectrum of sutherlandin  B in methanol-d4 (CD3OH) 
 
 
 
 
180 
 
 
 
Figure A 3.7:   NMR spectrum of sutherlandin  C in methanol-d4 (CD3OH) 
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Figure A 3.8:   NMR spectrum of sutherlandin  C in methanol-d4 (CD3OH) 
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Figure A 3.9:   NMR spectrum of sutherlandin  C in methanol-d4 (CD3OH) 
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Figure A 3.10:  NMR spectrum of sutherlandin  D in methanol-d4 (CD3OH) 
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Figure A 3.11:   NMR spectrum of sutherlandin  D in methanol-d4 (CD3OH) 
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Figure A 3.12:   NMR spectrum of sutherlandin  D in methanol-d4 (CD3OH) 
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Appendix  4: Dissolution profiles of sutherlandins A, B, C and D from S. frutescens 
materials at different pH conditions 
 
 
 
Figure A 4.1: Dissolution profiles of sutherlandin A (from S. frutescens materials) at pH 1.2, 4.5 and 
6.8. Data is presented as mean ± SD. 
 
 
 
 
Figure A 4.2: Dissolution profiles of sutherlandin B (from S. frutescens materials) at pH 1.2, 4.5 and 
6.8.  Data is presented as mean ± SD. 
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Figure A 4.3: Dissolution profiles of sutherlandin C (from S. frutescens materials) at pH 1.2, 4.5 and 
6.8. Data is presented as mean ± SD. 
 
 
 
 
 
Figure A 4.4: Dissolution profiles of sutherlandin D (from S. frutescens materials) at pH 1.2, 4.5 and 
6.8. Data is presented as mean ± SD. 
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Appendix  5:  Dissolution data for sutherlandins from different S. frutescens materials 
   at pH 1.2, 4.5 and 6.8 
 
Table  A 5.1:  Dissolution data for sutherlandin A 
 
LP                   
 pH 1.2  pH 1.2  pH 1.2  pH 4.5  pH 4.5  pH 4.5  pH 6.8  pH 6.8 pH 6.8 
 Time (mins) Ave SD % CV Ave SD CV % Ave SD CV % 
0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 
5 24.6 11.1 45.1 19.4 12.1 62.4 12.2 12.8 104.9 
10 45.4 11.0 24.2 53.2 19.7 37.0 47.1 15.1 32.1 
15 70.8 13.0 18.4 83.7 12.4 14.8 68.3 11.8 17.3 
20 78.9 13.4 17.0 95.4 4.7 4.9 76.2 7.9 10.4 
30 85.1 12.5 14.7 93.6 7.0 7.5 80.8 16.4 20.3 
60 93.7 8.0 8.5 95.4 4.9 5.1 90.2 12.6 14.0 
90 97.8 1.5 1.5 94.7 4.1 4.3 90.4 10.5 11.6 
120 97.3 6.4 6.6 90.3 7.0 7.8 86.0 8.6 10.0 
SDAE             
 
    
  pH 1.2  pH 1.2  pH 1.2  pH 4.5  pH 4.5  pH 4.5  pH 6.8  pH 6.8 pH 6.8 
 Time (mins) Ave SD % CV Ave SD CV % Ave SD CV % 
0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 
5 43.7 5.9 13.5 34.7 11.5 33.1 25.4 7.6 29.9 
10 78.9 10.7 13.6 54.0 7.7 14.3 72.8 9.0 12.4 
15 88.3 13.3 15.1 70.4 4.5 6.4 90.3 6.8 7.5 
20 93.1 10.2 11.0 81.7 7.5 9.2 95.6 6.0 6.3 
30 91.6 10.4 11.4 87.0 4.6 5.3 96.0 5.2 5.4 
60 89.1 11.1 12.5 94.0 7.0 7.4 91.4 6.6 7.2 
90 90.4 8.7 9.6 94.9 5.0 5.3 89.4 4.3 4.8 
120 83.0 16.5 19.9 97.0 5.1 5.3 86.1 6.5 7.5 
FDAE                   
  pH 1.2  pH 1.2  pH 1.2  pH 4.5  pH 4.5  pH 4.5  pH 6.8  pH 6.8 pH 6.8 
 Time (mins) Ave SD % CV Ave SD CV % Ave SD CV % 
0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 
5 3.3 11.4 345.5 0.0 0.0 0.0 0.0 0.0 0.0 
10 0.9 3.2 355.6 0.0 0.0 0.0 0.0 0.0 0.0 
15 2.5 6.4 256.0 0.0 0.0 0.0 0.0 0.0 0.0 
20 11.5 8.0 69.6 2.2 5.1 231.8 0.0 0.0 0.0 
30 27.6 5.8 21.0 14.8 8.3 56.1 10.0 9.7 97.0 
60 62.6 10.4 16.6 62.1 9.8 15.8 66.1 7.8 11.8 
90 90.8 8.2 9.0 86.9 8.7 10.0 90.9 8.7 9.6 
120 99.1 3.2 3.2 99.1 2.7 2.7 98.3 4.4 4.5 
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Table  A 5.2:  Dissolution data for sutherlandin B  
 
LP                   
  pH 1.2  pH 1.2  pH 1.2  pH 4.5  pH 4.5  pH 4.5  pH 6.8  pH 6.8 pH 6.8 
 Time 
(mins) Ave SD % CV Ave SD % CV Ave SD % CV 
0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 
5 22.5 12.6 56.0 31.6 13.0 41.1 7.9 12.0 151.9 
10 41.8 14.2 34.0 50.4 8.2 16.3 43.5 14.2 32.6 
15 66.2 17.5 26.4 64.8 8.8 13.6 63.8 10.3 16.1 
20 74.2 18.9 25.5 77.5 10.8 13.9 71.4 8.6 12.0 
30 80.1 17.9 22.3 82.6 8.6 10.4 77.8 16.3 21.0 
60 85.9 14.3 16.6 92.1 9.1 9.9 88.0 13.3 15.1 
90 94.1 8.6 9.1 94.6 7.2 7.6 87.7 14.7 16.8 
120 96.7 6.8 7.0 95.5 7.5 7.9 86.8 11.4 13.1 
   
              
SDAE                   
  pH 1.2  pH 1.2  pH 1.2  pH 4.5  pH 4.5  pH 4.5  pH 6.8  pH 6.8 pH 6.8 
 Time 
(mins) Ave SD % CV Ave SD % CV Ave SD % CV 
0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 
5 39.6 7.9 19.9 18.5 11.4 61.6 23.7 7.5 31.6 
10 77.4 15.3 19.8 51.0 19.8 38.8 69.3 8.8 12.7 
15 85.9 17.5 20.4 81.7 13.1 16.0 88.2 6.7 7.6 
20 92.7 13.0 14.0 95.0 5.1 5.4 94.1 7.4 7.9 
30 88.3 12.6 14.3 91.7 4.6 5.0 93.9 7.4 7.9 
60 81.3 17.5 21.5 94.7 5.5 5.8 88.4 8.9 10.1 
90 72.3 14.6 20.2 92.3 4.2 4.6 87.2 6.1 7.0 
120 53.6 20.5 38.2 88.2 9.2 10.4 82.2 8.9 10.8 
 
FDAE                   
  pH 1.2  pH 1.2  pH 1.2  pH 4.5  pH 4.5  pH 4.5  pH 6.8  pH 6.8 pH 6.8 
 Time 
(mins) Ave SD % CV Ave SD % CV Ave SD % CV 
0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 
5 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 
10 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 
15 1.3 3.2 246.2 1.5 2.7 180.0 0.9 2.2 244.4 
20 3.7 6.7 181.1 5.9 3.8 64.4 7.6 4.8 63.2 
30 14.2 13.9 97.9 15.9 6.6 41.5 19.5 8.2 42.1 
60 53.2 21.6 40.6 59.8 12.1 20.2 64.2 8.9 13.9 
90 91.9 9.6 10.4 85.3 8.4 9.8 89.0 10.5 11.8 
120 94.4 11.6 12.3 98.0 4.8 4.9 97.9 5.3 5.4 
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Table  A 5.3:  Dissolution data for sutherlandin C  
 
LP                   
  pH 1.2  pH 1.2  pH 1.2 pH 4.5  pH 4.5  pH 4.5 pH 6.8  pH 6.8 pH 6.8 
 Time 
(mins) Ave SD % CV Ave SD % CV Ave SD % CV 
0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 
5 24.2 10.2 42.1 34.9 11.2 32.1 13.2 13.6 103.0 
10 43.9 9.9 22.6 53.7 5.8 10.8 46.8 14.8 31.6 
15 68.6 11.1 16.2 69.5 5.1 7.3 65.1 15.3 23.5 
20 77.3 12.2 15.8 81.3 6.9 8.5 76.0 8.8 11.6 
30 84.8 10.9 12.9 86.0 5.8 6.7 83.3 14.3 17.2 
60 94.0 6.2 6.6 95.0 6.0 6.3 90.4 13.0 14.4 
90 98.0 2.3 2.3 96.8 3.3 3.4 93.1 9.7 10.4 
120 95.9 6.3 6.6 96.9 4.5 4.6 89.3 7.9 8.8 
   
              
SDAE                   
  pH 1.2  pH 1.2  pH 1.2 pH 4.5  pH 4.5  pH 4.5 pH 6.8  pH 6.8 pH 6.8 
 Time 
(mins) Ave SD % CV Ave SD % CV Ave SD % CV 
0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 
5 43.5 6.0 13.8 18.4 11.7 63.6 23.1 7.0 30.3 
10 77.4 11.5 14.9 51.5 19.8 38.4 71.3 10.1 14.2 
15 87.9 13.2 15.0 81.8 11.1 13.6 89.0 7.6 8.5 
20 92.0 11.4 12.4 94.3 4.9 5.2 96.3 5.8 6.0 
30 90.9 10.8 11.9 90.4 6.1 6.7 94.9 6.7 7.1 
60 89.5 11.3 12.6 95.0 5.1 5.4 92.9 7.9 8.5 
90 91.6 10.0 10.9 94.5 4.7 5.0 90.8 7.6 8.4 
120 86.3 16.4 19.0 86.7 8.2 9.5 87.0 8.7 10.0 
          
FDAE                   
  pH 1.2  pH 1.2  pH 1.2 pH 4.5  pH 4.5  pH 4.5 pH 6.8  pH 6.8 pH 6.8 
 Time 
(mins) Ave SD % CV Ave SD % CV Ave SD % CV 
0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 
5 2.3 4.3 187.0 0.2 0.8 400.0 0.0 0.0 0.0 
10 3.3 2.3 69.7 0.0 0.0 0.0 0.0 0.0 0.0 
15 7.7 3.7 48.1 1.3 3.2 246.2 0.9 2.1 233.3 
20 12.2 4.9 40.2 6.8 4.2 61.8 6.5 4.1 63.1 
30 22.7 7.9 34.8 18.4 5.2 28.3 18.8 8.7 46.3 
60 62.1 10.7 17.2 62.0 12.5 20.2 64.9 9.3 14.3 
90 87.9 8.0 9.1 87.0 7.2 8.3 91.5 9.2 10.1 
120 98.4 3.8 3.9 100.0 0.0 0.0 97.4 6.0 6.2 
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Table  A 5.4:  Dissolution data for sutherlandin D  
 
LP                   
  pH 1.2  pH 1.2  pH 1.2  pH 4.5  pH 4.5  pH 4.5 pH 6.8  pH 6.8 pH 6.8 
 Time 
(mins) Ave SD % CV Ave SD % CV Ave SD % CV 
0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 
5 21.9 14.1 64.4 33.5 11.4 34.0 11.4 13.1 114.9 
10 39.8 16.6 41.7 51.8 5.2 10.0 45.7 14.2 31.1 
15 62.0 20.7 33.4 66.2 9.9 15.0 66.3 13.6 20.5 
20 69.3 22.4 32.3 78.7 9.0 11.4 74.4 9.1 12.2 
30 75.9 22.6 29.8 82.0 11.9 14.5 82.0 14.3 17.4 
60 79.1 20.6 26.0 93.0 8.6 9.2 88.7 12.3 13.9 
90 89.7 15.5 17.3 95.7 4.9 5.1 92.4 10.7 11.6 
120 96.5 6.5 6.7 95.9 6.5 6.8 89.2 8.6 9.6 
         
 SDAE                   
  pH 1.2  pH 1.2  pH 1.2  pH 4.5  pH 4.5  pH 4.5 pH 6.8  pH 6.8 pH 6.8 
 Time 
(mins) Ave SD % CV Ave SD % CV Ave SD % CV 
0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 
5 44.9 13.4 29.8 17.5 10.2 58.3 16.6 9.7 58.4 
10 78.3 11.3 14.4 49.1 20.5 41.8 66.0 16.3 24.7 
15 91.4 10.9 11.9 78.3 11.5 14.7 85.2 16.5 19.4 
20 90.0 14.1 15.7 92.5 7.4 8.0 93.3 7.5 8.0 
30 83.3 14.6 17.5 86.4 7.4 8.6 92.2 8.5 9.2 
60 76.7 9.1 11.9 94.2 6.4 6.8 90.7 9.5 10.5 
90 70.9 18.0 25.4 93.3 5.1 5.5 85.9 14.9 17.3 
120 63.7 14.8 23.2 82.8 11.9 14.4 77.7 16.9 21.8 
         
 FDAE                   
  pH 1.2  pH 1.2  pH 1.2  pH 4.5  pH 4.5  pH 4.5 pH 6.8  pH 6.8 pH 6.8 
 Time 
(mins) Ave SD % CV Ave SD % CV Ave SD % CV 
0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 
5 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 
10 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 
15 0.7 2.4 342.9 1.1 2.5 227.3 0.4 1.3 325.0 
20 1.6 5.5 343.8 5.1 5.2 102.0 1.6 4.1 256.3 
30 19.7 15.8 80.2 17.1 7.6 44.4 17.1 10.2 59.6 
60 55.1 20.8 37.7 60.4 14.5 24.0 60.1 15.2 25.3 
90 95.7 6.9 7.2 87.4 11.5 13.2 92.1 9.3 10.1 
120 84.4 28.1 33.3 99.1 2.2 2.2 91.7 21.7 23.7 
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Appendix  6:  Fitting of dissolution data to mathematical models 
 
Table A 6.1:  Fitting of dissolution data at pH 1.2 for mathematical modelling, best values are highlighted 
 
 
LP: A LP: B LP: C LP: D SDAE: A SDAE: B SDAE: C SDAE: D FDAE: A FDAE: B FDAE: C FDAE: D
Zero order k0 1.188±0.016 1.186±0.011 1.242±0.014 1.252±0.013 0.988±0.094 0.870±0.125 1.058±0.127 0.886±0.145 0.876±0.052 0.778±0.099 0.869±0.033 0.787±0.114
R 2 -3.0575 -3.1309 -2.7536 -3.6018 -8.2291 -6.0427 -7.5255 -9.5853 0.9262 0.8570 0.9348 0.7976
R2adj -3.0575 -3.1309 -2.7536 -3.6018 -8.2291 -6.0427 -7.5255 -9.5853 0.9262 0.8570 0.9348 0.7976
First order k1 0.090±0.011 0.092±0.011 0.083±0.008 0.094±0.012 0.108±0.016 0.107±0.033 0.102±0.032 0.103±0.047 0.015±0.002 0.012±0.003 0.014±0.001 x
R 2 0.9482 0.9427 0.9514 0.9450 -0.1140 -0.5441 -0.2837 -1.5726 0.8509 0.7680 0.8575 x
R2adj 0.9482 0.9427 0.9514 0.9450 -0.1140 -0.5441 -0.2837 -1.5726 0.8509 0.7680 0.8575 x
Weibull_1 β 1.827±1.453 2.434±1.757 1.509±1.517 2.384±1.540 0.054±0.039 -0.078±1.415 0.083±0.068 -0.259±0.550 2.720±1.450 3.296±1.367 2.635±0.942 x
Ti -4.037±9.935 -6.648±9.583 -2.490±10.479 -7.197±9.230 5.000±0.000 -51.368±135.230 4.996±0.006 -69.206±181.766 -10.993±22.495 12.991±32.665 -8.717±24.988 x
R 2 0.9818 0.9818 0.9805 0.9819 0.6085 0.3747 0.5725 0.2722 0.9874 0.9665 0.9892 x
R2adj 0.9745 0.9745 0.9740 0.9759 0.4519 0.1245 0.4300 0.0296 0.9824 0.9531 0.9856 x
Weibull_2 β 1.232±0.416 1.325±0.414 1.169±0.345 1.302±0.397 0.540±0.522 0.360±0.685 0.722±0.828 0.038±0.132 2.032±0.253 4.462±2.375 2.683±1.912 x
R 2 0.9765 0.9745 0.9795 0.9755 0.3240 0.1519 0.4460 0.0568 0.9579 0.9651 0.9867 x
R2adj 0.9726 0.9702 0.9761 0.9714 0.2113 0.0105 0.3536 -0.1005 0.9509 0.9592 0.9849 x
Weibull_3 β 1.281±0.434 1.376±0.442 1.224v0.388 1.352±0.431 1.909±1.000 1.034±1.833 1.666±0.537 0.587±1.911 2.035±0.337 4.613±2.778 2.633±2.139 x
R 2 0.9787 0.9773 0.9800 0.9796 0.6553 0.4632 0.5988 0.2203 0.9873 0.9797 0.9890 x
R2adj 0.9701 0.9683 0.9733 0.9728 0.5174 0.2485 0.4651 -0.0396 0.9822 0.9715 0.9854 x
Weibull_4 β 2.108±1.382 2.428±1.477 1.655±1.123 2.510±1.418 0.461±0.844 -0.177±0.613 0.539±1.030 -0.473±0.567 1.936±1.325 2.830±1.265 2.427±0.949 x
Ti -4.959±6.945 -6.134±6.547 -2.759±6.660 -7.146±6.411 3.689±3.209 -53.410±143.074 3.008±4.858 -229.738±213.282 0.945±17.979 20.584±24.727 -5.116±23.064 x
R 2 0.9841 0.9853 0.9845 0.9871 0.6252 0.3787 0.5879 0.1934 0.9902 0.9816 0.9909 x
R2adj 0.9722 0.9742 0.9751 0.9793 0.3441 -0.0872 0.3407 -0.2906 0.9828 0.9677 0.9854 x
Makoid-Banakar 
with Tlag kMB 36.798±7.402 35.722±8.411 35.521±5.688 37.201±8.244 53.981±21.429 47.364±24.389 58.155±18.440 64.655±12.038 0.702±1.274. 0.702±1.658 0.116±0.220 x
n 0.322±0.065 0.346±0.079 0.316±0.056 0.329±0.075 0.220±0.242 0.566±0.928 0.149±0.187 0.101±0.088 1.829±0.954 6.831±6.380 3.039±2.291 x
k 0.005±0.001 0.006±0.002 0.004±0.001 0.005±0.002 0.005±0.006 0.014±0.015 0.003±0.006 0.006±0.002 0.014±0.011 0.067±0.071 0.024±0.027 x
Tlag 4.195±0.671 4.195±0.601 4.203±0.640 4.227±0.545 3.943±2.132 2.000±6.915 4.407±1.405 3.881±2.556 6.577±6.115 7.714±11.134 -7.082±12.312 x
R 2 0.9742 0.9482 0.9548 0.9473 0.7513 0.7131 0.6709 0.4662 0.9898 0.9949 0.9815 x
R2adj 0.9493 0.9094 0.9276 0.9156 0.5648 0.4980 0.4735 0.1460 0.9821 0.9911 0.9705 x
Peppas-Sahlin 1 with 
Tlag k1 39.702±7.984 39.169±8.751 37.435±5.854 40.311±8.533 65.837±21.693 66.464±39.516 70.731±21.329 115.347±63.518 -22.915±27.496 -0.089±51.167 -41.395±81.385 4.133±28.991
k2 -4.011v1.648 -3.908±1.873 -3.556±1.031 -4.153±1.853 -12.130±6.882 -17.332±21.039 -14.023±7.183 -49.016±46.217 19.258±20.005 14.105±20.359 16.235±25.915 13.834±22.051
Tlag 4.116±0.666 4.168±0.571 4.085±0.654 4.161±0.518 0.265±0.140 4.100±1.558 4.538±0.906 3.726±2.674 12.430±3.413 17.554±49.610 -16.171±48.055 37.105±18.592
R 2 0.9496 0.9469 0.9558 0.9468 0.7524 0.7268 0.6658 0.4831 0.9800 0.9555 0.9541 0.9714
R2adj 0.9118 0.9070 0.9292 0.9149 0.5667 0.5220 0.4653 0.1729 0.9651 0.9221 0.9266 0.9542
Logistic_2 α -3.943±1.421 -4.247±1.436 -3.794±1.257 -4.161±1.442 -10.473±13.600 2.462±21.355 -5.336±1.523 63.836±105.864 -9.257±0.938 -78.095±95.617 -14.007±14.052 x
β 4.313±1.365 4.652±1.361 4.052±1.214 4.595±1.325 14.967±19.357 3.542±12.707 7.628±2.123 -24.584±57.416 5.179±0.720 43.560±53.733 7.940±8.463 x
R 2 0.9718 0.9660 0.9620 0.9665 0.6418 0.4591 0.5894 0.2361 0.9850 0.9794 0.9881 x
R2adj 0.9605 0.9524 0.9683 0.9553 0.4985 0.2428 0.4526 -0.0186 0.9790 0.9712 0.9841 x
Logistic_3 k 0.202±0.067 0.217±0.065 0.187±0.060 0.212±0.062 0.492±1.045 -0.140±0.329 0.189±0.404 -0.038±0.339 0.066±0.009 0.218±0.220 0.085±0.062 x
γ 8.407±1.432 8.503±1.408 8.685±1.472 8.264±1.697 1905.214±4201.00106.289±51.195 336.261±480.146 115.929±57.965 55.111±6.892 63.409±9.467 52.739±4.902 x
R 2 0.9791 0.9797 0.9780 0.9824 0.4900 0.2911 0.4560 0.2046 0.9813 0.9775 0.9865 x
R2adj 0.9708 0.9716 0.9707 0.9766 0.2860 0.0075 0.2747 -0.0605 0.9738 0.9685 0.9820 x
Korsmeyer-
Peppas with Tlag kKP 10.196±11.431 10.196±11.431 9.821±11.852 6.678±12.657 x x x x 0.889±0.840 0.753±1.526 0.300±0.393 x
n 1.183±0.727 1.183±0.727 1.145±0.654 1.594±0.890 x x x x 1.455±0.853 1.709±2.252 1.663±0.588 x
Tlag -1.729±5.278 -1.729±5.278 -1.320±4.129 -3.949±3.904 x x x x 5.068±12.448 5.269±13.446 -4.691±11.053 x
R 2 1.0000 1.0000 0.9999 0.9953 x x x x 0.9998 0.3519 0.9998 x
R2adj 0.9999 0.9999 0.9998 0.9858 x x x x 0.9998 0.2799 0.9998 x
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Table A 6.2:  Fitting of dissolution data at pH 4.5 for mathematical modelling, best values are highlighted 
 
 
LP: A LP: B LP: C LP: D SDAE: A SDAE: B SDAE: C SDAE: D FDAE: A FDAE: B FDAE: C FDAE: D
Zero order k0 2.216±0.098 2.182±0.104 2.225±0.103 2.150±0.153 2.320±0.129 2.302±0.072 2.272±0.110 2.233±0.145 0.842±0.026 0.838±0.027 0.857±0.050 0.839±0.068
R 2 -1.2932 -0.9461 -1.1699 -0.9492 -0.4607 -0.3849 -0.4234 -0.3777 0.9223 0.9424 0.9469 0.9373
R2adj -1.2932 -0.9461 -1.1699 -0.9492 -0.4607 -0.3849 -0.4234 -0.3777 0.9223 0.9424 0.9469 0.9373
First order k1 0.079±0.017 0.073±0.015 0.078±0.018 0.071±0.018 0.085±0.013 0.081±0.009 0.081±0.011 0.077±0.013 0.013±0.001 0.013±0.001 0.013±0.002 0.013±0.002
R 2 0.9269 0.9066 0.9425 0.9064 0.8369 0.8447 0.8420 0.8345 0.8233 0.8468 0.8496 0.8417
R2adj 0.9269 0.9066 0.9425 0.9064 0.8369 0.8447 0.8420 0.8345 0.8233 0.8468 0.8496 0.8417
Weibull_1 β 1.102±0.902 0.729±0.199 1.189±1.015 1.200±1.241 2.995±1.814 3.398±2.102 2.730±1.991 2.539±1.874 1.563±0.184 2.225±0.403 2.119±0.222 3.272±1.710
Ti -0.461±9.485 3.077±1.438 -1.028±10.236 -1.314±11.327 -3.851±7.578 -5.342±8.112 -2.539±7.714 -2.027±7.317 18.981±2.481 3.656±6.216 4.623±3.358 -12.521±21.432
R 2 0.9665 0.9588 0.9690 0.9542 0.9628 0.9639 0.9576 0.9455 0.9968 0.9965 0.9979 0.9927
R2adj 0.9441 0.9313 0.9483 0.9236 0.9381 0.9399 0.9293 0.9092 0.9955 0.9951 0.9971 0.9898
Weibull_2 β 1.099±0.236 1.069±0.312 1.089±0.212 0.989±0.226 2.209±0.409 2.185±0.404 2.108±0.476 2.032±0.559 2.641±0.213 2.385±0.105 2.371±0.091 2.548±0.480
R 2 0.9434 0.9388 0.9551 0.9278 0.9569 0.9567 0.9499 0.9362 0.9932 0.9961 0.9976 0.9913
R2adj 0.9292 0.9235 0.9439 0.9097 0.9461 0.9459 0.9374 0.9203 0.9921 0.9954 0.9972 0.9899
Weibull_3 β 1.301±0.147 1.227±0.351 1.240±0.128 1.187±0.143 2.427±0.294 2.462±0.377 2.403±0.321 2.296±0.498 2.709±0.276 2.329±0.149 2.289±0.150 2.397±0.661
R 2 0.9702 0.9547 0.9723 0.9581 0.9774 0.9759 0.9759 0.9669 0.9938 0.9969 0.9981 0.9935
R2adj 0.9503 0.9244 0.9538 0.9302 0.9623 0.9599 0.9598 0.9448 0.9913 0.9957 0.9973 0.9909
Weibull_4 β 1.371±0.947 1.067±1.044 1.352±0.998 1.566±1.275 3.896±0.750 4.040±1.027 3.747±1.028 3.273±1.509 1.173±0.430 1.907±0.888 1.668±0.386 2.420±1.681
Ti -1.362±9.005 0.413±8.335 -1.297±8.867 -2.659±9.150 -6.305±3.827 -6.923±4.569 -5.806±4.347 -3.941±4.899 23.141±5.025 7.474±12.232 10.233±4.646 -0.186±19.207
R 2 0.9790 0.9729 0.9805 0.9708 0.9816 0.9819 0.9804 0.9713 0.9982 0.9983 0.9993 0.9961
R2adj 0.9474 0.9322 0.9512 0.9270 0.9541 0.9547 0.9509 0.9283 0.9969 0.9970 0.9988 0.9932
Makoid-Banakar 
with Tlag
kMB 22.759±3.263 27.002±11.581 21.783±3.497 20.561±6.194 23.792±8.912 21.678±9.395 22.491±8.840 19.632±9.795 0.036±0.049 0.070±0.064 0.093±0.109 1.047±1.900
n 0.526±0.100 0.443±0.197 0.532±0.078 0.535±0.130 0.598±0.168 0.634±0.188 0.614±0.186 0.685±0.254 2.996±1.347 2.284±0.848 2.139±0.549 2.176±1.544
k 0.012±0.002 0.008±0.007 0.012±0.003 0.011±0.005 0.017±0.006 0.018±0.006 0.018±0.007 0.020±0.010 0.027±0.011 0.018±0.010 0.017±0.005 0.016±0.019
Tlag 3.392±1.286 3.863±1.318 3.307±1.158 3.142±1.361 4.435±0.431 4.298±0.513 4.403±0.467 4.175±0.633 6.090±9.480 7.255±6.244 7.111±5.092 9.417±9.353
R 2 0.9718 0.9665 0.9733 0.9610 0.9446 0.9441 0.9449 0.9448 0.9958 0.9990 0.9988 0.9961
R2adj 0.9296 0.9161 0.9331 0.9025 0.8615 0.8603 0.8623 0.8621 0.9927 0.9983 0.9980 0.9931
Peppas-Sahlin 1
with Tlag
k1 25.240±6.295 25.422±5.356 23.893±3.878 22.076±6.718 28.046±8.336 33.822±17.780 26.664±8.074 23.943±8.896
5.562±29.914 -34.891±35.208-34.413±47.91232.270±51.202
k2 -1.797±1.103 1.545±5.386 -1.520±0.501 -1.354±0.745 -2.045±1.109 -3.544±3.916 -1.885±1.074 -1.575±1.102 7.135±12.412 26.892±30.769 28.091±42.439 26.647±44.565
Tlag 3.565±0.975 3.970±1.026 3.455±0.843 3.226±1.069 4.589±0.262 5.379±2.097 4.574±0.266 4.436±0.371 30.926±14.109 15.000±3.162 15.000±0.000 13.885±4.915
R 2 0.9708 0.9654 0.9724 0.9603 0.9404 0.9413 0.9405 0.9391 0.9990 0.9906 0.9929 0.9833
R2adj 0.9269 0.9134 0.9309 0.9008 0.8510 0.8533 0.8512 0.8478 0.9982 0.9836 0.9876 0.9708
Logistic_2 α -4.033±0.743 -3.915±1.242 -3.841±0.664 -3.690±0.598 -7.625±1.416 -7.583±1.386 -7.638±1.499 -7.764±2.227 -13.991±1.505 -11.364±0.661 11.075±0.649 -11.433±2.663
β 4.330±0.428 4.036±1.087 4.062±0.319 3.811±0.508 7.839±1.457 7.727±1.510 7.805±1.522 7.817±2.210 7.967±0.914 6.331±0.582 6.196±0.639 6.235±1.832
R 2 0.9692 0.9580 0.9705 0.9556 0.9647 0.9637 0.9636 0.9548 0.9959 0.9968 0.9983 0.9910
R2adj 0.9486 0.9300 0.9508 0.9260 0.9412 0.9395 0.9394 0.9246 0.9943 0.9955 0.9976 0.9874
Logistic_3 k 0.210±0.014 0.190±0.050 0.195±0.016 0.183±0.042 0.373±0.071 0.369±0.090 0.365±0.067 0.343±0.079 0.088±0.008 0.072±0.007 0.072±0.009 0.069±0.017
у 8.666±1.999 9.044±1.909 8.885±1.884 9.377±2.111 9.733±0.725 9.973±0.916 9.818±0.645 10.094±0.736 55.701±3.493 57.951±5.308 57.051±5.684 61.299±9.127
R 2 0.9673 0.9405 0.9682 0.9534 0.9786 0.9784 0.9770 0.9669 0.9901 0.9918 0.9928 0.9873
R2adj 0.9455 0.9008 0.9470 0.9223 0.9643 0.9640 0.9616 0.9448 0.9862 0.9886 0.9899 0.9822
Korsmeyer-Peppas with TlagkKP x x x x x x x x 6.488±5.223 0.266±0.228 0.392±0.463 0.410±0.582
n x x x x x x x x 1.059±1.011 1.681±0.718 1.647±0.770 2.044±1.049
Tlag x x x x x x x x 20.295±16.355 7.253±10.849 7.645±11.770 1.848±14.134
R 2 x x x x x x x x 0.9942 0.9976 0.9972 0.9958
R2adj x x x x x x x x 0.9936 0.9974 0.9969 0.9953
 
 
 
 
194 
 
Table A 6.3:  Fitting of dissolution data at pH 6.8 for mathematical modelling, best values are highlighted 
 
LP: A LP: B LP: C LP: D SDAE: A SDAE: B SDAE: C SDAE: D FDAE: A FDAE: B FDAE: C FDAE: D
Zero order k0 1.059±0.073 1.038±0.075 1.083±0.078 1.074±0.078 1.112±0.035 1.076±0.055 1.122±0.057 1.051±0.080 0.874±0.020 0.877±0.038 0.884±0.036 0.8450.120
R 2 -1.6599 -1.0765 -1.5455 -1.3726 -4.5829 -4.2639 -3.9857 -3.1304 0.8980 0.9250 0.9223 0.8740
R2adj -1.6599 -1.0765 -1.5455 -1.3726 -4.5829 -4.2639 -3.9857 -3.1304 0.8980 0.9250 0.9223 0.8740
First order k1 0.063±0.020 0.055±0.015 0.064±0.023 0.062±0.022 0.114±0.011 0.107±0.012 0.110±0.012 0.098±0.016 0.014±0.001 0.014±0.001 0.014±0.001 0.013±0.002
R 2 0.7103 0.6993 0.7866 0.7754 0.7287 0.6486 0.7259 0.5641 0.8055 0.8459 0.8445 0.7971
R2adj 0.7103 0.6993 0.7866 0.7754 0.7287 0.6486 0.7259 0.5641 0.8055 0.8459 0.8445 0.7971
Weibull_1 β 0.797±1.179 0.456±0.338 0.929±1.172 0.611±0.399 1.403±1.393 1.341±1.291 x 1.260±1.923 1.490±0.739 1.852±0.911 2.365±1.407 1.865±1.345
Ti 4.760±4.850 6.595±2.279 4.144±5.200 5.566±2.704 2.124±4.236 1.689±5.220 x 3.339±6.081 23.843±8.231 9.730±14.990 1.791±20.138 12.814±13.623
R 2 0.8925 0.8910 0.9188 0.9173 0.8922 0.8434 x 0.8031 0.9957 0.9908 0.9923 0.9531
R2adj 0.8495 0.8474 0.8863 0.8842 0.8491 0.7807 x 0.7243 0.9940 0.9871 0.9892 0.9343
Weibull_2 β 1.394±0.846 1.329±0.795 1.404±0.795 1.397±0.676 2.122±0.678 1.715±0.756 2.193±0.670 2.596±1.885 4.923±2.743 2.844±1.659 2.873±1.707 2.997±1.781
R 2 0.8093 0.7874 0.8660 0.8546 0.8406 0.7429 0.8410 0.6501 0.9907 0.9874 0.9893 0.9437
R2adj 0.7776 0.7520 0.8437 0.8304 0.8140 0.7000 0.8145 0.5918 0.9892 0.9853 0.9875 0.9343
Weibull_3 β 2.384±1.647 2.435±1.694 1.704±0.735 1.808±0.703 2.561±1.000 2.572±0.965 2.591±0.999 3.312±1.576 4.565±2.071 2.906±1.544 6.915±2.814 3.523±2.035
R 2 0.8842 0.8723 0.9079 0.9072 0.9431 0.9163 0.9390 0.8586 0.9930 0.9894 0.9912 0.9609
R2adj 0.8379 0.8212 0.8711 0.8701 0.9203 0.8828 0.9145 0.8020 0.9902 0.9852 0.9876 0.9453
Weibull_4 β 1.278±1.244 0.655±0.509 1.252±1.024 1.234±1.141 2.909±1.253 2.914±1.294 2.849±1.004 x 1.572±0.874 1.761±0.906 2.150±1.306 1.823±1.331
Ti 2.880±5.025 5.740±2.720 2.046±5.445 2.642±6.257 -2.295±3.824 -2.108±4.346 -1.850±3.534 x 24.471±8.548 12.006±11.478 5.056±17.600 18.277±17.599
R 2 0.9154 0.9043 0.9363 0.9364 0.9448 0.9093 0.9399 x 0.9974 0.9927 0.9948 0.9661
R2adj 0.8519 0.8326 0.8886 0.8886 0.9035 0.8412 0.8948 x 0.9954 0.9872 0.9909 0.9407
Makoid-Banakar 
with Tlag
kMB 41.073±13.192 41.024±13.335 34.504±17.971 41.223±13.929 59.387±8.810 55.269±9.625 57.004±11.508 51.260±15.642 8.528±15.582 1.887±2.790 1.242±2.058 2.878±3.034
n 0.266±0.160 0.250±0.177 0.442±0.423 0.262±0.153 0.188±0.061 0.209±0.083 0.205±0.095 0.258±0.140 1.810±1.480 1.879±1.270 2.315±1.245 2.383±2.359
k 0.004±0.004 0.003±0.005 0.006±0.004 0.004±0.004 0.005±0.001 0.005±0.002 0.005±0.002 0.007±0.004 0.018±0.019 0.017±0.015 0.021±0.012 0.030±0.046
Tlag 6.228±2.454 7.364±2.573 2.249±13.706 7.116±2.651 4.975±0.034 4.959±0.062 4.975±0.036 5.299±1.199 19.320±9.821 11.696±11.247 7.528±11.714 16.864±11.173
R 2 0.9245 0.9189 0.9216 0.9389 0.9368 0.9131 0.9319 0.8855 0.9979 0.9938 0.9944 0.9955
R2adj 0.8679 0.8580 0.8628 0.8930 0.8895 0.8479 0.8808 0.7995 0.9964 0.9891 0.9901 0.9922
Peppas-Sahlin 1
with Tlag
k1 42.643±15.884 39.670±18.358 39.766±15.933 40.056±14.956 73.062±24.062 68.465±22.598 72.750±31.113 62.291±23.503 -
71.361±198.03
3
-2.316±44.040 -
53.699±119.97
4
-
34.168±147.29
8
k2 -4.286±5.501 -3.488±6.180 -3.993±4.493 -2.374±7.178 -15.502±14.174 -13.996±12.264 -16.219±18.682 -11.779±9.935 70.198±146.34
3
21.917±49.288 55.473±100.40
4
44.532±124.96
9Tlag 6.217±2.410 6.551±2.386 6.119±2.494 6.637±2.516 4.941±0.057 4.933±0.077 4.956±0.044 5.310±1.261 20.607±31.264 26.201±15.452 19.685±8.281 27.281±11.700
R 2 0.9226 0.9149 0.9376 0.9351 0.9397 0.9169 0.9347 0.8889 0.9778 0.9869 0.9838 0.9543
R2adj 0.8645 0.8511 0.8908 0.8864 0.8945 0.8457 0.8858 0.8055 0.9611 0.9770 0.9716 0.9200
Logistic_2 α -6.976±2.616 -7.324±2.978 -6.040±2.787 -6.225±2.601 -
10.046±10.711
-9.596±8.798 -9.838±9.52 -
13.835±13.290
-
32.377±45.583
-13.475±5.474 -13.435±5.672 -
40.931±62.704
β 7.103±2.006 7.257±2.854 5.948±2.332 6.116±2.230 12.802±15.307 12.037±12.571 12.297±13.592 16.169±16.535 18.606±25.616 7.850±3.252 7.874±3.356 23.250±35.066
R 2 0.8925 0.8803 0.9131 0.9139 0.9326 0.9033 0.9298 0.8463 0.9943 0.9904 0.9910 0.9617
R2adj 0.8495 0.8324 0.8783 0.8795 0.9057 0.8646 0.9017 0.7848 0.9920 0.9866 0.9874 0.9464
Logistic_3 k 0.372±0.171 0.367±0.208 0.249±0.102 0.265±0.106 0.623±0.725 0.650±0.695 0.660±0.732 0.561±0.804 0.162±0.112 0.102±0.054 0.101±0.051 0.130±0.110
у 9.829±2.472 10.858±2.701 11.972±6.021 12.180±6.693 2.566±15.927 7.225±1.004 7.364±1.180 33.093±60.514 53.267±5.235 50.931±8.247 50.756±7.541 52.895±6.041
R 2 0.8832 0.8635 0.8941 0.8939 0.8714 0.9154 0.9378 0.7576 0.9908 0.9853 0.9875 0.9566
R2adj 0.8365 0.8088 0.8517 0.8514 0.8199 0.8816 0.9129 0.6607 0.9872 0.9794 0.9825 0.9392
Korsmeyer-
Peppas with Tlag
kKP x x x x x x x x 2.987±6.772 1.842±3.020 1.249±1.689 2.737±3.237
n x x x x x x x x 3.437±2.800 1.973±1.420 2.638±2.109 9.957±28.423
Tlag x x x x x x x x 7.293±16.043 6.062±14.101 1.302±14.286 11.040±12.791
R 2 x x x x x x x x 0.9795 0.9936 0.9970 0.9874
R2adj x x x x x x x x 0.9765 0.9928 0.9966 0.9858
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